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Summary 
The Doctoral Thesis has been structured into two parts preceded by a general introduction 
that covers basic concepts on biocatalysis with special focus on application of whole cells 
of unconventional yeasts and a new ketoreducatese from Pichia glucozyma. All these 
thematic issues give a background to the following two parts, where the experimental 
results have been deeply discussed. 
Part 1 The biocatalytic potential of whole cells of P. glucozyma have been studied through 
biotransformations using substrates of different chemical nature having interesting 
pharmaceutical and synthetic aspects. After optimization of the reaction conditions through 
the transformation of acetophenone in (S)-1-phenylethanol, the attention was focused on 
the reduction of different aromatic ketones. All the reactions occurred with high yields and 
high enantiomeric excess for the corresponding (S)-alcohols. 
Part 2 Bioreduction catalysed by NADPH-dependent benzil-reductase (KRED1-Pglu) 
from Pichia glucozyma provides an attractive approach for selectively reducing a 
broad range of aromatic ketones. After protein identification, characterization and 
over-expression in E. coli, we have established a procedure for the purification and 
storage of KRED1-Pglu. After optimization of the reaction parameters, a thorough 
study of the substrate range of KRED1-Pglu was conducted. KRED1-Pglu prefers 
space demanding substrates which are often converted with high stereoselectivity. The 
observed activities and enantioselectivities were explained with a molecular 
modelling study for understanding the structural determinants involved in 
the stereorecognition experimentally observed and unpredictable on the basis of steric 
properties of the substrate. 
In conclusion, different efficient and sustainable methods for the stereoselective reduction 
of prochiral ketones using both whole cells of unconventional yeasts such as P. glucozyma 
CBS 5766 and the isolated enzyme KRED1-Pglu have been proposed in this PhD work. 
 
 
 
 
Riassunto 
Questa Tesi di Dottorato è stata strutturata in due parti differenti precedute da 
un’introduzione riguardante i principi fondamentali della biocatalisi con particolare 
attenzione sull’applicazione di cellule intere di lieviti non convenzionali e una nuova 
chetoreduttasi proveniente dal lievito Pichia glucozyma. Tutte queste tematiche 
rappresentano il “background” per poter meglio comprendere le parti sperimentali descritte 
nei successivi paragrafi. 
 
Parte 1 Il potenziale biocatalitico rappresentato da cellule intere di P. glucozyma è stato 
studiato usando substrati di differente natura chimica interessanti sia dal punto di vista 
farmaceutico che sintetico. Dopo l’ottimizzazione delle condizioni di reazione, effettuata 
sulla trasformazione dell’acetofenone in (S)-1-feniletanolo, l’attenzione è stata focalizzata 
sulla riduzione di differenti chetoni aromatici. Tutte le reazioni generalmente avvengono 
con elevate rese ed elevata selettività per il corrispondente (S)-alcol.  
 
Parte 2 Riduzioni catalizzate da una benzil-reduttasi (KRED1-Pglu) NADPH-dipendente 
proveniente da P. glucozyma, rappresentano un’ interessante strategia sintetica per la 
riduzione stereoselettiva di chetoni aromatici. Dopo identificazione, la caratterizzazione e 
l’over-espressione della proteina in E. coli, un metodo di purificazione e conservazione 
dell’enzima è stato messo a punto. Dopo ottimizzazione dei parametri di reazione, è stato 
effettuato un accurato studio riguardante i substrati accettati da KRED1-Pglu. Questa 
proteina preferisce substrati stericamente ingombrati, spesso convertiti con elevata 
stereoelettività. La differente enantioselettività sperimentalmente osservata, è stata spiegata 
mediante studi di docking molecolare.  
 
In conclusione, due differenti metodi efficienti ed eco-sostenibili per la riduzione 
stereoselettiva di diversi chetoni aromatici, utilizzando sia cellule intere di lieviti non 
convenzionali tra cui P. glucozyma CBS 5766 e l’enzima isolato KRED1-Pglu sono stati 
presentati in questo lavoro di tesi. 
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Introduction 
 
1.1 Efficiency in organic chemistry 
 
In the recent history of organic chemistry the concept of reaction efficiency 
has undergone substantial changes. For long time the success of a chemical process 
was entirely related to the yield of the desired product. Aspects such as waste 
regeneration or toxic properties of the chemicals and solvents were neglected. For 
example till 1980 the production of 1 Kg of phloroglucinol (1,3,5-benzentriol), an 
antispasmodic agent with a lot of  applications also as precursor of pharmaceuticals 
and explosives, could generate up to 40 Kg of solid waste in a industrial process
1
.  
From a modern perspective, this limited viewpoint must be enlarged. In 90’s 
Trost redefined the reaction efficiency in terms of atom economy, as the percentage 
of reactants molecular mass incorporated in the final products.
2
 In this context 
synthetic method should  be designed to maximize the incorporation of all materials 
used during the process, in the final product. 
Additionally, increasing the environmental consciousness, in 1998 Anastas 
and Warner published the twelve principles of environmentally driven chemical 
processes
3
 (Fig. 1). The main topics were the utilization of raw materials with 
minimization of waste production through the implementation of catalytic process 
                                                          
1
 R.A. Sheldon, Green Chem. 2007, 9, 1273-1283 
2
 B.M. Trost, Science 1991, 254, 1471-1477 
3
 P.T Anastas, J.C Warner, Green Chemistry: Theory and Practise, Oxford University Press, Oxford, 
1998 
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and safety issues about the use of chemicals with particular emphasis on the research 
for alternative reaction media to replace the most health hazardous reaction 
conditions. The concept of Green Chemistry was coined and its principles have 
became relevant in chemical process design. 
As a result, an efficient chemical process started to be perceived as a 
procedure where minimal amount of waste was produced. The most widely accepted 
measure of the environmental impact of a chemical processes is the E factor, defined 
as the weight of waste generated in producing one Kg of product, including auxiliary 
reagents such as catalysts, solvents and others.
4
 Water is generally excluded as waste 
in this approximation. Other metrics have been proposed for measuring the 
environmental acceptability of processes such as mass intensity (MI) or carbon 
efficiency (CE) especially used in fine and pharmaceutical industry.
5
 
 
      P  Prevent wastes 
      R  Renewable materials 
      O  Omit derivatization steps 
      D  Degradable chemical products 
      U  Use of safe synthetic methods 
      C  Catalytic reagents 
      T  Temperature, Pressure ambient 
      I   In-Process monitoring 
      V  Very few auxiliary substrates 
      E  E-factor, maximise feed in product 
      L  Low toxicity of chemical products 
      Y  Yes, it is safe 
 
 
Fig. 1 The twelve principles of Green Chemistry 
                                                          
4
 R.A. Sheldon, CHEMTECH 1994, 24, 38-47 
5
 W.J.W. Watson, Green Chem. 2012, 14 251-259 
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Fig. 2 Most commonly used metrics for process efficiency  
 
The stoichiometric ratio and the use of solvents and catalysts are the practical 
problems associated with the realization of a chemical process dealing with the 
consumption of raw material and the production of waste as well as the yield. 
However, we are still far from an accurate assessment of environmental impact of a 
chemical process. The analyzed parameters, in fact, take into account the amount of 
waste but they do not consider their characteristics.  
Furthermore, the responsible management of natural resources through 
development of sustainable processes has motivated the research for the utilization of 
renewable resources such as biomass to produce biofuels, chemicals, pharmaceuticals 
and bioplastics.
6
 Sustainable development is defined as the environmental, economic 
and social well-being that allows “meeting the needs of the present generation 
without compromising the ability of the future generations to meet their own”.7  
  
                                                          
6
 K. Alfonsi, Green Chem. 2008, 10, 31-36 
7
 World Commission on Enviromental and development (WCED). Our common future. Oxford 
University Press, Oxford, 1987 
Introduction 
 
16 
 
1.2 Reaction media in a sustainable process  
 
Particular attention has been dedicated to the reaction media in synthetic 
chemistry because the major source of waste (around 50%) is represented by the 
solvent losses
8
. Furthermore, health and/or safety matters associated with many 
traditional organic solvents have led to their severely reduced use. On the other hand 
solvent utilization is necessary to facilitate mass and heat transfer during the reaction 
and affects reaction rate and selectivity. The American Chemical Society Green 
Chemistry Institute
®
 Pharmaceutical Roundtable (ACSGCIPR), taking into account the 
major issues of the use of organic media, such as carcinogenicity of halogenated 
solvents and flammability of highly volatile ones, has delivered guidelines for solvent 
use in pharmaceutical industry in order to improve the green chemistry worldwide (Fig 
3). 
 
 
Fig. 3 Guide for organic solvents regarding safety principles 
                                                          
8
 C. Jiminez-Gonzales, Int. J. Life Cycle Assess., 2004, 9, 115–121  
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1.3 Water in organic chemistry 
 
Recently, many efforts have been devoted to the finding of sustainable reaction 
media. In this contest, water has been regarded as naturally green solvent for 
conducting reaction processes. Indeed, water offers many advantages from both 
economic and environmental points of view because it is a cheap, readily available, 
non-toxic and non-inflammable solvent. On the other hand, water is considered a poor 
solvent for organic transformations because of the low solubility of organic 
compounds so, for a long time, it was considered a reaction contaminant.
9 However, it 
is now well established that the unique structure and physicochemical properties of 
water lead to particular interactions improving reactivity and selectivity of many 
reactions, simplifying the work-up procedure and recycling catalyst. 
The most important example of enhanced reactivity and selectivity is 
represented by Diels-Alder reactions conducted in water, recently redefined by 
Sharpless et al. “on water reactions” 10 using reactants hardly soluble in this solvent at 
room temperature. The cycloaddition of quadricyclane and dimethyl azodicarboxilate 
was performed in water giving an excellent yield in a very short time as shown in Fig. 
4a. Another example is the Passerini
11
 condensation, a multicomponent reaction 
transforming three or more starting materials in a single product.  In this case, using 3-
methylbut-2-enoic acid, 3-methylbutanal and 2-isocyano-2-methylpropane in water, 
the desired product was obtained quantitatively in 3.5 hours (Fig. 4b).   
 
                                                          
9
 M.O Simon et al.,  Chem. Soc. Rev. 2012, 41, 1415-1427 
10
 S. Narayan et al., Angew. Chem. Int. Ed. 2005, 44, 3275 
11
 M.C. Pirrung et al.,  J. Am. Chem. Soc. 2003, 126, 444-445 
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Fig. 4 Dies-Alder cycloaddition reaction and multicomponent Passerini condensation in water 
 
The increasing of reactivity can be explained by the repulsive interactions 
between hydrophobic molecules and water, which leads to the formation of 
hydrophobic aggregates which reduces the contact surface between them. In order to 
maintain the network of hydrogen bonds, water wraps itself around these aggregates, 
thus accelerating reactions such as Dies-Alder cycloadditions or Passerini 
multicomponent condensations. Moreover water can improve the yield of products 
because it reduces side reactions. An interesting example is the industrial synthesis by 
Novartis of 1-substituted-4cyano-1,2,3-triazoles from 2-chloroacrylonitrile and organic 
azides (Fig. 5a)
12
.  
  
                                                          
12
 R.Portman, World Patent, WO 9802423 
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Fig. 5 (a) Minimization of side products formation and (b) enhancement of chemo- and regioselectivity in 
water as reaction medium. 
 
In this reaction, the 1,3-dipolar cycloaddition is followed by an aromatization, 
which generates hydrogen chloride as a side product. 2-Chloroacrylonitrile is known to 
polymerize under acid conditions resulting in a low yield of desired product. The use 
of water as medium reaction leads to solubilize hydrogen chloride allowing minor 
polymerization of the alkene. 
Selectivity is also a very important parameter for sustainable chemistry 
because a non-selective reaction increases the environmental impact both increasing 
waste, and determining through tedious and complicated purification steps. A good and 
well-known example is the nucleophilic opening of epoxides in the synthesis of a lot of 
natural products. As shown in Fig. 5b, β-aminoalcohols could be synthesized in high 
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yields by a reaction between epoxides and amines in water at room temperature
13
. In 
most cases, a total region- and stereoselectivity was obtained. In the case of styrene 
oxide however, both regioisomers were obtained but their yields were maximized 
using water as a reaction medium.   
 
1.4 Biocatalysis 
 
Biocatalysis is the use of biologically-derived catalysts (i.e. enzymes or whole 
cells) to perform chemical transformations of organic compounds. Biocatalysis offers 
an increasing potential for the production of goods to meet various human needs. New 
biocatalytic processes, have been developed to produce compounds of food, chemical 
and pharmaceutical interest. Enzymes are also important molecules both in terms of 
environmental, analytical and diagnostic aims. The driving forces in the development 
of the industrial enzyme technology are 
 the obtainment of  new products or processes to meet these needs; 
 the improvement of the quality of processes for the preparation of 
existing products starting from raw materials. 
Both these approaches may lead to an innovative product or process that is not 
only competitive, but also meet sustainability criteria.
14
 
 
                                                          
13
 N.Azizi et al.,  Org. Lett. 2005, 7, 3649-3651 
14
 K. Buchhols, V. Kasche, U. T. Bornscheuer Biocatalysts and Enzyme Technology, Wiley-VCH 
Verlag GmbH & Co. 2005 
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1.5 Advantages and disadvantages of biocatalysis 
 
Biocatalysis combines many appealing features that could overcome its certain 
limitations. The employment of biologic systems, such as whole cells or isolated 
enzymes, offers important advantages: 
 
 Chemo- regio- and  stereoelectivity. These intrinsic properties 
indicate, respectively, the enzyme capability of selectively interacting 
with a functional group in presence of other similar or more reactive 
groups, of distinguishing between chemical groups located in different 
positions and of producing molecules with a specific stereochemistry. 
Triple-level of substrate recognition by a biocatalyst consists of 
chemo- regio- and stereodiscrimination which in practice leads to 
shorter time of synthesis due to elimination of protection and 
deprotection steps as well as to cleaner work-up due to prevailed 
formation of only one product.
15
   
 Catalytic efficiency.  While chemical catalysts are generally used in 
concentrations of 0.1-1%, enzymatic reactions can be conducted with 
biocatalyst concentration  of 10
-3
-10
-4
%. 
 Mild reaction conditions. Most of the enzymes works in water around 
physiological pH and temperature between 20 and 40 °C. These 
reaction conditions let the reduced utilization of solvents, toxic 
reagents and heavy metals. 
                                                          
15
 K. Faber, Biotransformation in organic chemistry. A textbook, 5
th
 Ed., Springer, Heidelberg, 2004. 
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  Sustainability. Biocatalysts are completely biodegradable substances. 
 One-pot multienzymatic reactions. It is possible to set up 
multienzymatic cascade systems because many proteins are stable and 
active under similar reaction conditions.
16
 In this way, reaction time, 
costs and product recovery steps can be reduced. Moreover, the 
isolation of instable intermediates can be avoided.  
 Protein ability to accept a broad range of organic molecules. Enzymes 
and whole cells can transform very different substrates from those 
involved in the conventional cellular metabolisms. Finally, enzymatic 
reactions can usually proceed in both directions since enzymes do not 
modify the thermodynamic equilibrium of the reaction, but act on the 
activation energy. Moreover, recent advances in metabolic and protein 
engineering make possible to adapt biocatalysts to very different and 
unnatural substrates.  
On the other hand, some of these same advantageous traits of enzymes may also 
constitute their limitations. 
 Narrow operational window. The temperature, pH and salts 
concentration conditions may be unfavourable for organic compounds 
as well as the aqueous environment.  
 Low productivity. Proteins are subjected to substrate and/or product 
inhibition phenomena. To overcome this problem, continuous 
processes may be advantageously applied.   
                                                          
16
 P.A. Santacoloma et al.,  Org. Process Res. Dev. 2011, 15, 203-212. 
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 Low number of commercially available biocatalyst. 
 High time required for the development of an industrial process. 
 Cofactor-depending enzymes. Many proteins require specific and very 
expensive cofactors, such as NAD(P)H or FADH2 for the redox 
reactions. It is possible to overcome this limitation by using recycling 
systems such as a second protein able to re-establish the initial 
oxidized/reduced cofactor form or whole cells bearing recombinant 
enzymes.    
 Enzyme enantiospecificity. In nature often enzymes show only one 
defined enantiospecifity and a natural enantiocomplementary 
counterpart is not common. However it is common to find enzymes 
showing stereocomplementary behaviour, as they possess “mirror- 
image” active site.17 Therefore, a desired stereospecific enzyme has to 
be found in tedious screenings, or by means of molecular engineering 
techniques,
18
 altering the enzyme structure to produce the opposite 
enantiomer. 
 Catalyst recovery and reuse. A requisite to cut down the costs of a 
process is the possibility to recycle the (bio)catalysts. In the case of 
enzymes or whole cells, they are often used as immobilized 
biocatalysts to improve their recovery and reuse. 
To overcome these issues various strategies are necessary. It is possible to 
stabilize biocatalysts by protein engineering and/or metabolic interventions in order to 
                                                          
17
 P.F. Mugford et al., Amgew. Chem. Int. Ed. 2008, 47, 8782-8793 
18
 G.A. Behrens et al., Adv. Synth. Catal. 2011, 353, 2191-2215  
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produce industrial, selective and robust catalysts; or to immobilize them for their use in 
continuous (flow) reactors.  
 
1.6 Isolated enzymes versus whole cells systems 
 
 These two systems show different features and it is necessary to consider the 
type of reaction, cofactor recycling and biotransformation scale in order to decide to 
employ microorganisms or purified proteins as catalysts. In Table 1 possible advantages 
and disadvantages of the two kind of types of biocatalysts are summarized.
19
 
 
Biocatalyst Form Advantages Disadvanatges 
 
Isolated 
enzymes 
 
Dissolved in water 
 
 Simple apparatus 
 Simple workup 
 Better 
productivity 
 High substrate 
concentration 
tolerance 
 High catalytic 
activity 
 
 Cofactor recycling 
necessary 
 Side reaction 
possible 
 Lipophilic substrates 
insoluble 
 Workup requires 
extraction 
 
Suspended in 
organic solvents 
 
 Easy to perform 
 Simple workup 
 Lipophilic 
substrates soluble 
 
 Reduced catalytic 
activity 
                                                          
19
 K. Faber Biotranformations in Organic Chemistry. A Textbook. 6
th
 Ed. Springer- Verlag Berlin 
Heidelberg 2011 
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 Easy enzyme
recovery
Immobilized 
 Easy enzyme
recovery
 Enzymatic
recycling
 Possibility to use
continuous flow
reactors
 Loss of activity
during
immobilization
Whole cells 
Growing cultures 
or resting cells 
 No cofactor
recycling
necessary
 High activity
 Simple workup
 Fewer byproducts
 Expensive
equipment
 Tedious workup
 Low productivity
 Low substrate
concentration
tolerance
 Low organic
solvents tolerance
 Uncontrolled side
reactions
Immobilized cells 
 Possible cell re-
use
 Possibility to use
continuous flow
reactors
 Loss of activity
during
immobilization
Table 1 Advantages and disadvantages in using isolated enzymes or whole cells 
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1.7 Thermodynamic aspects of enzyme catalysis  
 
By analogy to other catalytic processes, enzymes act on the activation energy of 
the reaction by lowering the energy barrier between substrate and product. An enzyme 
reaction consists of a first binding step and a subsequent reaction step. In a non-catalyzed 
reaction, one or more substrates are, at the beginning, in their respective ground states. 
During the reaction, the reactants pass the point of maximum free energy, called  transition 
state, and continue to the ground state of the products. (Fig. 6). 
 
 
 
Fig. 6 Thermodynamic aspects of enzymatic catalysis 
 
In an enzyme-catalyzed reaction, initially, free enzyme E and free substrate S 
likewise are in their respective grounds state. From the ground state, enzyme and substrate 
become a reversible enzyme-substrate complex [ES]. The [ES] complex passes through 
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another lower transition state, and finally the enzyme-product complex [EP] on the ground 
state of free enzyme E and free product P. The maximum of the Gibbs free energy 
between the ground state of substrate and product forms the Gibbs free energy of 
activation ΔG, which determines the rate of the reaction. Like every catalyst, an enzyme 
decreases the value of ΔG accelerating the reaction.20 
 
1.8 Enzyme classification and nomenclature 
 
The widely accepted international enzyme classification was introduced by  
the Enzyme Commission. For identification purpose, every enzyme has a four-digit 
number in the general form EC A.B.C.D., where EC stands for ‘Enzyme Commission’, 
A denotes the type of reaction catalyzed as shown in Table 2 , B indicates the substrate 
class or type of transferred molecule, C indicates co-substrate class and D is the 
individual enzyme number. 
  
                                                          
20
 A. S. Bommarius, B.R. Riebel Biocatalysis, Wiley-VCH Verlag GmbH & Co. 2004 
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EC number Enzyme class Reaction Type 
1 Oxidoreductases Oxidation-reduction of double bonds, alcohols/ 
carbonyl groups 
2 Transferases Transfer of methyl, acyl, amino, carbonyl, glycosyl,  
or phosphoryl groups 
3 Hydrolases Hydrolysis-formation of esters, lactones, amides, 
lactams, epoxides, anhydrides, nitriles, glycosides. 
4 Lyases Addition-elimination of small molecules to multiple 
bounds like C=C, C=O, C=N 
5 Isomerases Racemization, epimerization, rearrangement 
6 Ligases Formation-cleavage of C-C, C-O, C-N, C-S bonds 
with concomitant triphosphate cleavage 
Table 2 Enzyme classification 
Information about catalytic activity is expressed by katal (1 kat = 1 mol s
-1
 of 
substrate transformed), but it has not widely accepted because of its too big magnitude to 
practical application. As consequence a more used measure has been International Unit (1 
I.U.= 1 µmol min
-1
 of substrate transformed).  The biocatalyst catalytic power can be
described by turn over frequency (TOF). It indicates the number of substrate molecules 
converted by a single catalyst molecule during a specific time. For the majority of enzymes 
Introduction 
 
29 
 
TOF values are between 10 and 1000 s
-1
, whereas for chemical catalyst about one order of 
magnitude lower. The productivity of a biocatalyst is indicated by the turn over number 
(TON). It represents the number of substrate molecules converted by a single catalyst 
during its lifetime and indicates the durability of the catalytic system.
21
 
 
1.9 Development of a biocatalytic process in the pharmaceutical industry 
 
The use of biocatalyst has acquired importance as a complement to conventional 
chemical techniques in various application fields. In particular, biocatalyst selectivity is 
important for obtaining pharmaceuticals, whose stereochemistry affect their 
pharmacological characteristics. The isomer with the highest activity is defined ‘eutomer’ 
and its enantiomer with less or undesired activities ‘distomer’.22 
For a convenient employment of a biocatalyst in an industrial process, it is 
necessary to consider  also development time of a large-scale process and final 
productivity.
23
 Within an industrial process a biocatalyst has to be active on elevate 
substrate concentrations (around 50-100 g/L) and the ratio between product grams and 
catalyst grams should be about 1000.
24
 The scale-up from laboratory conditions to 
industrial ones could be a problematic step. In fact, the extension of reaction time, the 
increasing of substrate concentration, the improvement of energy and instrumentations for 
large tanks could cause catalyst degradation or loss of activity and productivity. In order to 
                                                          
21
 P. Atkins, J.De Paula Physical Chemistry, 8
th
 Ed. Chapter 23, Oxford University Press, New York, 
2006 
22
K. Faber Biotranformations in Organic Chemistry. A Textbook. 6
th
 Ed. Springer- Verlag Berlin 
Heidelberg 2011 
23
J.D. Pollard et al., Trend Biotechnol. 2006, 25, 66-73 
24
J. D. Rozzel et al., Bioorg. Med. Chem., 1999, 7, 2253-2261. 
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obtain high products yield, different strategies are possible such as product removal from 
reaction environment or controlled substrate supplying using hydrophobic resins, ionic 
liquids or crystallization/precipitation techniques.
25
 
Fig. 7 Example of biphasic system and liquid ionic solvent biotransformation 
Most likely, the most important reason for the biocatalysts employing in 
medicinal chemistry is their stereoselectivity. The production of optically pure compounds 
by pharmaceutical industries has become a very important issue overall after the 
publication of guidelines provided by the Food and Drug Administration (FDA) in 1992. 
In this document is underlined the importance to characterize and verify the 
pharmacological and toxicological effects of both the enantiomers of a racemic mixture.
26
 
In this contest, the chiral synthesis for obtaining a single isomer has become a key point for 
synthetic medicinal chemistry. In Fig. 8 is shown the increasing of the optical pure active 
molecules on sale from 1980 to 2000. In the 1990 the pure optical pharmaceutical 
preparations were only the 25% while in 2000 they were improved to 60%. 
25
 G. J. Lye et al., Trend Biotechn. 1999, 17, 395-402 
26
 www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122833.htm 
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Fig. 8 The increasing of the production of pure optical pharmaceuticals 
The possibility of using a biocatalytic process is particularly meaningful if it is 
adopted during the first phase of a drug development, because the late substitution of an 
optimized chemical step is very difficult. Firstly, the industrial employment of isolated 
enzymes is more convenient because of the possibility to quickly produce pilot drug 
amounts for clinical tests (phase I and II). Subsequently, for the production on large scale, 
the utilization of whole recombinant cells with over-expressed desired enzymes is 
economically favourable.
27
 For an industrial process development various disciplines such 
as chemistry, molecular biology, enzymology, microbiology and engineering, are needed. 
Moreover, in order to reduce developing time, to utilize low substrate amounts and to 
obtain many process data, preliminary studies are made in miniaturized conditions using 
for example ninety-six wells microplates containing lyophilized isolated enzymes or using 
microscale analytic techniques. For the same aims, mathematic models furnishing 
27
M.D. Truppo et al., Org. Proc. Res. Dev. 2006, 10, 592-598;  A.J.J. Straathof et al., Curr. Opin.
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simulating reaction conditions are applied. These models are less widespread for 
biocatalytic processes than chemical ones.   
Fig. 9 Drug discovery timeline and cost 
1.10 Examples of chiral drugs 
Biocatalytic methods for the preparation of some popular drugs, such as 
profens, statins and ACE inhibitors, have been thoroughly studied.  
The profens family belongs to the most important non-steroidal anti-
inflammatory drugs (NSAIDs); 2-arylpropionic acids are the key intermediates in the 
preparation of NSAIDs used for the inhibition of cyclooxygenase-1 and 2 (COX-1 and 
COX-2), responsible for the synthesis of prostaglandins involved in inflammatory 
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process.
28
 It is known that the pharmacological effect is determined by (S)-enantiomer, 
so the production of this optically pure compound is of great interest.
29
  
Fig. 10  Non-steroidal anti-inflammatory drugs 
Ibuprofen, well-known anti-inflammatory drug, can be produced as (S)-
enantiomer by various biocatalytic processes involving lipases. One method comprises the 
use of an immobilized lipase from Candida rugosa (CRL) for catalysing the kinetic 
resolution (KR) of racemic ibuprofen methylester. The lipase catalyzes the hydrolysis of 
the racemic mixture of ibuprofen methylester, with selectivity for the (S)-enantiomer (Fig. 
11).  In order to obtain good yields, it has been developed a two-phase system where the 
esterified substrate better dissolves in the hydrophobic phase whereas (S)-ibuprofen 
partitions in aqueous phase. The CRL is immobilized on a membrane placed to the 
interface. 
28
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Fig. 11 Enantioselective hydrolysis of Ibuprofen methylester 
KR has been applied also to obtain the (S)- enantiomer of flurbiprofen. (S)-
flurbiprofen has anti-inflammatory properties, while the (R)-enantiomer shows anticancer 
effects in vivo and in vitro studies. KR of (R,S)-flurbiprofen may be achieved via 
esterification  carried out in organic media (Fig. 12);  a particular innovative one, using an 
immobilised lipase B from Candida antarctica (Novozym 435
®
) in a continuous flow 
reactor, has been reported to exhibit a relatively high enantiopreference toward (R)-
flurbiprofen.  
Fig. 12 Enantioselective esterification of (R,S)-flurbiprofen 1 with n-BuOH catalysed by Novozym 435 with 
the addition of molecular sieves, in toluene. 
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One general limitation of KR is the maximum conversion obtainable (50%) for 
recovering an enantiopure product; dynamic kinetic resolution (DKR), where the slow-
reacting enantiomer racemizes with a rate faster than the asymmetric transformation, offers 
an impactful alternative, since 100% of the racemic substrate can be converted to the 
enantiopure product. Continuous flow reactors could help to overcome some of the 
limitations of traditional enzymatic KR in batch, such as long reaction times, product 
inhibition of the enzymes scalability. Moreover, in continuous flow reactors recovery of 
the products and set-up of DKR processes are relatively easy. In the case of the 
esterification of racemic flurbiprofen, the use of a continuous flow reactor allowed for 
higher reaction rates, higher biocatalyst stability, and recovery of the unreacted (S)-
carboxylic acid using an ionic exchange resin. The process was further implemented by 
racemization of the unreacted flurbiprofen directly into the polymer-supported resin and 
recycle of the racemic substrate. 
30
 
 
 
 
Fig. 13 Flow chemistry reactor and immobilized Novozyme 435 column 
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Fig. 14 Kinetic resolution of Flurbiprofen and in-line purification 
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Statins are cholesterol lowering drugs, which inhibit the enzyme HMG-CoA 
reductase, an enzyme playing a central role in the production of endogenous cholesterol. 
Statins are administered to prevent cardiovascular disease and mortality in those who are at 
high risk.
31
 
 
 
 
Fig. 15 Statins  
 
The essential structural components of all statins are a dihydroxyheptanoic acid 
unit and a ring system with different substituents. The statin pharmacophore is a modified 
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hydroxyglutaric acid component, which is structurally similar to the endogenous substrate 
HMG-CoA. It binds the same active site as the substrate of HMG-CoA and inhibits the 
HMGR enzyme. It has also been shown that HMGR is a stereoselective enzyme and, as a 
result, all statins need to have the required 3R,5R stereochemistry.
32
 The chemical 
synthesis could be very complex, in particular for obtaining of the correct stereochemistry. 
The conventional production of atorvastatin requires numerous steps and drastic reaction 
conditions such as temperature -90°C or use high quantities of solvents. To overcome these 
problems several biocatalytic alternatives for the synthesis of the different building blocks, 
in particular ethyl (R)-4-cyano-3-hydroxybutyrate, also called hydroxynitrile and its 5-
hydroxy-3-keto derivative have been developed. 
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Fig. 16 Synthesis of atorvastatin with biocatalityc (BT) and chemical steps (C) 
 
As shown in Fig. 16 (R)-4-cyano-3-hydroxybutyrate can be obtained by a 
mutant nitrilase from 3-hydroxy glutaronitrile (Step 1).
33
 The acid was esterified with tert-
butyl acetate and oxidized to give the 5-hydroxy ketoderivate. Two alternative steps can be 
used for synthesizing this intermediate: an asymmetric reduction of 4-chloroacetoacetate 
(Step 2) and a subsequent oxidation to obtain the 5-hydroxy ketoderivate. For the synthesis 
of this key intermediate, Codexis has developed a biocatalytic method using three different 
enzymes: a ketoreductase (KRED) to obtain (S)-CHBE with an excellent e.e. (> 99.0%), a 
glucose dehydrogenase (GDH) for the recycle of NADPH used in the first step by KRED, 
and a halohydrin dehalogenase (HHDH) which, by removing hydrogen chloride, generates 
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an epoxy ring; the stoichiometric HCl produced in this step activates sodium cyanide 
allowing for the opening of epoxy ring.
34
  
 
 
Fig. 17 Syntesis of HN by Codexis 
 
For the reduction of ketone of the 3-hydroxy-5-cyano derivate, an alcohol 
dehydrogenase NADPH-dependent from Lactobacillus brevis over-expressed in E. Coli 
has been employed. The same enzyme is able to regenerate the cofactor because of the 
oxidation of 2-propanol into acetone.
35
 The last biotransformation step forms the lactone 
from chloro acetaldehyde by employing a mutant aldolase (DERA) as shown in Fig. 18. 
 
.  
Fig. 18 Biocatalytic synthesis of lactone 
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Angiotensine Converting Enzyme (ACE) inhibitors are pharmaceuticals used for 
the treatment of hypertension and congestive heart failure. They inhibit the enzyme 
responsible for the conversion of Angiotensin I into Angiotensin II, important component 
of the rennin-angiotensin-aldosterone system. The most important drug is Captopril (Fig. 
19) 
 
 
 
Fig. 19 Captopril  
 
The pharmaceutical effect depends on side chain containing the –SH group. 
Noteworthy is the S configuration of the chiral centre in 2 position, which confers a 
hundred times major activity than the opposite enantiomer.
36
 There for, a stereoselective 
synthesis of the side chain is very important. Lipases from Rhizopus orizae and 
Pseudomonas cepacia hydrolyze stereoselectively the thioester of racemic mixture of 3-
acetylthio-2-methylpropanoic acid, in order to obtain the (S)-enantiomer (yield 28%, e.e. 
95%). The best yield and enantiomeric excess were obtained using an esterase from 
Pseudomonas sp. MRC, which catalyzes the hydrolysis of the methyl ester of 3-acetylthio-
2-methylpropanoic acid (yield 49%, e.e. >99.0%) as shown in Fig.20.
37
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Fig. 20 Enantiselective reactions to obtain the key intermediate for Captopril synthesis 
 
Another alternative for the preparation of (S)-acid of the side chain of Captopril 
could be an enantioselective esterification of the racemic mixture of the 3-benzothio-2-
methylpropanoic acid. Lipases of Rhizopus orizae and Pseudomonas cepacia in toluene are 
able to esterify only the (R)-enantiomer, leaving the unreacted acid in the S-form.
38
 
 
 
 
Fig. 21 Enantioselective esterification of the 3-benzothio-2-methylpropanoic acid  
 
An early chirogenic step has been introduced by oxidation of different meso 
compunds, as shown in Figure 22. (R)-3-hydroxy-2-methylpropanoic acid has been 
obtained by hydroxylation of isobutyric acid or by oxidation of 2-methyl-1,3-propanediol. 
Both the microbial oxidation proceeded with high yields and enantioselectivity. 
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Fig. 22 Oxidation of different molecules for obtaining the key intermediate for the synthesis of Captopril 
 
Also for the synthesis of the Monopril, biocatalitic strategies have been studied 
in order to obtain the (S)-monoacetate ester, key intermediate for the synthesis of this 
ACE-inhibitor. Lipases such as porcine pancreatic lipase (PPL), or that from 
Chronobacterium viscosum, stereoselectively hydrolyze diacetate esters as shown in Fig. 
23.
39
 
 
Fig. 23 Monopril and its key intermediate 
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2.1 Aim of the PhD project 
 
This PhD project is divided in two parts. The first one aims at exploring the 
biocatalytic capabilities of the whole cells of the unconventional yeast Pichia glucozyma 
CBS 5766, evaluating its reducing activity towards different substrates of pharmaceutical 
interest. The second one aims at isolation, biochemical characterization, cloning and over-
expression of one of the enzyme responsible for the stereoselective reduction of aromatic 
ketones.
Pichia glucozyma whole cells 
Pichia glucozyma whole cells 
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The investigation of Pichia glucozyma as whole cells biocatalyst   
 
3.1 Why yeasts? 
 
In recent times, because of their peculiar features and history, yeasts have 
become important experimental models in both microbiological and genetic research as 
well as the main characters in many pharmaceutical industrial fermentative production 
processes. For these reasons yeasts have a great importance both in science and in every 
days human life. The modern exploitation of yeast in biotechnology has found place in a 
wide range of different fields such as food/chemical industries, health-care industries, 
fundamental biological research, biomedical research, environmental technologies and 
fermentation industries.
40
 Such uses are also possible because of genetic modifications, 
especially for the strains of Saccharomyces cerevisiae, which is by now the best 
characterized yeast specie.
41
 The wide utilization of yeast in industrial processes goes 
together with the fact that since they are widely cultivated and the same time genetically 
well accessible, they have represented as an ideal model system. Multiple features make 
this simple eukaryote a model organism of choice. First of all, an increasing number of 
species are well genetically and genomically defined. Moreover, highly annotated online 
database have become available, which provide multitudes of detailed information on yeast 
genes and proteins. Yeast is easy to grow, with a doubling time relatively short and 
survives for long time in frozen glycerol stock. Other versatile characteristics of this 
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organism are the ease transformation and the ability to integrate genes by homologous 
recombination. Although not ubiquitous as bacteria, yeasts are widespread in the natural 
environment. Yeast cells lack chlorophyll (are not photosynthetic) and strictly 
chemoorganotrophic, meaning that they require fixed, organic forms of carbon for growth.  
Sources of carbon for yeast metabolism can be various such as sugars, polyols, organic 
fatty acids, aliphatic alcohols, hydrocarbons and different heterocyclic compounds. 
Furthermore, yeasts are usually growing well also at lower pH value than those that are 
optimal for bacteria, and they are insensitive to antibiotics that inhibit bacteria growth: that 
means the possibility to keep free of contamination by fast-growing bacteria yeast culture. 
Because of their large size yeast are more easily and cheaply harvested than bacteria. 
Regarding yeast taxonomy they are classified as plants and trees: strains are grouped into 
species, species are arranged into genera and genera in families. Families are assembled in 
orders and orders in classes and these ones in divisions. While some yeasts use exclusively 
aerobic respiration, others, in oxygen absence, can use an anaerobic respiration process, 
called fermentation. These yeast types produce energy by converting sugars in carbon 
dioxide and ethanol. In the alcoholic beverages fermentation the production of ethanol is 
useful, while in the leavened bread and derivates, the carbon dioxide raises the dough and 
ethanol evaporates.
42
 Respiration processes are more favourable from metabolic point of 
view and are the more used conditions for biocatalytic reactions. 
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3.2 Pichia glucozyma    
 
Pichia glucozyma (Hansenula glucozyma or Ogatea glucozyma) CBS 5766 is an 
unconventional yeast belonging to ascomycota phylum. It was isolated from parasites of 
Picea engelmanii, a typical North American fir.
43
 Macroscopically it appears between 
white and cream colour. Budding is its reproduction mode. In our laboratory this strain 
grows up in M5YE medium (5 g/L yeast extract dissolved in malt infusion) at 28°C in 48 
hours and it was conserved in frozen glycerol stocks.  
The increasing attention for this microorganism derives from its stereoselective 
reducing activity. In the last few years it was widely studied and employed as whole cell 
biocatalyst for obtaining optically pure products interesting from pharmaceutical point of 
view.  
   
Fig. 24 Whole cells of P. glucozyma (magnification 400X) 
 
3.3 Aromatic ketones and ketoesters as substrates  
 
Enantiomerically pure alcohols including α- β- and γ-hydroxyesters are 
important and valuable intermediates in the synthesis fine chemicals and pharmaceuticals
44
 
such as penem and carbapenem antibiotics, L-carnitine and inhibitors of HMG-CoA 
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reductase.
45
 They also can be considered synthons for the preparation of a large group of 
anti-depressants and α- or β-adrenergic drugs.46 Various synthetic methods have been 
investigated to obtain optically pure alcohols, α- β- and γ- hydroxyl acids and their 
derivates. Among these methods, a straightforward approach is the reduction of prochiral 
ketones to chiral alcohols. In this contest a different chemical catalysts such as metal 
complexes in particular Rhutenium, Rhodium and Iridium ones
47
, or organometallic 
reagents (DIBAL-H, BINAL-H)
48
 have been developed for the asymmetric ketones 
reduction. In comparison to metal hydride reducing agents (NABH4, LiAlH4) these 
reagents offer conveniences in handling and stoichiometric addition as well as major or 
completely stereoselectivity.  However, in many cases, some difficulties remain in the 
process operations and for obtaining the optically pure desired product. Moreover, residual 
metal in the final products originated by using metal catalysts presents another challenge 
because of ever more stringent regulatory restrictions on the level of metal allowed in 
pharmaceutical products.
49
 An alternative to chemical asymmetric reduction processes is 
the biocatalytic transformation with whole cells of yeasts, as said before, offers advantages 
such as mild and environmentally conditions, high chemo- regio- and stereoselectively, 
and being void a residual metal in the alcohols.  
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a b s t r a c t
The non-conventional yeast Pichia glucozyma CBS 5766 has been used for the biotransformation of
different aromatic ketones and ketoesters. The growth and biotransformation conditions were optimised
for the reduction of acetophenone and under optimised conditions, propiophenone, butyrophenone
and valerophenone were reduced to the corresponding (S)-alcohols with high yields and enantioselectiv-
ity. Ketoreductase(s) of Pichia glucozyma showed high catalytic activities also towards aromatic
b- and c-ketoesters, being often competitive with esterase(s). These concurrent activities allowed for
the preparation of hydroxyesters, hydroxyacids and lactones often in a very selective manner.
Ó 2014 Elsevier Ltd. All rights reserved.
The asymmetric reduction of prochiral ketones using isolated or
cell-bound ketoreductases is a well-recognised method for the
preparation of chiral alcohols.1 The major drawback encountered
with enzymatic reduction using isolated enzymes is the necessity
for cofactor recycling, which can be circumvented by two-enzyme
or one-enzyme recycling methodologies.2 Microbial whole cells
exhibit as a major advantage that cofactors are already present
and can be recycled via the oxidation of a second substrate (i.e.,
glucose or glycerol).3 Beside the easily available Saccharomyces
cerevisiae,4 other microbial species have been widely employed
for asymmetric reductions or more generally as sources for new
selective ketoreductases.5 However, there is still a need for new
biocatalysts able to perform stereoselective reductions with differ-
ent or ameliorated chemo-, regio- and stereoselectivity, especially
towards bulky substrates.6 Non-conventional yeasts are plentiful
sources of different carbonyl reductases and during our past works
on enantioselective carbonyl reduction we have found that whole
cells of the yeast Pichia glucozyma CBS 5766 (now reclassified as
Ogataea glucozyma) catalysed the stereoselective reduction of
different ketones, often showing remarkable results in terms of
stereoselectivity.7 In this work, we have studied in detail the
potential of whole cells of Pichia glucozyma CBS 5766 for the
biotransformation of various aromatic ketones and ketoesters
under optimised conditions.
Reduction of acetophenone (1a) was firstly studied with whole
cells of Pichia glucozyma grown using different culture media.
Experiments were performed with cells harvested after 24 and
48 h and suspended in phosphate buffer (0.1 M, pH 7) in the pres-
ence of 5% glucose. The best results were observed when P. glu-
cozyma was grown in a medium composed with malt extract and
0.5% yeast extract for 24 h: reduction of 1a with Pichia glucozyma
grown under these conditions, furnished (S)-1-phenylethanol
(2a) with good enantioselectivity (92%) and yield (70%). The
conditions of the sequential experimental trials aimed at the
optimisation of the biotransformation conditions were selected
employing the MultisimplexÒ 2.0 software;8 control variables were
biocatalyst and substrate concentrations, pH and temperature. The
best results in terms of yields and enantioselectivity were observed
employing 25 mg of dry cells and 20 mM substrate concentration,
in the presence of glucose (277 mM, 50 g/L) at pH 7.0 and 28 °C;
whole cell based specific activity towards acetophenone under
these conditions was 1.33 mmol/gdry cells min (see Supplementary
data for definition). The influence of different co-substrates (etha-
nol, glucose, glycerol, sucrose xylose at 50 g/L) was independently
assayed. The results obtained using glucose, glycerol and xylose
were very similar, while a slight decrease of enantioselectivity
was detected with ethanol.
http://dx.doi.org/10.1016/j.tetlet.2014.10.133
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Reduction of acetophenone (1a), propiophenone (1b), butyro-
phenone (1c) and valerophenone (1d) under optimised conditions
(resting cells 20 mgdry weight/ml suspended in phosphate buffer
0.1 M, pH 7 in the presence of 50 g/L of glucose) is reported in
Table 1.9 Reductions occurred with moderate to high conversion
and with reaction rates increasing when hydrophobicity of the
substrates was increased; high enantioselectivity was always
observed, giving the corresponding (S)-alcohol (Prelog rule). The
absolute configuration was determined by comparison with
reported chiral HPLC data.6a,7a
Aromatic b-ketoesters were also assayed (Table 2). It is known
that biotransformations of ketoesters with yeasts occur with com-
petition between ester hydrolysis and carbonyl reduction, due to
the occurrence of cell-bound esterase activities;10 this competitive
enzymatic activity can be modulated by using appropriate sub-
strate/co-substrate concentrations: with high co-substrate concen-
trations (e.g., glucose >50 g/L) the activity of ketoreductases is
generally predominant, as a consequence of redox cofactor regen-
eration, whilst esterase activity is mostly observed in the absence
of cosubstrates.7g The biotransformations were performed in opti-
mal conditions for favouring ketone reduction (50 g/L glucose;
Table 2).
The biotransformation of ethyl benzoylacetate 1e showed that
ketoreductase activity was predominant in the first part of the
biotransformation leading to (S)-ethyl-3-hydroxy-3-phenylpro-
panoate (2e, yield 87%, ee 86% after 4 h; Table 2, entry 1), which
was further enzymatically hydrolysed at a prolonged time (24 h),
giving optically pure (S)-3-hydroxy-3-phenylpropionic acid (3e)
and leaving low amounts of (R)-2e (ee 95%; Table 2, entry 2).
The absolute configuration of 2e and 3e was determined by
comparison with reported chiral chromatographic data.11,12 These
results can be explained by suggesting the occurrence of an
enantioselective esterase able to preferentially hydrolyse (S)-2e,
therefore leaving unreacted (R)-2e with high ee. Ethyl 2-methyl-
3-oxo-3-phenylpropanoate 1f was reduced to the corresponding
alcohol 2f with limited enantiomeric and diastereomeric excesses
(Table 2, entry 3); absolute configuration of 2f was determined
by comparison with reported chiral chromatographic data.6b, No
traces of ester hydrolysis were found even at prolonged times,
most likely due to the steric hindrance caused by the methyl in
2-position. Ethyl-2-(benzamidomethyl)-3-oxo-phenylpropanoate
(1g) was selectively reduced to ethyl-2-(benzamidomethyl)-3-
hydroxy-phenylpropanoate (2g); the biotransformation occurred
with higher conversion rate and yield than what was reported
before with cells used under non-optimised conditions of growth
and biotransformation (Table 2, entry 4).7g
Biotransformation of ethyl c-ketoesters 1h–i gave a mixture
of lactones and ketoacids (conversion and stereochemical
composition after 12 and 24 h, Table 3).
Biotransformation of ethyl 4-oxo-4-phenylbutanoate 1h gave a
prevalence of the corresponding ketoacid 3h (55%), whereas lactone
(S)-4h was obtained in 40% yield and low enantioselectivity (14%;
Table 3, entry 1). Racemic ethyl 2-methyl-4-oxo-4-phenylbutano-
ate 1i was resolved as a result of the action of enantioselective
esterase(s) with formation of the ketoacid (R)-3i (ee 82% at 44%
conversion), while reduction of the carbonyl afforded lactone
(3S,5S)-3-methyl-5-phenyldihydrofuran-2(3H)-one (4i) with high
diastereoselectivity and good enantioselectivity (Table 3, entry 2).
Stereochemical compositionswere determined by combining chiral
HPLC analysis and 1H NMR.13a–c
Table 1
Reduction of aromatic ketones (20 mM) with Pichia glucozyma CBS 5766
Entry Substrate Yield (%) ee 2 (%) Time (h)
1 1a 39 97 (S) 4
2 1a 90 97 (S) 18
3 1b 28 97 (S) 1
4 1b 97 97 (S) 6
5 1c 41 >98 (S) 1
6 1c 96 >98 (S) 4
7 1d 46 >98 (S) 1
8 1d 97 >98 (S) 4
Biotransformations were carried out with freshly prepared cells (50 mgdry weight/ml)
suspended in phosphate buffer (0.1 M, pH 7) in the presence of 5% glucose. Enan-
tiomeric excesses were determined by chiral HPLC analysis (see Supplementary
data for details).
Table 2
Reduction of aromatic ethyl b-ketoesters (20 mM) with Pichia glucozyma CBS 5766
Entry Substrate 2 3
Yield (%) ee (%) de (%) Yield (%) ee (%) Time (h)
1 1e 87 86(S) — <5 — 4
2 1e 14 95(R) — 75 >97(S) 24
3 1f 96 80(S) 34(2S,3S) 0 — 24
4 1g 95 >98(S) 70(2R,3S) 0 — 16
Biotransformations were carried out with freshly prepared cells (50 mgdry weight/ml) suspended in phosphate buffer (0.1 M, pH 7) in the presence of 50 g/L glucose.
Stereochemical compositions were determined by chiral HPLC analysis (see Supplementary data for details).
Table 3
Biotransformation of ethyl c-ketoesters with P. glucozyma
Substrate 3 4
Yield (%) ee (%) Yield (%) ee (%) de (%) Time (h)
1 1h 55 — 40 14(S) 12
2 1i 44 82(R) 40 70 92(3S,5S) 24
Biotransformations were carried out with freshly prepared cells (50 mgdry weight/ml)
suspended in phosphate buffer (0.1 M, pH 7) in the presence of 50 g/L glucose.
Stereochemical compositions were determined by chiral HPLC analysis (see Sup-
plementary data for details).
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For the preparation of c-hydroxyester by microbial reduction,
we decided to test the activity of Pichia glucozyma using (enzymat-
ically) difficult to hydrolyse tert-butyl c-ketoesters (Table 4).
Reduction of tert-butyl 4-oxo-4-phenylbutanoate (1l) gave
(S)-tert-butyl 4-hydroxy-4-phenylbutanoate (2l) with sluggish
enantioselectivity (Table 4, entry 1), whereas the formation
of the corresponding c-lactone was not observed; tert-butyl
2-methyl-4-oxo-4-phenylbutanoate (1m) was also converted into
tert-butyl 4-hydroxy-2-methyl-4-phenylbutanoate 2m, as the only
detectable product (70% yield after 24 h) affording the syn- and
anti-diastereomers (2R,4S)-2m and (2S,4S)-2m with 75% ee
(Table 4, entry 2). The stereochemical composition of 2m was
determined after purification of the four stereoisomers by
preparative chiral HPLC. Relative configuration of the syn- and
anti-diastereomers was assigned by 1H NMR,13c whereas compari-
son of the retention times in chiral HPLC with literature data13d
allowed for assignment of the absolute configuration.
In conclusion, we have shown that whole cells of Pichia glu-
cozyma CBS 5766 can be used for the enantioselective reduction
of different aromatic ketones; enantioselectivity towards simple
aromatic ketones under optimised conditions is sometimes
remarkable. Enantioselectivity was generally lower with c-ketoest-
ers respect to b-ketoesters; the occurrence of competitive esterase
activities can be modulated by choosing the best biotransformation
conditions and/or the suited substrate, turning whole cells of
P. glucozyma into a useful system for multistep reactions.
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.tetlet.2014.10.133.
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Table 4
Biotransformation of tert-butyl c-ketoesters with P. glucozyma
Entry Substrate 2
Yield (%) ee (%) de (%) Time (h)
1 1l 60 10(S) 18
2 1m 70 75(S) <5 24
Biotransformations were carried out with freshly prepared cells (50 mgdry weight/ml)
suspended in phosphate buffer (0.1 M, pH 7) in the presence of 50 g/L glucose.
Stereochemical compositions were determined by chiral HPLC analysis (see
Supplementary data for details).
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1. General 
 
1H-NMR and 13C-NMR spectra were recorded with a Varian Mercury 300 (300 
MHz) spectrometer. Chemical shifts (δ) are expressed in ppm, and coupling 
constants (J) are expressed in Hz. 
 
Gas chromatography (GC) analyses were performed with a Dani 6500 gas 
cromatograph: gas carrier H2 (0.6 bar, T=100°C), Detector FID (Flame 
Ionization Detector), Tmax = 300°C. The following chiral capillary GC columns 
were used: DMePeBeta-CDX-PS086 (diameter 0.25 mm, length 25 m, thickness 
0.25 μ, MEGA), Mega-Dex DET beta (diameter 0.25 mm, length 25 m, thickness 
0.25 lm, MEGA). 
HPLC analyses were performed with a Jasco Pu-980 equipped with a UV-vis 
detector Jasco UV-975. The following chiral HPLC columns were used: Lux 
Amylose-2 column (150 x 4.6 mm, Phenomenex), Chiralcel OD (250 x 4.6 mm, 
Daicel), Chiralcel OD-H (250 x 4.6 mm, Daicel), Chiralpack AD-H (250 x 4.6 mm, 
Daicel), Chiralpack AD (250 x 4.6 mm mm, Daicel). All the columns were 
equipped with a 80 x 4 mm precolumn.  
Preparative HPLC was performed with a 1525 Extended Flow Binary HPLC pump, 
equipped with a Waters 2489 UV-vis detector and Phenomenex Lux-Amylose-2 
column (21.2 x 250 mm) at flow rate of 15 mL/min. 
  
1. Substrates 
 
 
Substrates 1a-e were from Aldrich.  
 
 
Substrates 1f1 and 1g2 was prepared according to the literature methods. 
 
 
Substrates 1h and 1i were prepared from commercially available 4-oxo-4-
phenylbutanoic acid and 2-methyl-4-oxo-4-phenylbutanoic acid (Aldrich), 
respectively, using conventional Steglich esterification. Typical procedure: 37.5 mg 
of 4-dimethylaminopyridine (4-DMAP) and 610 mg of dicyclohexylcarbodiimide 
(DCC) were added to a stirred solution of 2-methyl-4-oxo-4-phenylbutanoic acid 
(500 mg) in dry CH2Cl2 (20 mL) at 4°C. The reaction mixture was stirred for 2 h at 
room temperature and then paper-filtered and the filtrate evaporated at 35 °C under 
vacuum. The residue was purified by flash chromatography (n-hexane/EtOAc = 
98:2) to give 478 mg of pure 1i (84%) as a colourless liquid. 
 
Ethyl 4-oxo-4-phenylbutanoate 1h: 1H-NMR (CDCl3, 300 MHz) (A): δ 1.26 (t, 
J= 7.2 Hz, 3H), 2.75 (t, J= 6.4 Hz, 2H), 3.31 (t, J= 6.4 Hz, 2H), 4.15 (q, J= 7.2 Hz, 
2H), 7.46 (dd, J1= 7.8 Hz, J2=  7.2 Hz, 2H), 7.56 (t, J= 7.2 Hz, 1H), 7.98 (d, J= 7.8 
Hz, 2H) ppm. 13C-NMR (CDCl3, 75.5 MHz) (A): δ 14.1, 28.2, 33.3, 60.6, 128.0, 
128.5, 133.1, 136.6, 172.8, 198.1 ppm. 
 
Ethyl 2-methyl-4-oxo-4-phenylbutanoate 1i: 1H-NMR (CDCl3, 300 MHz) (A): δ 
1.26 (t, J= 7.0 Hz, 3H), 1.33 (d, J= 7.0 Hz, 3H), 3.02 (dd, J1=17.3, J2= 5.6, 1H), 
3.08-3.18 (m, 1H), 3.48 (dd, J1= 17.3, J2= 7.6, 1H ), 4.15 (q, J= 7.0, 2H), 7.39 (dd, 
J1= 8.0 Hz, J2= 7.4 Hz, 2H), 7.50 (t, J= 7.4, 1H), 7.90 (d, J= 8.0, 2H) ppm. 13C-
NMR (CDCl3, 75.5 MHz) (A): δ 14.4, 17.5, 35.3, 42.2, 60.8, 128.3, 128.8, 133.3, 
137.7, 176.1, 198.3 ppm.  
 
 
Substrates 1l and 1m were prepared from commercially available 4-oxo-4-
phenylbutanoic acid and 2-methyl-4-oxo-4-phenylbutanoic acid (Aldrich) using 
tert-butyl trichloroacetamidate as esterification reagent.3 Typical procedure: tert-
butyl trichloroacetamidate (1.364 g) and BF3-Et2O (62 mg) were added to a stirred 
solution of 4-oxo-4-phenylbutanoic acid (600 mg) in dry CH2Cl2 (18 mL) and dry 
THF (10 mL) at room temperature. The reaction mixture was stirred for 21 hours at 
room temperature and then evaporated under reduced pressure; 10 mL of CH2Cl2 
were added to the crude residue and the solution washed with 10 mL of an aqueous 
solution (5%) of NaHCO3.  The aqueous phase was re-extracted twice with 10 mL 
of CH2Cl2 and the collected organic extracts were dried over Na2SO4 and the 
solvent evaporated. The crude residue was purified by flash chromatography (9:1 
hexane:EtOAc) giving 700 mg (78%).  
tert-Butyl 4-oxo-4-phenylbutanoate (1l) Colourless oil; 1H-NMR (CDCl3, 300 
MHz) (A): δ 1.45 (s, 9H), 2.68 (t, J= 7.0 Hz, 2H), 3.26 (t, J= 7.0, 2H), 7.45 (dd, J1= 
8.0 Hz, J2=  7.2 Hz,, 2H), 7.57 (t, J= 7.2 Hz, 1H), 7.98 (d, J= 8.0 Hz, 2H) ppm. 13C-
NMR (CDCl3, 75.5 MHz) (A): δ 28.2, 29.4, 33.3, 80.6, 128.0, 128.5, 133.1, 136.6, 
172.8, 198.1 ppm. 
tert-Butyl 2-methyl-4-oxo-4-phenylbutanoate (1m) White solid, m.p. 59-60 °C; 
1H-NMR (CDCl3, 300 MHz) (A): δ 1.25 (d, J= 7.0 Hz, 3H), 1.44 (s, 9H), 2.90-3.10 
(m, 2H), 3.42 (dd, J1= 17.2 Hz, J2= 7.6 Hz, 1H), 7.45 (dd, J1= 7.8 Hz, J2= 7.4 Hz, 
2H), 7.55 (t, J= 7.4, 1H), 7.98 (d, J= 7.8, 2H) ppm. 13C-NMR (CDCl3, 75.5 MHz) 
(A): δ 17.6, 28.2, 35.3, 42.2, 80.2, 128.3, 128.8, 133.3, 137.7, 176.1, 198.3 ppm.  
  
 2. Preparation of the biocatalyst and set-up of biotransformations 
 
Preparation of the biocatalyst 
Pichia glucozyma CBS 5766 was cultured using different media in 3.0 L 
fermenters with 1.0 L of liquid medium for 24 and 48 h, at 28°C and agitation 
speed 100 rpm The liquid media used were:  
1) malt extract medium (malt broth pH 6.0);  
2) malt extract + 0.5% yeast extract medium (malt broth, yeast extract 5 g/L, pH 
6.0);  
3) malt extract + 5% yeast extract medium (malt broth, yeast extract 50 g/L, pH 
6.0);  
4) YPD medium (yeast extract 10 g/L, peptone 20 g/L, glucose 20 g/L, pH 5.6).  
Fresh cells from submerged cultures were centrifuged and washed with 0.1 M 
phosphate buffer, pH 7.0 prior the use for biotransformations. 
 
Biotransformations 
Reductions were carried out in 100 mL screw-capped test tubes with a reaction 
volume of 50 mL with cells (25-75 g/L, dry weight) suspended in 0.1 M phosphate 
buffers with pH ranging from 5.8 to 8.0 with or without the addition of different 
co-substrates (ethanol, glucose, glycerol, sucrose, xylose) in concentration of 50 
g/L. After 30 min of incubation, neat substrates were added and the incubation 
continued for 24 h under magnetic stirring. When the reaction was over, pH was 
brought to pH 1 by the addition of 1 M HCl and 35 mL of EtOAc were added and 
the resulting mixture was shaken and centrifuged; the aqueous phase was extracted 
twice more with 35 ml of EtOAc. The organic phases were collected and dried over 
Na2SO4 and the solvent was evaporated. The crude residues were purified by flash 
chromatography.  
  
1. Analytical data of the products 
 
Chiral HPLC analyses for determination of e.e. of 2a-2d 
Compound Column Conditions (λ 254 nm) Retention times 
(min) 
 
2a  
Chiralcel OD n-hexane/2-propanol 97/3 
flow 0.7 ml/min 
14.8 (R), 18.0 (S) 
 
2b  
Chiralcel 
OD-H 
n-hexane/2-propanol 96/4 
flow 0.5 ml/min 
17.6 (R), 21.4 (S) 
 
2c   
Chiralcel 
OD-H 
n-hexane/2-propanol 96/4 
flow 0.5 ml/min 
16.4 (R), 17.5 (S) 
 
2d 
Chiralcel 
OD-H 
n-hexane/2-propanol 96/4 
flow 0.5 ml/min 
15.9 (R), 16.8 (S) 
 
2.  
 
 
Ethyl-3-hydroxy-3-phenylpropanoate (2e) was purified by flash chromatography 
(9:1 hexane:EtOAc). 1H-NMR (CDCl3, 300 MHz): δ 1.26 (t, J= 7.2 Hz, 3H), 2.80-
2.90 (m, 2H), 3.30 (d, J= 3.3 Hz, 1H), 4.20 (q, J= 7.2 Hz, 2H), 5.10-5.20 (m, 1H), 
7.22-7.42 (m, 5H) ppm. 13C-NMR (CDCl3, 75.5 MHz): δ 14.3, 43.4, 60.9, 70.3, 
125.5, 127.6, 128.3, 142.2, 172.1 ppm. [α]D25 = -47.2 (c=1.0 CHCl3); lit. = -52 
(c=1.0 CHCl3).4 Chiral GC analysis using a Mega-Dex DET beta column using the 
following temperature program: 3 min at 70 °C, increased to 170 °C over 25 min 
and then held at 170 °C for 10 min; tr (S)-2e = 22.1 min; tr (R)-2e = 22.4 min. Anal. 
calcd for C11H14O3: C, 68.02; H, 7.27; found: C, 67.83; H, 7.64. 
 
 
 
3-Hydroxy-3-phenylpropionic acid (3e) was purified by flash chromatography 
(99:1 EtOAc:AcOH). 1H-NMR (C3D6O, 300 MHz): δ 2.67 (dd, J1= 15.3 Hz,  J2= 
4.8 Hz, 1H), 2.71 (dd, J1= 15.3 Hz,  J2= 8.5 Hz, 1H), 5.19 (dd, J1= 8.5  Hz,  J2= 4.8  
Hz, 1H), 7.25 (dd, J1= 8.0 Hz, J2= 7.2 Hz, 2H), 7.33 (t, J= 7.2 Hz, 1H), 7.39 (d, J= 
8.0 Hz, 2H) ppm. 13C-NMR (C3D6O, 75.5 MHz): δ 42.5, 70.2, 124.7, 127.5, 128.2, 
145.0, 174.3 ppm. [α]D25 = -20.0 (c=0.5, CH3OH); lit. [α]D23 –21.9 (c 4, MeOH).5 
The stereochemical outcome of the reaction was monitored by GC after treatment 
of the organic extracts with CH2N2. Chiral GC was performed using a Mega-Dex 
DET beta column using the following temperature program: 3 min at 70 °C, 
increased to 170 °C over 25 min and then held at 170 °C for 10 min; tr (S)-3e = 
10.9 min; tr (R)-3e = 11.3 min. Anal. calcd for C9H10O3: C, 65.05; H, 6.07; found: 
C, 64.80; H, 6.43. 
 
 
 
 
Ethyl 3-hydroxy-2-methyl-3-phenylpropanoate (2f) was purified by flash 
chromatography (8:2 hexane:EtOAc). 1H-NMR syn-product (CDCl3, 300 MHz): δ 
1.15 (d, J= 7.1 Hz, 3H), 1.21 (t, J= 7.1 Hz, 3H), 2.35 (m, 1H, OH), 2.75-2.80 (m, 
1H), 4.12 (m, 2H), 5.10 (d, J= 4.4 Hz, 1H), 7.30-7.40 (m, 5H) ppm. 13C-NMR syn-
product (CDCl3, 75.5 MHz): δ  10.8, 14.0, 46.4, 60.7, 73.7, 125.5, 128.0, 128.3, 
141.4, 175.9 ppm. 1H-NMR anti-product (CDCl3, 300 MHz): δ 1.00 (d, J= 7.1 Hz, 
3H), 1.25 (t, J= 7.1 Hz, 3H), 2.35 (m, 1H, OH), 2.72–2.81 (m, 1H), 4.17 (q,  J= 7.1 
Hz, 2H), 4.73 (dd, J1 = 8.4 Hz, J2= 4.5 Hz, 1 H), 7.24–7.36 (m, 5H) ppm. 13C-NMR 
anti-product (CDCl3, 75.5 MHz): δ 14.1, 14.4, 47.1, 60.7, 76.3, 126.6, 128.0, 
128.4, 141.6, 175.9 ppm. Chiral HPLC was performed with a Chiralcel OD-H 
column using n-hexane/2-propanol 97/3, flow 0.8 ml/min, λ= 216 nm: tr (2R,3R)-2f 
= 13.4 min; tr (2S,3S)-2f = 15.2 min; tr (2R,3S)-2f = 17.8 min; tr (2S,3R)-2f = 26.5 
min. Anal. calcd for C12H16O3: C, 69.21; H, 7.74; found: C, 68.96; H, 8.07. 
 
 
 
Ethyl-2-(benzamidomethyl)-3-hydroxy-phenylpropanoate (2g) was purified by 
flash chromatography (3:7 cyclohexane:EtOAc). 1H-NMR (CDCl3, 300 MHz): δ 
1.01 (t, J= 7.0 Hz, 3H,), 3.15–3.24 (m, 1H, anti diastereoisomers), 3.61–3.69 (m, 
2H), 3.98 (q, J= 7.0, 2H), 4.12–4.18 (m, 2H), 4.95 (d, J= 7.3 Hz, 1H,), 6.72 (br s, 
1H), 7.29–7.53 (m, 8H), 7.65-7.82 (m, 2H); 13C-NMR (CDCl3, 75.5 MHz): δ 14.0 
38.0 53.0 61.1 72.6 126.4–132.0 173.5. Chiral HPLC was performed with a 
Chiralpack AD column using n-hexane/2-propanol 90/10, flow 0.6 ml/min, λ= 230 
nm: tr (2S,3R)-2g = 49.3 min; tr (2R,3S)-2g = 67.9 min. Anal. calcd for C19H21NO4: 
C, 69.71; H, 6.47; N, 4.28; found: C, 69.53; H, 6.72; N, 4.12.  
 
 
 4-Oxo-4-phenylbutanoic acid (3h) was purified by flash chromatography (99:1 
EtOAc:AcOH). 1H-NMR  (CDCl3, 300 MHz) (C): δ 2.81 (t, J= 6.6 Hz,  2H),  3.32 
(t, J= 6.6 Hz, 2H), 7.42-7.58 (m , 3H), 7.96-8.00 (m, 2H) ppm. 13C-NMR (CDCl3, 
75.5 MHz) (C): δ 28.2, 33.4, 128.3, 128.9, 133.6, 136.65, 178.8, 198.0 ppm. Anal. 
calcd for C10H10O3: C, 67.41; H, 5.66; found: C, 67.14; H, 5.94. 
 
 
 
(S)-5-phenyldihydrofuran-2(3H)-one (4h) was purified by flash chromatography 
(85:15 hexane:EtOAc). 1H-NMR  (CDCl3, 300 MHz) (B): δ  2.20 (m, 1 H), 2.67 
(m, 3H), 5.50 (dd, J1= 8.0 Hz,  J2= 6.3 Hz , 1H), 7.37 (m, 5H) ppm. 13C-NMR 
(CDCl3, 75.5 MHz) (B): δ 29.0, 31.0, 81.3, 125.4, 128.5, 128.9, 139.5, 178.0 ppm. 
Chiral GC was performed using a Mega-Dex DET beta column using the following 
temperature program: 1 min at 110 °C, increased to 170 °C over 15 min and then 
held at 170 °C for 10 min; tr (S)-4h = 16.4 min; tr (R)-4h = 16.6 min. Anal. calcd 
for C10H10O2: C, 74.06; H, 6.21; found: C, 73.72; H, 6.49. 
 
 
2-Methyl-4-oxo-4-phenylbutanoic acid (3i) was purified by flash chromatography 
(99:1 EtOAc:AcOH).  1H-NMR (CDCl3, 300 MHz) (D): δ 1.24 (d, J= 7.0, 3H), 
3.00-3.21 (m, 2H), 3.50 (dd, J1= 16.9,  J2=7.0, 1H ), 7.50 (dd, J1= 8.0 Hz, J2= 7.4 
Hz, 2H), 7.60 (t, J= 7.4, 1H), 7.90 (d, J= 8.0, 2H) ppm. 13C-NMR (CDCl3, 75.5 
MHz) (D): δ 17.3, 35.0, 42.0, 128.3, 128.8, 133.5, 136.8, 182.1, 198.0 ppm. [α]D25 
= +13.0 (c=0.3, CHCl3); lit. [α]D25 = +21.1 (c= 0.8, CHCl3).6 The stereochemical 
outcome of the reaction was monitored by HPLC after treatment of the organic 
extracts with CH2N2. Chiral HPLC was performed with a Chiralcel AD column 
using n-hexane/2-propanol 95/5, flow 1.0 ml/min, λ= 254 nm. Anal. calcd for 
C11H12O3: C, 68.74; H, 6.29; found: C, 68.44; H, 6.53. 
 
 
 
3-Methyl-5-phenyldihydrofuran-2(3H)-one (4i) was purified by flash 
chromatography (9:1 hexane:EtOAc).  1H-NMR syn-product (CDCl3, 300 MHz): δ 
1.33 (d, J= 7.2 Hz, 3H), 1.79-1.93 (m, 1H),  2.75-2.89 (m, 2H), 5.36 (dd, J1= 10.7 
Hz,  J2= 5.3 Hz, 1H ), 7.30-7.44 (m, 5H) ppm. 13C-NMR syn-product (CDCl3, 75.5 
MHz): δ 15.4, 36.8, 41.4, 79.6, 126.2, 128.9, 129.2, 139.9, 179.6 ppm. 1H-NMR 
anti-product (CDCl3, 300 MHz): δ 1.27 (d, J= 7.3 Hz, 3H), 2.24-2.45 (m, 2H), 
2.67-2.75 (m, 1H), 5.51(dd, J1= 7.6 Hz, J2= 5.4 Hz, 1H ), 7.25-7.37 (m, 5H) ppm. 
13C-NMR anti-product (CDCl3, 75.5 MHz): δ 15.5, 33.7,  38.4, 77.8, 126.6, 128.7, 
129.0, 138.4, 179.7 ppm. Chiral HPLC was performed with a Lux Amylose-2 
column using n-hexane/2-propanol 90/10, flow 1.0 ml/min, λ= 220 nm. tr (3R,5S)-
4i = 10.5 min; tr (3R,5R)-4i = 11.6 min; tr (3S,5R)-4i = 12.4 min; tr (3S,5S)-4i = 13.0 
min. Anal. calcd for C11H12O2: C, 74.98; H, 6.86; found: C, 74.60; H, 7.11 . 
 
 tert-Butyl 4-hydroxy-4-phenylbutanoate (2l) was purified by flash 
chromatography (9:1 hexane:EtOAc). 1H-NMR (300 MHz, CDCl3) (B): δ 1.44 (s, 
9H), 2.00 (t, J= 7.0 Hz, 2H), 2.34 (t, J= 7.0 Hz, 2H), 4.7 (t, J= 6.5 Hz, 1H), 7.17-
7.31(m, 5H) ppm. 13C-NMR (75.5 MHz, CDCl3): δ 28.2, 32.0, 33.3, 72.3, 80.7, 
126.0, 127.5,  128.5, 143.6, 172.8 ppm. Chiral HPLC was performed with a 
Chiralcel AD column using n-hexane/2-propanol 98/2, flow 1.0 ml/min, λ= 220 
nm. tr (R)-2l= 21.9 min; tr (S)-2l = 23.0 min. Absolute configuration was assigned 
by comparison with previously reported chiral HPLC data.7 Anal. calcd for 
C11H12O2: C, 71.16; H, 8.53; found: C, 70.94; H, 8.70. 
 
 
tert-Butyl 4-hydroxy-2-methyl-4-phenylbutanoate (2m) was purified by flash 
chromatography (9:1 hexane:EtOAc). 1H-NMR syn-product (CDCl3, 300 MHz): δ 
1.15 (d, J= 7.2 Hz, 3H), 1.47 (s, 9H), 1.81 (ddd, J1= 13.9 Hz, J2= 9.1 Hz, J3= 4.4 
Hz, 1H), 2.04 (ddd, J1= 13.6 Hz, J2= 9.6 Hz, J3= 3.7 Hz, 1H), 2.54-2.66 (m, 1H), 
4.78 (dt, J1= 9.1 Hz, J2= 3.7 Hz, 1H), 7.27-7.37 (m, 5H) ppm. 13C-NMR syn-
product (CDCl3, 75.5 MHz): δ 18.0, 28.3, 37.5, 43.2,  73.0, 80.3, 125.3, 127.2, 
128.2, 144.1, 175.7 ppm. 1H-NMR anti-product (CDCl3, 300 MHz): δ 1.80 (d, J= 
7.0 Hz, 3H), 1.46 (s, 9H), 1.69 (ddd, J1= 14.0, J2= 11.1, J3= 5.2, 1H), 2.19 (ddd, 
J1= 17.0, J2= 14.0, J3= 8.3, 1H), 2.50-2.57 (m, 1H) 4.73 (dt, J1= 11.1 Hz, J2= 8.3 
Hz, 1H), 7.25-7.37 (m, 5H) ppm. 13C-NMR anti-product (CDCl3, 75.5 MHz): 
18.15, 28.3,  38.3,  43.1, 72.2,  80.3, 125.5, 127.3,  128.1, 144.2,  176.0 ppm. Chiral 
HPLC was performed with a Chiralpack AD-H column using n-hexane/2-propanol 
97/3, flow 1.0 ml/min, λ= 220 nm. tr (2S,4R)-2m = 12.0 min; tr (2R,4S)-2m = 12.8 
min; tr (2S,4S)-2m = 13.8 min; tr (2R,4R)-2m = 15.5min. The stereochemical 
composition of 2m was determined after purification of the four stereoisomers by 
preparative chiral HPLC using a Phenomenex Lux-Amylose-2 column (21.2 x 250 
mm) at flow rate of 15 mL/min. Relative configurations was determined by 1H 
NMR,8 while absolute configuration by comparison with previously reported chiral 
HPLC data.7 Anal. calcd for C11H12O2: C, 71.97; H, 8.86; found: C, 71.71; H, 9.03. 
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Importance of Prostaglandins and their analogues  
 
4.1 Prostaglandins and inflammation 
 
Inflammation is the immune system’s response to infection and damage and it is 
implicated in the generation of various pathologies such as arthritis, cancer, stroke as well 
as neurodegenerative and cardiovascular diseases. Inflammation is an intrinsically 
beneficial event because of the possibility to remove the offending factors and to restore 
tissues and physiological functions.
50
 The cardinal signs of acute inflammation are: 
 rubor (redness) caused by vasodilatation which produces the increasing of 
blood amount and the decreasing of blood rate flow in the injured area 
 calor (heat) caused by temperature and increased metabolism 
 dolor (pain) for biochemical local alterations 
 tumor (swelling) produced by increasing of vascular permeability 
responsible for leakage of plasma proteins from vascular bed  
 functio laesa (function inhibition) because of imbalances induced by 
inflammatory mechanisms.
51
 
The usual outcome of acute inflammation is a good resolution with restoration of 
tissue damage and recovery of organ function.
52
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 Prostaglandins, and more in general eicosanoids, whose biosynthesis is 
significantly increased in inflamed tissue, play a key role in the genesis of the 
inflammatory response because of their contribution to development of the cardinal signs 
of acute inflammation.  
 
4.2 Eicosanoids biosynthesis  
 
Prostaglandins and tromboxane A2 (TXA2), collectively termed eicosanoids, 
belong to the family of autacoids, substances released by cells into the extracellular 
environment where they induce biological responses by interacting with specific receptors 
on the cell that generated them or on cells in the immediate vicinity. They are synthesized 
from arachidonic acid, a 20-carbon unsatured fatty acid present in the cell membranes as 
an ester of phosphatidylinositol or other membrane phospholipids. It is released by 
phospholipase A2 able to attack the C2 position of the phospholipids generating 
monoglyceride phosphate and one molecule of arachidonic acid (Fig. 25).
53
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Fig. 25 PLA2 activity and arachidonic acid 
 
The term eicosanoids stands for several inflammatory mediators characterized 
by having a short plasma half-life as rapidly synthesized on demand and quickly 
inactivated by enzymes. The most important are leukotrienes and three types of 
prostanoids: prostaglandins, prostacyclin and thromboxanes. Prostanoids production (Fig. 
26) depends on the activity of COXs, bifunctional enzymes that contain both 
cyclooxygenase and peroxidase activity and which exist as distinct isoforms referred to as 
COX-1 and COX-2.
54
 COX-1, expressed constitutively in most cells, is the predominant 
source of prostanoids involved in homeostasis for example in gastric epithelial 
cytoprotection. COX-2, induced by inflammatory stimuli, is the most important source of 
prostanoid involved in inflammation and in pathogenesis of various diseases.
55
 However, 
both enzymes contribute to the production of healthy prostanoids, and both can contribute 
to their release during inflammation. 
The conversion of arachidonic acid takes place by means the uptake of two 
molecules of oxygen and cyclization of the hydrocarbon chain (cyclooxygenase activity), 
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followed by the reduction of hydroperoxide group into hydroxide one, crucial for 
biological activity and the generation of oxygen free radical (peroxidase activity).  
 
 
 
Fig. 26 Biosynthetic pathway of prostanoids 
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By further enzymatic modifications of PGH2 the following prostanoids will be 
obtained: 
TXA2: it is predominantly produced by platelets and the renal cortex. It is 
responsible for platelets aggregation, vasoconstriction, decreased blood flow and 
glomerular filtration rate. 
PGI2: it is produced mainly by the vessel wall and from the renal cortex. It 
regulates tone of smooth muscles inducing vasodilation and increasing the renal blood 
flow and glomerular filtration. 
PGD2, PGE2, PGF2: they are produced mainly by monocyte - macrophages, 
hypothalamus, renal medulla, uterus and gastric cells. They regulate the decreasing of 
smooth muscle tone, gastric secretions, the increasing of body temperature, the release of 
neurotransmitters in the nervous system, the decreasing of the pain threshold. 
 
4.4 Prostanoids receptors  
 
Prostanoids exert their effect by activating seven transmembrane spanning G-
protein coupled receptors (GPCRs). They can be grouped in different classes according to 
their trasduction signal Tab. 3.  
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Table 3 Signal transduction of prostanoid receptors 
 
While EP2, EP4, IP and DP receptors activate adenylyl cyclase via Gs, 
increasing intracellular cAMP, EP1 and FP receptors activate phosphatidylinositol 
metabolism via Gq, increasing the formation of inositol triphosphate with mobilization of 
intracellular free calcium.
56
 TP receptors stimulating different types of G-proteins, activate 
various transduction pathways mediated by phospholipase C and by adenylate cyclase. On 
the contrary, EP3 and CRTH2 being inhibitory receptors, mediate the reduction of 
intracellular cAMP and elevate the concentration of intracellular Ca
2+
. 
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 However, the effects of prostanoids on these G protein–coupled signalling 
pathways may change depending on the ligand function, concentration or structure
57
 (Fig. 
27)
58
.  
Fig. 27 Pathway of prostanoids 
Because of the numerous biological effects, prostaglandins have been subject of 
study and research for the synthesis of analogues, which could be potential drugs. PGs may 
57
S. Narumiya et al., J. Clin. Invest. 2001, 108, 25-30
58
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be useful in the therapy of several diseases. Open-angle glaucoma,
59
 characterized by 
increased intraocular pressure which causes poor blood flow and progressive damage of 
the optic nerve, ischemia caused by corneal vasoconstriction and blood hypo-perfusion of 
the primary structures of the eye, are examples. Moreover, the PGs involved in therapy of 
peptic duodenal ulcer
60
 provide an increased production of mucus and bicarbonate by the 
parietal cells of the stomach in order to decrease the acid level into the gastric lumen, 
characteristic of this disease. In addition, analogues of PGs are also used in obstetrics both 
to induce uterine contractions during labor because of the activity they have on smooth 
muscle and to induce abortion in combination with mifepristone.
61
 
 
4.5 PGF2α prostaglandin analogues as a potent and selective anti-glaucoma agents 
 
Glaucoma, is a progressive eye disorder, characterized by increasing of intraocular 
pressure (IOP), damage of the optic nerve, and gradual loss of vision. Initial therapy 
usually involves topical application of muscarinic agonists such as pilocarpine or 
adrenergic agonists and antagonists such as epinephrine and timolol, respectively. If 
treatment with such topically applied drugs is not effective, systemic administration of 
carbonic anhydrase inhibitors or surgical intervention may be employed.
60
 For over forty 
years, attention has been focused on PGs, particularly on PGF2α as IOP-lowering 
substances.
62
 Several studies indicate that PGF2α reduces IOP by increasing uveoscleral 
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outflow of aqueous humor.
63
 Thus, there has been a great deal of interest in developing 
synthetic PGF2α analogues with IOP-lowering efficacy. PGs and their pro-drugs, such as 
PGF2α isopropyl ester, not only are able to reduce IOP, but also cause conjunctival 
hyperemia, foreign-body sensation and superficial irritation
64
. The development of pro-
drugs of potent, selective synthetic prostaglandin FP receptors agonists as clinically 
effective IOP-lowering agents devoid of ocular side-effects has been an important advance 
in the glaucoma treatment.
65
 Phenyl substituted PGF2α analogues such as Latanoprost and 
Bimatoprost (Fig. 28) are the active ingredients of topically medications that have 
revolutionized the glaucoma therapy.  
 
 
 
 
Fig. 28 Structures of PGF2α and analogues 
 
In this context we have developed an alternative chemoenzymatic synthesis of 
analogues of PGF2α having potent and selective action in glaucoma treatment. Whole cells 
of Pichia glucozyma and of Pichia anomala have been proved excellent catalysts for the 
biosynthesis of key intermediates for the total synthesis of Latanoprost and Bimatoprost.
                                                          
63
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a  b s t  r  a  c  t
Bimatoprost (1)  and Latanoprost (2) are  prostaglandin  analogues widely  used  for glaucoma  treatment.
We have  developed a  new chemoenzymatic  synthesis for  1  and 2, which  utilizes  a highly  stereoselec-
tive  sequence  of  biotransformations  catalyzed  by enzymes  belonging to  a single  microorganism  (the
yeast  Pichia anomala).  The  original  synthesis, starting from (–)-Corey  lactone  benzoate  (3aR,4R,5R,6aS)-3,
was  modified  by replacing  three synthetic  steps  (C  C reduction,  stereoselective  C  O reduction  and
hydrolysis/deprotection  of  the benzoate ester)  with  a one-pot, three-enzymes  reaction. The overall
biotransformation  gave  good yields and it was highly stereoselective; noteworthy, by  engineering  the
reaction medium,  C C reduction  could be modulated  so that  unsaturated  (3aR,4R,5R,6aS,3′S)-6  or satu-
rated  intermediate  (3aR,4R,5R,6aS,3′R)-7  could be preferentially  obtained.
© 2014 Elsevier  B.V.  All  rights  reserved.
1. Introduction
Bimatoprost (1) and Latanoprost (2) (Scheme 1)  are
prostaglandin analogues used for controlling the progression
of glaucoma by reducing intraocular pressure and have become
billion-dollar drugs [1,2].  The industrial manufacture of Bimato-
prost and Latanoprost is  mostly based on variants of the original
strategy developed by Corey [3–9], although different synthetic
strategies have been proposed, including a  shorter stereocon-
trolled organocatalytic synthetic procedure recently reported
[10].  In the conventional route, the  key ketoprostaglandin
intermediate (3aR,4R,5R,6aS)-4 is  obtained by Horner-
Wadsworth–Emmons (HWE) condensation of (–)-Corey lactone
benzoate (3aR,4R,5R,6aS)-3 with the suited ketophosphonate. Key
intermediate (3aR,4R,5R,6aS)-4 is  then reduced by  chemoselective
hydrogenation (i.e. lithium selectride at low temperature) to
give the unsaturated secondary alcohol (3aR,4R,5R,6aS,3′S)-5 that
can be used for the synthesis of Bimatoprost after hydrolysis to
(3aR,4R,5R,6aS,3′S)-6 (also known as Lactondiol B); alternatively,
(3aR,4R,5R,6aS,3′S)-5 can be  reduced at the double bond with Pd/C
catalytic hydrogenation and hydrolyzed at the ester moiety to
∗ Corresponding author. Tel.: +39 0250319134; fax: +39 0250319148.
E-mail addresses: diego.romano@unimi.it, diegoromano76@gmail.com
(D. Romano).
furnish (3aR,4R,5R,6aS,3′R)-7 (also known as Lactondiol L), the
actual intermediate for Latanoprost synthesis (Scheme 1).
The transformations occurring in  the overall conversion of
(3aR,4R,5R,6aS)-4 into (3aR,4R,5R,6aS,3′S)-6 (C O  reduction and
ester hydrolysis) or into (3aR,4R,5R,6aS,3′R)-7 (C O and C  C
reduction, ester hydrolysis) can be also enzymatically catalyzed
(Scheme 1,  in blue colour); more specifically, enoate reduc-
tases catalyze the reduction of C  C  conjugated to an  electron
withdrawing group (such as C  O  groups) [11], dehydrogenases
(carbonyl reductases) catalyze the reduction of C  O  groups [12]
and esterases catalyze the hydrolysis of esters [13]. Microbial
reduction of (3aR,4R,5R,6aS)-4 into the corresponding alcohol
(3aR,4R,5R,6aS,3′S)-5 has been already reported using different
yeasts, with Kloeckera jensenii ATCC 20110 giving the best yields
[14].
In this work, we  have studied the possibility to set up a one-
pot biocatalytic method for the stereocontrolled transformation of
(3aR,4R,5R,6aS)-4 directly into (3aR,4R,5R,6aS,3′S)-6 (Lactondiol B)
or  (3aR,4R,5R,6aS,3′R)-7 (Lactondiol L) by using different yeasts.
2. Experimental
2.1. General experimental methods
All reagents and solvents were obtained from commercial sup-
pliers and were used without further purification. Merck Silica
Gel 60 F254 plates were used for analytical TLC;
1H and 13C
http://dx.doi.org/10.1016/j.molcatb.2014.05.022
1381-1177/© 2014 Elsevier B.V.  All rights reserved.
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Scheme 1. Synthetic routes to Bimatoprost and Latanoprost.
NMR  spectra were recorded on a  Varian-Gemini 200 spectrome-
ter. Flash column chromatography was performed on Merck Silica
Gel (200–400 mesh). 1H  and 13C chemical shifts are expressed in ı
(ppm) and coupling constants (J) in Hertz (Hz). MS analyses were
performed on a  Thermo-Finnigan LCQ ADVANTAGE mass spec-
trometer equipped with an electron spray ionization (ESI) source.
Microanalyses (C, H, N) of new compounds were within 0.4% of
theoretical values.
2.2. General procedures for microbial screening of  transformation
of 4
Eighteen yeasts were used in  the primary screening for LB  enone
4 modification; the strains were chosen among 12 yeasts known for
esterase and/or ketoreductase activity (Candida boidini CBS6056,
Kluyveromyces lactis CBS2359, Kluyveromyces marxianus CBS1553,
K. marxianus var. lactis CL69 Pichia anomala CBS110, Pichia etchellsii
MIM, Pichia glucozyma CBS 5766, S. cerevisiae CBS1782, S. cerevisiae
CBS3093, S. cerevisiae CBS3081, S. cerevisiae NCYC 73, S. cerevisiae
Zeus)11 and 6 strains with ketoreductase and/or enoate reductases
activity (S. cerevisiae BY4741, S.  cerevisiae BY47411Oye1, S. cere-
visiae BY47411Oye2, S. cerevisiae BY47411Oye2Cc, S.  cerevisiae
BY47411Oye2Ks, S. cerevisiae L12) [16,17,21].
Strains from official collections or  from our collection (Micro-
biologia Industriale Milano) were routinely maintained on M5YE
slants (Barley malt flour 100 g/L (Diagermal), 5  g/L yeast extract
(Difco), agar 15 g/L, pH 5.6). To obtain cells for biotransformations,
the microorganisms were cultured in  2  L Erlenmeyer flasks con-
taining 300 mL of M5YE liquid medium (Barley malt flour 100 g/L
(Diagermal), 5 g/L yeast extract (Difco), distilled water pH  5.6),
incubated for 48 h at 28 ◦C  on a  reciprocal shaker (150 spm). Fresh
cells from submerged cultures were centrifuged (5000 rpm, 20  min)
and washed with 0.1 M phosphate buffer, pH 7.0, prior to use.
Biotransformations were carried out in 10 mL screw-capped test
tubes with a  reaction volume of 3  mL  with cells (20 g/L, dry weight)
suspended in  0.1 M phosphate buffer, pH 7, containing 5% of glucose
and 1  g/L of 4, at 28 ◦C  under magnetic stirring (500 rpm).
2.3. Analyticals
Biotransformations were monitored by  HPLC. Samples (0.5 mL)
were taken at regular intervals, centrifuged and the aqueous phase
was extracted with an  equal volume of ethyl acetate; substrate and
product concentrations were  determined by HPLC using a Puro-
spher Star RP18e250*4.6 mm (5 mm)  (Merck, Darmstadt, Germany),
UV detection at 220 nm with a  Merck-Hitachi 655-22 detector
and CH3CN/H2O/MeOH (18/72/10) as eluent with a flow rate of
0.8 mL/min.
The retention time of substrates and products was: 4 =  29.0 min;
5  = 37.8 min; 6 =  58.2 min; 7/11 = 61.6 min; 8  =  22.7 min;
9 = 69.8 min; 10 =  76.7 min.
The stereochemical composition of 6 was  determined by HPLC
using a Pinnacle II silica 250*4.6 mm  (4 mm,  Restek, Bellefonte, PA,
US), UV detection at 220 nm with a Merck-Hitachi 655-22 detec-
tor and n-heptane/iPrOH (90/10) as eluent with a  flow rate of
1.5 mL/min.
Separation of isomers 7  and 11 was performed by  HPLC
using a  Phenomenex Lux Cellulose-1 column 250*4.6 mm (5 mm)
(Phenomenex, Torrance, CA, US), UV detection at 220 nm with a
Merck-Hitachi 655-22 detector and cyclohexane/iPrOH (85/15) as
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eluent with a flow rate of 1.0 mL/min. Diastereoisomers were iden-
tified by comparison with authentic reference materials chemically
synthesized.
2.4. Optimization studies
Optimization studies were carried out with P.  anomala CBS
110. The desired amount of cells was suspended in  different vol-
umes of 0.1 M phosphate buffers containing co-substrates and
neat substrate was added to reach the desired concentration; the
suspensions obtained were shaken (150 rpm) at different tem-
peratures. Samples of 100 mL  were withdrawn from the reaction
mixture, centrifuged, extracted with EtOAc (100 mL)  and analyzed
by HPLC.
2.5. Preparative scale synthesis
2.5.1. [(3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxy-5-
phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one]
(Lactondiol B, (3S)-6)
P. anomala CBS 110 was grown in  a 3.0 L fermenter with 1.5 L of
M5YE liquid medium for 48 h, 28 ◦C and agitation speed 150 rpm.
Fresh cells from submerged cultures were centrifuged and washed
with 0.1 M phosphate buffer, pH  7.0, resuspended in 0.5 L of phos-
phate buffer to reach 25 gdry cells/L concentration of cells and used
for biotransformations. Reactions were carried out in  2 L Erlen-
meyer flask by adding glycerol (25 g) and 4 (500 mg)  dissolved in 1%
of DMSO and keeping the reaction mixture under reciprocal shak-
ing (150 spm) at 28 ◦C. After 7 days, the biotransformation mixture
was centrifuged, and the aqueous supernatant was extracted twice
with EtOAc (350 mL); the organic extract was dried over Na2SO4
and the solvent was evaporated to give a crude mixture and the
single products were purified by flash chromatography (gradient
7:3; 5:5; 2:8 n-hexane/EtOAc), furnishing 6  (232 mg,  62%).
Colourless oil. Rf = 0.085 (n-hexane/EtOAc 4:6); [a]D
24 = −5.2
(c  = 1.00 CH3CN);
1H  NMR  (CDCl3,  200 MHz): ı 1.78–1.98 (m,
2H), 2.23–2.36 (m,  1H), 2.44–2.78 (m,  7H), 3.91 (q, J = 7.70, 1H,
CH2CHOHCH2),  4.07 (q, J  =  6.97, 1H, CHOH), 4.83–4.92 (m,  1H,
CHOC O), 5.44 (dd, J1 = 8.06, J2 = 15.40, 1H, Csp2-H), 5.62 (dd,
J1 = 6.60, J2 = 15.40, 1H, Csp2-H), 7.16–7.29 (m,  5H, Csp2-H).
13C NMR  (CDCl3,  50.4 MHz): ı  177.06 (C O), 141.79 (Csp2quat.),
136.65, 130.51 (Csp2-H), 128.68, 128.63, 126.20 (Csp2-H),
82.69 (OCHCH2), 76.74 (CHOH), 72.17 (CH2CHOHCH2), 56.39
(CH2CHCHCHOH), 42.69 (CH2CHCHCHOH), 40.05, 38.89, 34.38,
31.95 (CH2).
MS (ESI + m/z%): 325.3 [M++Na+]  (100).
2.5.2. [(3aR,4R,5R,6aS)-5-hydroxy-4-((R)-3-hydroxy-5-
phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-one)]
(Lactondiol L, (3R)-7)
P. anomala CBS 110 was grown in  a 3.0 L fermenter with 1.5 L of
M5YE liquid medium for 48 h, 28 ◦C and agitation speed 150 rpm.
Fresh cells from submerged cultures were centrifuged and washed
with 0.1 M phosphate buffer, pH 7.0, resuspended in  0.5 L of
phosphate buffer to reach 25 gdry cells/L  of cells and used for bio-
transformations. Reactions were carried out in 2  L  Erlenmeyer flask
by adding fumaric acid (719 mg)  and 4 (500 mg)  dissolved in 1%
of DMSO and keeping the reaction mixture under reciprocal shak-
ing (150 spm) at 28 ◦C. After 7 days, the biotransformation mixture
was centrifuged, and the aqueous supernatant was extracted twice
with EtOAc (350 mL); the organic extract was dried over Na2SO4
and the solvent evaporated to yield a  crude mixture and the prod-
ucts were purified by  flash chromatography (gradient 7:3; 5:5; 2:8
n-hexane/EtOAc), furnishing 7  (308 mg,  82%).
Colourless oil. Rf = 0.087 (n-hexane/EtOAc 4:6); [a]D
24 = −25.0
(c = 2.00 CH3CN);
1H NMR  (CDCl3,  200  MHz): ı  1.22–1.28 (m,  1H),
1.46–1.59 (m,  3H), 1.73–1.81 (m,  3H), 2.21–2.28 (m,  2H), 2.43–2.50
(m,  2H), 2.64–2.80 (m,  3H), 3.60–3.66 (m,  1H, CH2CHOHCH2), 3.97
(q, J  =  5.1 1H, CHOH), 4.88–4.96 (m,  1H, CHOC O), 7.16–7.27 (m,  5H,
Csp2-H).
13C NMR  (CDCl3, 50.4 MHz): ı  177.95 (C O), 142.13
(Csp2quat.), 128.68, 128.62, 126.15 (CHsp2),  84.20 (OCHCH2),
77.65 (CHOH), 71.52 (CH2CHOHCH2), 54.16 (CH2CHCHCHOH),
43.43 (CH2CHCHCHOH), 40.69, 39.31, 36.22, 35.43, 32.26, 29.18
(CH2).
MS (ESI +  m/z%): 327.3 [M++Na+]  (100).
2.5.3. [(3aR,4R,5R,6aS)-5-hydroxy-4-((E)-3-oxo-5-phenylpent-1-
en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one]
(9)
Intermediate 9 was obtained following the same procedure
described above, stopping the reaction after 4  days. The reaction
mixture was purified by flash chromatography (gradient 7:3; 1:1;
2:8 n-hexane/EtOAc), furnishing 9 (67 mg,  18%).
Brown oil. Rf =  0.28 (n-hexane/EtOAc 4:6);
1H NMR (CDCl3,
200 MHz): ı  1.97–2.10 (m,  1H), 2.39–2.56 (m,  3H), 2.67–2.97 (m,
6H), 4.10 (q,  J  =  6.90, 1H, CHOH), 4.90–4.98 (m,  1H, CHOC O), 6.15
(d, J  =  15.30, 1H,Csp2-H), 6.50 (dd, J
1 = 6.23, J2 = 15.33, 1H, Csp2-H),
7.20–7.32 (m,  5H, Csp2-H).
13C NMR  (CDCl3, 50.4 MHz): ı  198.94 (C O), 176.34 (OC  O),
144.47 (CHsp2)  141.12 (Csp2quat.), 131.79, 128.74, 128.63, 126.43
(CHsp2), 82.62 (OCHCH2), 76.78 (CHOH), 56.32 (CH2CHCHCHOH),
42.60 (CH2CHCHCHOH), 42.82, 40.64, 34.62, 30.26 (CH2).
Anal. calcd for C18H20O4: C 71.98, H 6.71; found: C 71.59, H 6.93.
MS (ESI +  m/z%): 301.2 [M+] (70).
2.5.4. [(3aR,4R,5R,6aS)-2-oxo-4-(3-oxo-5-
phenylpentyl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate]
(8) and [(3aR,4R,5R,6aS)-5-hydroxy-4-(3-oxo-5-
phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-one]
(10)
S. cerevisiae BY47411Oye2Ks was grown in  a 3.0 L  fermenter
with 1.5 L of M5YE liquid medium for 48 h, 28 ◦C  and agitation speed
150 rpm. Fresh cells from submerged cultures were centrifuged
and washed with 0.1 M phosphate buffer, pH 7.0, resuspended in
0.5 L of phosphate buffer to reach 20 gdry  cells/L concentration of
cells and used for biotransformations. Reactions were carried out
in 2 L Erlenmeyer flask by adding glucose (50 g) and 4 (500 mg)
dissolved in 1% of DMSO and keeping the reaction mixture under
reciprocal shaking (150 spm) at 28 ◦C. After 7  days, the biotrans-
formation mixture was centrifuged, and the aqueous supernatant
was extracted twice with EtOAc (350 mL); the organic extract was
dried over Na2SO4 and the solvent was evaporated to yield a crude
mixture and the single products were purified by flash chromatog-
raphy (gradient 7:3; 1:1; 2:8 n-hexane/EtOAc), furnishing 392 mg
of 8  (392 mg,  78%) and 10 (30 mg,  8%).
8: White solid. Rf = 0.55 (n-hexane/EtOAc 4:6);
1H NMR  (CDCl3,
200 MHz): ı  1.56–1.72 (m,  3H), 2.00–2.20 (m, 1H), 2.35–2.42 (m,
2H), 2.49–2.66 (m,  3H), 2.70–2.95 (m,  5H), 5.08–5.15 (m,  1H,
CHOC O), 5.16–5.20 (m, 1H, PhC OOCH), 7.10–7.29 (m,  5H, Csp2-
H), 7.40–7.60 (m,  3H, Csp2-H), 7.95–7.99 (m, 2H, Csp2-H).
13C NMR  (CDCl3, 50.4 MHz): ı  209.10 (C O), 176.78 (OC O),
166.23 (PhC O), 141.06 (Csp2quat.), 133.55, 129.85 (CHsp2),  129.81
(OC OCsp2quat.), 128.76, 128.72, 128.52, 126.39 (CHsp2), 84.50
(OCHCH2), 79.96 (PhC OOCH), 52.54 (CHCHCHOC OPh), 44.56
(CH2), 44.00 (CH2CHCHCHOC OPh), 40.79, 37.87, 36.37, 29.97,
26.94 (CH2).
Anal. calcd for C25H26O5: C  73.87, H 6.45; found: C 73.50, H  6.65.
MS (ESI +  m/z%): 429.4 [M++Na+]  (100).
10:  Colourless oil. Rf =  0.25 (n-hexane/EtOAc 4:6);
1H NMR
(CDCl3,  200 MHz): ı 1.50–1.80 (m, 3H), 1.90–2.10 (m,  2H),
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Scheme 2.  Biotransformation of 4 with  Pichia glucozyma.
2.25–2.52 (m,  4H), 2.60–2.94 (m,  5H), 3.85 (q, J  =  5.6, 1H, CHOH),
4.84–4.93 (m,  1H, CHOC O), 7.15–7.32 (m,  5H, Csp2-H).
13C NMR  (CDCl3, 50.4 MHz): ı 209.89 (C O), 177.24 (OC O),
141.10 (Csp2quat.), 128.74, 128.59, 126.43 (CHsp2),  83.45
(OCHCH2), 77.43 (CHOH), 53.2 (CH2CHCHCHOH), 44.50 (CH2),
43.19 (CH2CHCHCHOH), 40.86, 35.69, 35.69, 30.05, 26.08 (CH2).
Anal. calcd for C18H22O4: C 71.50, H  7.33; found: C  71.13, H 7.53.
MS (ESI + m/z%): 325.4 [M++Na+] (100).
2.5.5. [(3aR,4R,5R,6aS)-5-hydroxy-4-((S)-3-hydroxy-5-
phenylpentyl)hexahydro-2H-cyclopenta[b]furan-2-one]
(11)
P. glucozyma CBS 5766 was grown in a  3.0 L fermenter with 1.5 L
of M5YE liquid medium for 48  h, 28 ◦C and agitation speed 150 rpm.
Fresh cells from submerged cultures were centrifuged and washed
with 0.1 M phosphate buffer, pH 7.0, resuspended in  0.5 L  of phos-
phate buffer to reach 25  gdry  cells/L concentration of cells and used
for biotransformations. Reactions were carried out in  2  L Erlen-
meyer flask by adding glucose (25 g) and 4  (500 mg)  dissolved in  1%
of DMSO and keeping the reaction mixture under reciprocal shaking
(150 spm) at 28 ◦C. After 7  days, the biotransformation mixture was
centrifuged, and the aqueous supernatant was extracted twice with
EtOAc (350 mL); the organic extract was dried over Na2SO4 and
the solvent was evaporated to give a crude mixture and the single
products were purified by flash chromatography (gradient 7:3; 1:1;
2:8 n-hexane/EtOAc), furnishing 11 (260 mg,  69%). Absolute con-
figuration was assigned by comparison with authentic reference
materials chemically synthesized.
3. Results and discussion
A screening for the identification of yeasts (see experimental
section for the complete list) able to transform (3aR,4R,5R,6aS)-
4 into (3aR,4R,5R,6aS,3′S)-6 and/or (3aR,4R,5R,6aS,3′R)-7 was
carried out using resting cells suspended in  phosphate buffer in
the presence of 5% glucose and neat (3aR,4R,5R,6aS)-4 (1 g/L).
Two wild-type strains (P. anomala CBS110 [15,16] and P.  glu-
cozyma CBS 5766 [17–20])  and the recombinant strain S.  cerevisiae
BY47411Oye2Ks (which has the original OYE2 deleted and bears
the highly expressed enoate reductase gene from Kazachstania
spencerorum) [21] gave molar conversion of (3aR,4R,5R,6aS)-4
above 30%.
P. glucozyma CBS 5766 gave ketone (3aR,4R,5R,6aS)-10 (18%
yield) and (3aR,4R,5R,6aS,3′S)-11 (69% yield, 72% d.e.) as final prod-
ucts. During the reaction, traces of the transient intermediates
(3aR,4R,5R,6aS)-8 and (3aR,4R,5R,6aS)-9 were observed, indicat-
ing that the overall transformation likely occurred as reported in
Scheme 2. The reduction of the carbonyl was partially enantiose-
lective, furnishing (3aR,4R,5R,6aS,3′S)-11 with 72% d.e. Absolute
configuration was assigned by comparison with authentic refer-
ence materials chemically synthesized.
S. cerevisiae BY47411Oye2Ks showed, as expected, high enoate
reductase activity giving the saturated ketone (3aR,4R,5R,6aS)-8 as
the main product (78%) and minor amounts of 10,  deriving from
subsequent ester hydrolysis (Scheme 3).
P. anomala CBS 110 gave a  mixture of Lactondiol B
(3aR,4R,5R,6aS,3′S)-6 (44% yield, 95% d.e.) and (R)-Lactondiol L
(3aR,4R,5R,6aS,3′R)-7 (30% yield, 97% d.e.). Interestingly, the oppo-
site epimer (with respect to the one obtained with P. glucozyma)
was obtained by C  O reduction, with high stereoselectivity (d.e.
97%). Scheme 4  shows the biotransformations involved in  the con-
version of (3aR,4R,5R,6aS)-4 with P.  anomala, based on the  different
intermediates observed during the overall transformation.
It  is  known that the use of whole cells of yeasts generally
furnishes a mixture of saturated and unsaturated alcohols in
the reduction of a,b-unsaturated carbonyls, depending on the
strain and conditions employed [22]; this is due to the  relative
rates of enoate reductase and carbonyl reductase activities, which
Scheme 3.  Biotransformation of 4 with Saccharomyces cerevisiae BY47411Oye2Ks.
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Scheme 4. Biotransformation of 4  with Pichia anomala.
Table 1
Biotransformation of (3aR,4R,5R,6aS)-4 with P.  anomala in presence of different cosubstrates.
Entry Co-substrate Concentration of
co-substrate (g/L)
6 7
Yield (%) d.e. (%)a Yield (%) d.e. (%)a
1  Ethanol 5 5 n.d.  12 92
2  Ethanol 50 10 97 20 92
3  Fumaric acid 5 8 n.d.  75 97
4  Fumaric acid 50 13 97 70 97
5  Glucose 5 38 95 25 97
6  Glucose 50 44 95 30 97
7  Glycerol 5 57 97 29 97
8  Glycerol 50 58 97 30 97
9  Xylose 5 – n.d.  21 96
10  Xylose 50 – n.d.  33 95
a Determined by HPLC analysis.
determine the final ratio of the  products. The type of co-substrates
added for favouring co-factors regeneration may  play  a  crucial role
in the activity of the different reductases. Thus, the biotransforma-
tion with P. anomala was carried out using various conventional
co-substrates (glucose, ethanol, glycerol, xylose) showing the pre-
dominant formation of Lactondiol B (3aR,4R,5R,6aS,3′S)-6 with d.e.
in the range of 95–97%; in particular the use of glucose gave
(3aR,4R,5R,6aS,3′S)-6 with 44% yield and 95  d.e., while in pres-
ence of glycerol 58% yield and 97% d.e. were observed. Interestingly
the use of fumaric acid as cosubstrate in  the same reaction sys-
tem gave higher amounts of Lactondiol L (3aR,4R,5R,6aS,3′R)-7 (75%
yield, 97% d.e.); fumaric acid is  an  unconventional co-substrate
for cofactor regeneration and it  is assumed that the yeast like P.
anomala may  oxidize fumaric acid in Krebs cycle, therefore allow-
ing for regeneration of NAD(P)H. Table 1 summarizes the results
obtained using different co-substrates.
The biotransformation of (3aR,4R,5R,6aS)-4 catalyzed by P.
anomala was optimized using the  Multimplex® experimental
design, which simultaneously evaluates different parameters of
the biotransformation and had previously shown to be  suited
for the fast optimization of different biotransformations [23,24].
The response parameters were  product yields and d.e., while the
control variables were temperature, pH, concentration of cells,
DMSO and co-substrate. The best performance for the prepara-
tion of (3aR,4R,5R,6aS,3′R)-7 (82% yield, 97% d.e.) was obtained
using 0.1 mM  phosphate buffer at pH 7.0, 28 ◦C, 1 g/L substrate
concentration in the presence of 1.5 g/L fumaric acid (correspond-
ing to a  5/1 molar ratio of fumaric acid/substrate), while the
best conditions for the preparation of (3aR,4R,5R,6aS,3′S)-6 (62%
yield, 97% d.e.) were found using 0.1 mM phosphate buffer at pH
7.2, 28 ◦C, 1  g/L substrate concentration in the presence of 50 g/L
glycerol.
4. Conclusions
In conclusion, here we  propose an alternative chemoenzymatic
approach for the synthesis of Bimatoprost and Latanoprost, based
on the biotransformation of 15-ketoprostaglandin (3aR,4R,5R,6aS)-
4 with whole cells of non-conventional yeast P. anomala. This
appears like a  useful method for preparing optically pure Lacton-
diol B (3aR,4R,5R,6aS,3′S)-6 and Lactondiol L (3aR,4R,5R,6aS,3′R)-7
in high yields depending on the co-substrate employed: Lactondiol
B (3aR,4R,5R,6aS,3′S)-6 was  obtained with 62% yield using glyc-
erol, whereas the use of fumaric acid gave 82% yield of Lactondiol L
(3aR,4R,5R,6aS,3′R)-7 in a simple one-pot, three-step modification
of substrate (3aR,4R,5R,6aS)-4.
Supporting information
Copies of 1H NMR, 13C NMR  and mass spectra of all characterized
compounds 6–10 are provided.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in  the online version, at http://dx.doi.org/10.1016/j.molcatb.
2014.05.022.
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Employment of  a new ketoreductase from P. glucozyma for 
stereoselective reductions 
 
5.1 Productions of recombinant proteins 
 
The demand of recombinant proteins has increased, as more applications in 
several fields become a commercial reality. Recombinant proteins have been utilized as 
tools for cellular and molecular biology. Various applications areas have experienced 
substantial advances thanks to the possibility of producing large amounts of recombinant 
proteins by an increasing availability of genetically manipulated microorganisms. For 
instance, a lot of diseases have been treated because of the accessibility of therapeutic and 
prophylactic proteins that in the past could be obtained in a very small amount and using 
unsafe sources. To date, more than 75 recombinant proteins are used as pharmaceuticals 
and more than 360 new therapeutic proteins are under development.
66
 The use of 
recombinant DNA for cloning and gene expression in a host microorganism was 
introduced in 1973. In particular the Salmonella thyphimurium gene coding for the 
streptomycin resistance was cloned in Escherichia coli, verifying the antibiotic tolerance.
67
  
Among the many systems available for heterologous proteins production, the Gram-
negative bacterium Escherichia coli still remains one of the most attractive because of 
genetically and physiologically well characterized. Among its strengths the ability to 
rapidly grow up on inexpensive substrates, easily to genetically manipulate, the high level 
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of protein expression, the availability of an increasingly large number of cloning vectors 
and mutant host strains.
68
 On the other hand the recombinant proteins expressed in E. coli, 
sometimes do not present the post-trasductional correct modifications such as 
phosphorilations and glycosylations, and the overproduction of heterologous proteins in E. 
coli cytoplasm could be accompanied by their misfolding and segregation into insoluble 
aggregates known as inclusion bodies. To overcome this limit it is necessary the reduction 
of the transcription and traduction efficiency for example lowering the expression 
temperature at 15-20 °C. In this way the proteins have the time to fold and became active. 
69
 For the heterologous protein expression in eukaryotes the yeasts Pichia pastoris and 
Saccharomyces cerevisiae, microorganisms rapidly to grow and easily to genetically 
manipulate are the most used. Moreover, they have the ability to carry out many post-
trasductional modifications such as glycosylation. However they lack some post-
traductional pathways which could be important when recombinant proteins have animal 
origin, such as hydroxylation, amidation and many types of phosphorilation and 
glycosylation. 
In order to maximize the production of heterologous protein is necessary take 
into account these aspects: 
 Selection of the host cell 
 Selection and design of the promoter for the interested gene. Promoters 
of E. coli consist of a hexanucleotide sequence located approximately 35 
bp upstream of the transcription initiation base separated by a short 
spacer from another hexanucleotide sequence. A useful promoter 
                                                          
68
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exhibits several desirable features: it is strong, it has a low basal 
expression level (it is tightly regulated), it is easily transferable to other 
E. coli strains to facilitate testing of a large number of strains for protein 
yields, and its induction is simple and cost effective . 
 Increase of mRNA half-life 
 Adaptation of codons to codon-usage of host microorganism. Genes in 
both prokaryotes and eukaryotes show a non-random usage of 
synonymous codons. The systematic analysis of codon usage patterns in 
E. coli led to the following observations: (i) Certain codons are most 
frequently used by all different genes irrespective of the abundance of 
the protein; for example, CCG is the preferred triplet encoding proline. 
(ii) Highly expressed genes exhibit a greater degree of codon bias than 
do poorly expressed ones. (iii) The frequency of use of synonymous 
codons usually reflects the abundance of their cognate tRNAs. These 
observations imply that heterologous genes enriched with codons that 
are rarely used by E. coli may not be expressed efficiently in E. coli. 
 Modifications of gene sequence in order to send the protein to a specific 
cellular compartment such as cytoplasm, periplasm or extracellular 
secretion. 
 Optimization of fermentation conditions (composition of cell growth 
medium, temperature, pH, oxygen, agitation) 
70
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5.2 Expression systems  
 
The E. coli expression systems are based on the utilization of expression vectors 
which both simplify the cloning operations and require high stability obtained with 
antibiotics resistance markers. The success of the production of heterologous protein often 
depends on the accurate choice of expression system suitable for both the protein and for 
the coding gene. The expression system most used for E.coli is the “pET Expression 
System” (Novagen). A pET vector is a bacterial plasmid designed to enable the quick 
production of large quantity of any desired protein when activated. The plasmid contains 
several important elements such as a lacI gene which codes for lac repressor protein, a T7 
phage promoter which is specific only for T7 RNA-polymerase (not bacterial ones) and 
also does not occur anywhere in the prokaryotic genome, a lac operator which can block 
transcription, a polylinker, an f1 origin the replication, an ampicillin resistance gene and 
ColE1 origin of replication (Fig. 29). 
To start the process the gene (YFG) is cloned into pET vector at the polylinker 
site. Both the T7 promoter and the lac operator are located 5' to YFG. When the T7 RNA 
polymerase is present and the lac operator is not repressed, the transcription of YFG 
proceeds rapidly. Because T7 is a viral promoter, it transcribes rapidly and profusely for as 
long as the T7 RNA polymerase is present. The expression of the protein (YFP) increases 
rapidly as the amount of mRNA transcribed from YFG increases. Within a few hours, YFP 
is one of the most prevalent components of the cell.  
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Fig. 29 The pET vector 
One of the most important parts of the pET Expression System involves the fact 
that YFG is not transcribed unless the T7 RNA polymerase is present. Prokaryotic cells do 
not produce this type of RNA, and therefore the T7 RNA polymerase must be added. 
Usually, the host cell for this expression system is a bacteria which has been genetically 
engineered to incorporate the gene for T7 RNA polymerase, the lac promoter and 
the lac operator in its genome. When lactose or a molecule similar to lactose is present 
inside the cell, transcription of the T7 RNA polymerase is activated. Typically, the host 
cell used is E. coli strain BL(DE3).  
Control of the pET expression system is accomplished through the lac promoter 
and operator. Before YFG can be transcribed, T7 polymerase must be present. The gene on 
the host cell chromosome usually has an inducible promoter which is activated by IPTG. 
IPTG displaces the repressor from the lac operator. Since there are lac operators on both 
KRED1-Pglu 
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the gene encoding T7 polymerase and YFG, IPTG activates both genes. Therefore, when 
IPTG is added to the cell, the T7 polymerase is expressed, and quickly begins to transcribe 
YFG which is then translated as YFP. IPTG works to displace a lac repressor since IPTG 
is an analogue of lactose. The lac genes express enzymes which are involved in the 
breaking down of lactose, and therefore, the presence of lactose (or it's analogue) would 
trigger the initiation of transcription of lac genes (Fig. 30) 
Fig. 30 IPTG mechanism of action 
In order to facilitate the recombinant protein expression and purification many 
fusion partners have been developed. 
71
 In vivo the fusion partners can be advantageous 
71
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because they could protect the new produced protein from intracellular proteolysis
72
 and 
could increase their solubility.
73
 
 
5.3 Choice of host microorganism 
 
The genetic base of the host strain is an important characteristic for the production 
of recombinant proteins. The expression strains could be mutated for the natural host 
proteases, maintaining stable the new formed recombinant protein and lending the strain 
many relevant genetic elements in the expression system.  E. coli BL21 is the most utilized 
host, it is a robust strain able to vigorously grow up on a minimal media. BL21 strain lacks 
OmpT and Lon, two different proteases that could interfere with the production of 
recombinant protein degrading it. Moreover, the mutated strain utilized in this PhD thesis, 
BL21 DE3Star, presents a mutation on rne gene, coding for truncated RNasi E unable to 
degrade mRNA.
74
 This endonuclease consists of 1061 amino acids and it is involved in the 
mRNA degradation. The truncated enzyme lacks the C-terminal tail (about 477 a. a.) 
appointed for this function, so the increased stability of mRNA. Because of the choice of 
pET Expression System, in which the interesting gene is under the control of the T7 
promotor, it is required that the chosen host has the phage fragment DE3 coding for the 
polymerase T7.   
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5.4 Oxidoreductases 
 
This class of enzymes, responsible for redox transformations in living organisms is 
composed by three different families according to the funtion: (i) dehydrogenases, catalyze 
the oxidations of alcohols to ketones and formation of double bonds, as well as the 
reversive reactions (ii) oxigenases, catalyze the hydroxylation of non-activated C-H bonds, 
epoxidation or dihydroxylation of C=C bonds, and (iii) oxidases, which catalize electron 
transfer processes.
75
 Common feature shared by the members of oxidoreductases is their 
dependence on a specific cofactor molecule whose presence in the active site ensures the 
enzymes performance. For example, alcohol dehydrogenases (ADH) also called 
ketoreductases or carbonyl reducatases are able of reducing  carbonyl groups into alcohols 
as well as the opposite oxidation reaction, because of the presence of nicotinamide 
cofactors NAD(P)H or NAD(P)
+ 
 which provides the hydride atom to the carbonyl 
substrate or abstract the hydride from the alcohol. In more details, as showed in Fig. 31, 
the hydride could be transferred in four different stereochemical ways to the prochiral 
substrate. It can attack either si or re face of the carbonyl depending on the orientation of 
the substrate in the active site. On the other hand, enzyme facilitates the transfer of either 
pro-R or pro-S hydride of the cofactor depending on the type of ADH. Moreover, 
stereospecificity of ADH-catalyzed reactions is classified following Prelog’s rule based on 
the size of the substituents bonded to the carbonyl group. It is based on the stereochemisry 
of microbial reduction using Curvularia falcata cells and it states that the ADH delivers 
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the hydride from re-face of a pro-chiral ketone affording the (S)-alcohol. On the contrary, 
in case of (R)-enantiomer is produced, the ADH is describe as an anti-Prelog enzyme. 
Fig. 31 Stereospecificity of ADHs is determined by the mutual position of the nicotinamide cofactor and 
carbonylic substrate in the active site. 
The majority of the commercially available ADHs used for the stereospecific reduction of 
ketones and the majority of microorganisms (for instance, S. cerevisiae) follow the 
Prelog’s rule.76 
76
K. Faber Biotranformations in Organic Chemistry. A Textbook. 6
th
 Ed. Springer- Verlag Berlin
Heidelberg 2011 
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5.5 Cofactors recycling 
 
In the redox processes catalyzed by dehydrogenases, the cofactors like 
nicotinamide NAD(P), flavin FNM or FAD derivatives play a key role by providing the 
necessary redox equivalents, acting as electron donor or acceptor.  
 
 
 
Fig. 32 Chemical structure of oxidoreductase cofactors: (A) nicotinamide; (B) flavin. 
 
The cofactors are molecules very expensive and unstable that are consumed in a 
stoichiometric amount. As shown in Fig. 33, the oxidation of a generic alcohol to ketone 
determines the consumption of NAD(P)
+
, while the reduction of a generic alcohol leads the 
consumption of NAD(P)H
+
. For the development of an industrial application of 
oxidoreductases, this problem has been overcome by the in situ recycling techniques 
allowing the use of catalytic amounts of these compounds. 
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Fig. 33 Redox system using a co-substrate for the recycle of cofactors 
 
The main strategies for the regeneration of cofactors concern the use of 
enzymatic reactions, and electrochemical or photochemical systems.  
- Electrochemical regeneration: it usually employs metals to obtain the 
electron transfer between an electrode and reduced/oxidized cofactors. Fig. 
34a 
- Photochemical regeneration: it employs photosensitizers in homogeneous 
phase derived from complexes such as zinc complexes or colloids such as 
derivatives of cadmium or titanium dioxide. Fig. 34b 
- Enzimatic regeneration: it is divided in two different categories. The 
“enzyme coupled system” based on the use of another enzyme such as GDH 
(glucose dehydrogenase) with glucose, or FDH (formate dehydrogenase) 
with a formate salt, consists in two parallel different reactions catalyzed by 
different enzymes. The first one is the interesting reaction that is the 
transformation of the reagent in the desired product, while the second one is 
the regeneration of the cofactor. The most important features of this system 
are both the substrate specificity of the different employed biocatalysts and 
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the high affinity for the same cofactor. On the other hand, “the coupled 
substrate system” based on the constant regeneration of cofactor by the same 
enzyme because of the addition of the co-substrate. The auxiliary substrate 
let the biocatalyst performs a secondary reaction in order to have the desired 
cofactor form. While in the first case the “enzyme coupled system” is 
thermodynamically favoured because of the shifted equilibrium towards the 
formation of the product, the “coupled substrate system” is less 
thermodynamically favoured. It is a common good practise the adding of a 
huge molar excess of co-substrate in order to force the equilibrium of the 
interesting reaction to have the desired product. Fig. 35. 
Fig. 34 A: platinum nanoparticles (n-Pt) in electrolyte enhance electron transferfrom electrode to NAD+ in 
electrolyte during an indirectelectrochemical regenerationof NADH. The intermediate nPt-Hads, formed a 
negative potential, helps the primary mediator turnover by donating proton and electron in a kinetically 
favourable way.77 B: CO2 conversion into CH3OHusing light  to regenerate the enzyme cofactor (NADH) by
ZnS-A photocatalysis, with bioglicerol as H- and e- donor78 
77
C. Hwang et al., Scientific report 2015, 5, 1-10.
78
A. Dibenedetto et al. Chem. Sus. Chem. 2012, 5, 373-378.
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Fig. 35 Enzymatic regeneration of cofactors 
 
5.6 Benzilreductases and SDR (short chain dehydrogenases)  
 
The benzilreductase is an oxidoreductase NAD(P)H-dependent belonging to the 
family of SDR (short chain dehydrgenases), proteins with a simpler molecular architecture, 
with largely one-domain subunit without metal derived from coenzyme-binding fold and 
with more or less extension. Members of the SDR superfamily are non-metalloenzymes 
with molecular masses between 25 and 35 kDa.  Substrates for the SDR include 
prostaglandins, steroids, aliphatic and aromatic compounds and xenobiotcs, too. The 
benzyl-reductase, catalyzing the reduction of aromatic ketones in particular the 
stereoselective reduction of benzil into (R)- or (S)-benzoin, has at least two binding 
domains, one for the substrate bond and important to determine the substrate specificity, it 
contains the amino acids involved in the catalysis, and the so called Rossman fold, a N–
terminal domain binding  the nucleotidic co-factor and showing a very conserved sequence 
formed by 70 residues with a super secondary structure type βαβαβ. The conserved 
sequence is made up of GXGXXG in which the first and the second glycines are involved 
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in the binding with cofactor while the third facilitates the approach between the α-helix and 
the β-sheet.79 
The typical catalytic triad of the active site in the SDR family is composed by a 
Tyr, Lys and a Ser, which form a proton relay system. An additional Asn also play an 
important role by maintaining the active site configuration during the proton transfer.
80
 In 
particular it is involved both by maintaining the Lys position during the proton relay and 
by stabilizing the side chain interaction. The Tyr residue plays an important role in the 
catalytic system because it is the responsible for the abstraction or donation (in oxidation 
or reduction respectively) of the proton from/to the substrate. Moreover, the Lys residue 
participates with its amino group in binding the ribose of the co-factor, while Ser residue 
stabilizes the oxygen atom of the product. 
81
 In the end, the carbonyl group of Asn residue 
binds with an H-bond a water molecule to the Lys chain stabilizing the proton relay 
system.   
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Fig. 36 SDR (3β/17β-HSD) mechanism. Tyr 151 is the catalytic base, Ser 138 fixes the substrate while Lys 155 
forms the H-bon with NADH. 
 
5.7 The synthetic importance of the α-hydroxyketones 
 
Enantiomerically pure α-hydroxyketones can be used as precursors for the 
synthesis of pharmaceuticals, such as antitumor antibiotics e.g. olivompicina A and 
chromomycin A3, farnesyl transferase inhibitors e.g. kurasoin A and B2, inhibitors of the 
production of β-amyloid proteins and antidepressants such as bupropion. They also can be 
exploited for the preparation of important structures such as amino alcohols and diols.
82
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Fig. 37 Derivatives of hydroxyketones 
  
In literature numerous methods for the synthesis of hydroxyketones such as 
benzoin and derivatives have been reported. They include both chemical methods and 
enzymatic ones. Between these we include the ketohydroxylation of olefins,
83
 the 
asymmetric mono-oxidation of the corresponding 1,2- diol,
84
as well as the kinetic 
resolution via oxidation of racemic α-hydroxyketone. Moreover, a lot of organocatalytic 
techniques consisting into α–oxygenation of ketones in the presence of proline or alanine 85 
have been proposed. Finally, benzoin condensation by the use of chiral salts such as 
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thiazole, imidazole and triazole, which increase both the yield of the product and the 
selectivity has been reported. 
These salts exploit the same mechanism of the thiazolic ring of thiamine 
(vitamin B1), coenzyme universally present in all living systems; after the formation of the 
carbanion because of the removal of hydrogen of the thiazolic group, it attacks the 
electrophile carbon of a molecule of benzaldehyde, which adds another molecule of this 
aldehyde. The use of thiamine or molecules with analogous thiazole ring as catalysts 
allows dimerization in a basic environment (e.g.triethylamina ) of many either aliphatic or 
aromatic aldehydes. 
 
 
 
Fig. 38 Chemical strategies for the asymmetric synthesis of α-hydroxyketones  
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To overcome the problems of chemical approaches such as significant number 
of steps, reduced yields and difficulty to obtaining enantiopure products several 
biocatalytic methods were proposed. Among these the use of lyase thiamine diphosphate-
dependent for aldehydes condensation, lipases for stereoselective hydrolysis and 
oxidoreductases for stereoselective reduction/oxidation are noteworthy.  
 
 
 
Fig. 39 Biocatalytic strategies for the asymmetric synthesis of α-hydroxyketones   
 
The ThdDP-lyase catalyzes condensation of aldehydes to give α-
hydroxyketones. The more studied enzymes are benzaldehyde lyase (BAL) isolated from 
Pseudomonans fluorescens 
86
and pyruvate decarboxylase (PDC). The first one catalyzes 
the carboligation both of aromatic aldehydes  and of  aliphatic ones, the second is a good 
example of a robust catalyst used in industrial scale processes for the production of  L-
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phenylacethylcarbinol (CAP), the precursor of ephedrine, from benzaldehyde and pyruvic 
acid.
87
  
Hydrolases, such as lipases and esterases, convert both aliphatic and aromatic 
compounds, giving different α-hydroxyketones;88 Jeon et al . reported the enantioselective 
transesterification of racemic ketones by an immobilized lipase B from Candida Antarctica 
(CAL-B) in organic solvents.
89
 
Fig. 40 Example of esterification of (R)-2-hydroxy-1-phenylpropan-1-one mediated by CAL-B 
Finally, an important role is played by the oxidoreductases, which act both as 
isolated enzymes and as whole cells. In literature, there are many examples of 
microorganisms employed as biocatalysts for the reduction of α-diketones.90 
87
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88
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Fig. 41 Microorganisms employed for the reduction of benzoin  
 
Another strategy involves the application of dehydrogenases or oxidases capable 
of performing reaction of (de)racemization. For example Rhizopus oryzae is able to reverse 
the chirality of benzoin depending on the  pH of the reaction medium,
91
 while the whole 
cells of Pichia glucozyma are able to deracemize a racemic mixture of (R)- and (S)-benzoin 
because of the activity of different dehydrogenases: the first one responsible for the 
oxidation of (R)-benzoin to benzil and the second one responsible for the reduction of 
benzil in the opposite enantiomer.
92
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Fig. 42 Deracemization of benzoin catalyzed by Rhizopus oryzae 
 
 
 
Fig. 43 Deracemization of (R)-benzoin catalyzed by Pichia glucozyma 
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Abstract A new NADPH-dependent benzil reductase
(KRED1-Pglu) was identified from the genome of the
non-conventional yeast Pichia glucozyma CBS 5766 and
overexpressed in E. coli . The new protein was
characterised and reaction parameters were optimised
for the enantioselective reduction of benzil to (S)-ben-
zoin. A thorough study of the substrate range of
KRED1-Pglu was conducted; in contrast to most other
known ketoreductases, KRED1-Pglu prefers space-
demanding substrates, which are often converted with
high stereoselectivity. A molecular modelling study
was carried out for understanding the structural determi-
nants involved in the stereorecognition experimentally
observed and unpredictable on the basis of steric prop-
erties of the substrates. As a result, a new useful cata-
lyst was identified, enabling the enantioselective prepa-
r a t i o n o f d i f f e r e n t a r om a t i c a l c o h o l s a n d
hydroxyketones.
Keywords Ketoreductase . Carbonyl reductase . Pichia
glucozyma . Enantioselective reduction . Biocatalysis .
Stereoselective
Introduction
The use of ketoreductases (KREDs, often also described as
carbonyl reductases (CR) or alcohol dehydrogenases (ADH))
is a well-recognised method for the enantioselective reduction
of prochiral ketones into stereodefined chiral alcohols (Hall
and Bommarius 2011; Hollmann et al. 2011). Reduction of
aromatic ketones has been studied with different reductases,
with particular focus on the reduction of sterically hindered
(bulky) substrates, not easily recognised by most of the avail-
able KREDs (Lavandera et al. 2008). Commercially available
or engineered KREDs can reduce structurally different (in-
cluding bulky) ketones and their use has been also scaled-up
to industrial processes (Huisman et al. 2010; Liang et al.
2010). Other alcohol dehydrogenases, such as the ones from
Rhodococcus ruber (ADH-A; Stampfer et al. 2004), Ralstonia
sp. (RasADH; Lavandera et al. 2008), and Lactobacillus
brevis (LBADH; Haberland et al. 2002) have been identified
as suitable biocatalysts for the reduction of different aromatic
bulky substrates. Steric effects of the substrates on the activity
of LBADH towards aromatic ketones (acetophenone deriva-
tives) were accurately studied. In most cases, a tendency for
higher activity with smaller substrates could be detected, but
noticeable deviations from this general trend were observed
due to stereoelectronic effects (Rodríguez et al. 2014).
Understanding how substrate-binding residues of the protein
affect substrate binding orientation and thus sterereocognition
is necessary not only for predicting enantioselectivity, but also
for designing rational or semirational mutations, aimed at in-
creasing or changing the stereobias of a given reduction
(Baerga-Ortiz et al. 2006; O’Hare et al. 2006). This approach
was employed for mutating a carbonyl reductase from
Sporobolomyces salmonicolor AKU4429 (SSCR) and
switching its enantiopreference in the reduction of para-
substituted acetophenones (Zhu et al. 2008). This SSCR
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variant has been recently used for the enantioselective reduc-
tion of asymmetric benzophenone derivatives (Li et al. 2009).
Whole cells of the non-conventional yeast Pichia
glucozyma CBS 5766 (now reclassified as Ogataea
glucozyma) have been used for the reductive biotransforma-
tion of various aromatic ketones and ketoesters (including
bulky ones), often showing interesting stereoselectivity
(Forzato et al. 2001; Gandolfi et al. 2009; Rimoldi et al.
2011a; Husain et al. 2011; Rimoldi et al. 2011b; Contente
et al. 2015). The reduction of these substrates frequently oc-
curred with activity and enantioselectivity strongly dependent
on the conditions of growth and biotransformation, suggesting
the possible occurrence of different ketoreductases acting on
aromatic ketones. Notably, whole cells ofP. glucozyma carried
out the selective monoreduction of different 1,2-diaryl-
ethanediones (benzils) (Hoyos et al. 2008; Fragnelli et al.
2012). Enzymes with benzil reductase activity, belonging to
the short-chain dehydrogenase/reductase (SDR) family, have
been found in bacteria (Maruyama et al. 2002; Pennacchio
et al. 2013) and yeasts (Johanson et al. 2005). Here, we report
the identification of a benzil reductase from P. glucozyma and
a study of its activity/enantioselectivity towards different aro-
matic ketones using the recombinant protein (KRED1-Pglu)
overexpressed in Escherichia coli.
Materials and methods
General
Phusion DNA polymerase was from New England
Biolabs (EuroClone S.p .A. , Pero (MI) , I ta ly) .
pET26b(+) vec to r was f rom Novagen (Merck
Millipore, Vimodrone (MI), Italy).
HIS-Select® Nickel Affinity Gel used for protein purifica-
tion was purchased from Sigma Aldrich (Milano, Italy).
Pichia glucozyma CBS 5766 was from CBS-KNAW
Fungal Biodiversity Centre (Utrecht, The Netherlands).
Stocks of the strain were stored at −20 °C in 15 % v/v glycerol
and revitalized liquid YPD (yeast extract 5 g/L, peptone 5 g/L,
glucose 20 g/L, pH 6.0) medium prior use. The bacterial strain
E. coli XL1 blue was used for the propagation of the recom-
binant plasmid. E. coli BL21(DE3)Star (Merck Millipore,
Vimodrone, Italy) was used for expression of KRED1-Pglu.
Both were used according to the instruction of the suppliers.
All the DNA manipulations and bacterial transformations
were carried out according to standard protocols (Sambrook
and Russell 2001) or manufacturers’ instructions, unless oth-
erwise stated.
Protein concentration was determined with the Bradford
method on a Pharmacia Biotech Ultrospec 1000 using bovine
serum albumin as standard (Bradford 1976).
Production of the recombinant protein
Identification of KRED1-pglu gene
Genome of P. glucozyma CBS 5766 was sequenced by
Baseclear (BaseClear B.V., Leiden, The Netherlands) using
Illumina Casava pipeline version 1.8.0; assembly has been
performed using the Bde novo assembly^ option of the CLC
GenomicsWorkbench version 5.1. Annotation has been made
on the assembled contig or scaffold sequences using the
GAPS Annotation Pipeline from Progenus (Gembloux,
Belgium). Upon analysis, 311 oxidoreductases, 517 transfer-
ases, 512 hydrolases, 71 lyases, 53 isomerases and 109 ligases
were annotated and, among the oxidoreductases, a unique
benzil reductase gene (named KRED1-Pglu) was found after
BLAST analysis.
Cloning
KRED1-Pglu gene, coding for a putative benzil reductase, was
amplified from the genomic DNA of P. glucozyma by PCR
using the following primers, carryingNdeI andHindIII restric-
tion sites: forward 5′-ATACCATATGACGAAGGTGA
CTGTTGTGAC-3 ′; reverse 5 ′-AGAGAAGCTTGG
CGTACTCCTTCAACTCTG-3′.
The amplified gene was then cloned into a pET26b(+)
vector using the NdeI and HindIII restriction sites. With
this cloning strategy, the resulting protein is expressed
with an N-terminal His6 tag. The correct construction of
the expression plasmid was confirmed by direct
sequencing.
Protein expression
Cultures of E. coli BL21(DE3)Star transformed with the
resulting plasmid were grown overnight at 37 °C in LB me-
dium supplemented with 25 μg/mL kanamycin. The seed cul-
ture was then diluted into a stirred bioreactor (Biolafitte &
Moritz bioreactor, Pierre Guerin Technologies) contain-
ing 4 L of cultivation medium (Terrific Broth, 12 g/L
bacto-tryptone, 24 g/L yeast extract, 4 g/L glycerol,
2.3 g/L KH2PO4, 9.4 g/L K2HPO4, pH 7.2) to an initial
OD600nm of 0.05. Cultivation was carried out in batch-
mode at 37 °C, 250 rpm stirring and 250 L/h aeration
rate. Cells were grown until OD600nm reached the value
of 0.8. The cultures were induced for 20 h with
isopropyl-β-D-thiogalactopyranoside (IPTG) to a final
concentration of 0.5 mM. Cells were then harvested by
centrifugation at 4500 rpm for 30 min, washed once
with 20 mM phosphate buffer at pH 7.0 and stored at
−20 °C.
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Protein purification
Cells were suspended in 50 mM Tris–HCl, 100 mM NaCl,
6 mM imidazole, pH 8.0 buffer. Proteins were extracted by
sonication (5 cycles of 30 s each, in ice, with 1 min interval)
and cell debris were harvested by centrifugation at 15,000 rpm
for 30 min at 4 °C. The enzyme was purified by affinity chro-
matography with HIS-Select®Nickel Affinity Gel. Briefly, the
column was equilibrated with 50 mM Tris–HCl, 100 mM
NaCl, 6 mM imidazole, pH 8.0 and the crude extract loaded;
column was then washed with 50 mM Tris–HCl, 100 mM
NaCl, 6 mM imidazole, pH 8.0; finally, the adsorbed enzyme
was eluted with 50 mM Tris–HCl, 100 mM NaCl, 250 mM
imidazole, pH 8.0.
Pellets, crude extracts and collected fractions were
analysed by SDS-PAGE. The fractions showing the presence
of a band of the expected size (27 kDa) were pooled, dialysed
against 50 mM Tris–HCl buffer pH 8.0 and stored at −20 °C.
Typically, starting from 4 g of wet cell paste, it was possible to
obtain 70 mg of pure protein.
Benzil-reductase activity test
Activity measurements were performed spectrophotometrical-
ly at 340 nm by determining the consumption of NAD(P)H at
25 °C in a half-microcuvette (total volume 1 mL) for 5 min.
One unit (U) of activity is defined as the amount of enzyme
which catalyses the consumption of 1 μmol of NAD(P)H per
minute under reference conditions, namely with 0.25 mM
NAD(P)H and 0.47 mM benzil as substrate (added as concen-
trated DMSO solution; final DMSO concentration in cuvette
amounts to 0.1 %), in 50 mM Tris–HCl buffer, pH 8.0.
Temperature and pH activity and stability studies
Temperature and pH optima were studied conducting the
benzil-reductase test at temperatures between 15 and 50 °C
and at pH values between 4 and 12 (using suitable buffers). To
investigate its temperature-dependent stability, the enzyme
was incubated at different temperatures (15, 28, 37, 50 and
60 °C) in 50 mM Tris–HCl buffer pH 8.0; residual activity
was assessed conducting the benzil reductase test under refer-
ence conditions at different time points between 0 and 24 h of
incubation. pH-dependent stability was investigated preincu-
bating the enzyme in different buffers at pH between 5 and
11 at 25 °C. Residual activity was measured at pH 8.0, 25 °C,
at different time points between 0 and 24 h, and compared to
the value before incubation.
Substrate range
KRED1-Pglu substrate range was studied carrying out the
reduction assay under reference conditions (0.25 mM
NADPH, 50 mM Tris–HCl buffer pH 8.0, 25 °C), using
0.5 mM of each compound (in final 0.1 % DMSO); relative
activities were expressed as per cent values versus benzil.
Determination of kinetic parameters
Kinetic parameters for the reduction of benzil were deter-
mined using the reduction assay (0.07 g/L of KRED1-Pglu,
0.25 mM NAD(P)H, 50 mM Tris–HCl buffer pH 8.0, 30 °C).
Data were fitted to suitable kinetic models with KaleidaGraph
software (Synergy Software Inc., USA); kinetic parameters
were calculated with the same program.
Preparative reductions
Molar conversion and enantioselectivity towards different ar-
omatic ketones and ketoesters were determined by performing
biotransformations at 50-mg scale, using an enzyme-coupled
system (glucose-glucose dehydrogenase (GDH) from Bacillus
megaterium; Bechtold et al. 2012) for cofactor recycling.
Reductions were carried out in 10-mL screw-capped test tubes
with a reaction volume of 5 mL with KRED1-Pglu (20 mU/
mL), GDH (1 U/mL), NADP+ (0.1 mM), substrate (1 g/L),
glucose (4× mmol of substrate) suspended in 50 mMTris/HCl
buffer pH 8.0. GDH activity and stability in our reaction sys-
tem were checked before its use (data not shown).
Analyses 1H-NMR and 13C-NMR spectra were recorded with
a Varian Mercury 300 (300 MHz) spectrometer. Chemical
shifts (δ) are expressed in ppm, and coupling constants (J)
are expressed in Hz.
HPLC analyses were performed with a Jasco Pu-980
equipped with a UV–vis detector Jasco UV-975. The follow-
ing HPLC columns were used: LichroCART (250×4.6 mm),
Chiralcel OD (250×4.6 mm, Daicel), Chiralcel OD-H (250×
4.6 mm, Daicel), Chiralcel OJ (250×4.6 mm, Daicel), Lux
cellulose 2 (250×4.6 Phenomenex) Lux cellulose 3 (250×
4.6 Phenomenex). (R) and (S) isomers were identified by com-
parison of their retention times with those of synthetic
standards.
Analytical data of product of biotransformations are as
follows:
Benzoin (2a)
[α]D
25=+37.1° (c 0.8 Acetone) lit.1 [α]D
25=+44.2° (c 1.0
acetone)
1H-NMR (300 MHz, CDCl3): δ 7.88–7.93 (m, 2H), 7.48–
7.53 (m, 1H), 7.23–7.41 (m, 7H), 5.95 (d, J=6 Hz, 1H), 4.55
(d, J=6 Hz, 1H) ppm.
13C-NMR (75 MHz, CDCl3): δ 199.1, 139.2, 134.0, 133.7,
129.3, 129.2, 128.8, 128.7, 127.9, 76.4 ppm.
The enantiomeric excess (ee %) was determined by HPLC
using Chiralcel OD column (n-hexane/i-PrOH 90:10, 0.7 mL/
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min, 254 nm): tr (S)-benzoin 14.7 min, tr (R)-benzoin
21.6 min).
Diphenylmethanol (2b)
1H-NMR (300 MHz, CDCl3): δ 2.19 (d, J=4.0 Hz, 1H),
5.86 (d, J=4.0 Hz, 1H), 7.25–7.28, (m, 2H), 7.32–7.35 (m,
4H), 7.38–7.40 (m, 4H) ppm.
13C-NMR (75 MHz, CDCl3): δ 143.8 128.5, 127.6, 126.5,
76.2 ppm.
The molar conversion was determined by HPLC using
LichroCART 250–4,6 MeOH/H2O 65:35, 0.7 mL/min,
220 nm: tr diphenylmethanol 12.5 min, tr benzophenone
20.6 min.
Ethyl mandelate (2d)
[α]D
25=+88.7° (c 0.7 EtOH ) lit.2 [α]D
22=+97.33° (c 1.1
EtOH).
1H-NMR (300MHz, CDCl3): δ 7.35–7.42 (m, 5H), 5.15 (s,
1H), 4.15–4.25 (m, 2H), 1.20 (m, 3H) ppm.
13C-NMR (75 MHz, CDCl3): δ 173.7, 138.5, 128.7, 128.5,
126.6, 73.0, 62.3, 14.2 ppm.
The enantiomeric excess (ee %) was determined by HPLC
using Chiralcel OD-H column (n-hexane/i-PrOH 90:10,
1.0 mL/min, 210 nm): tr (S)-ethyl mandelate 6.0 min, tr (R)-
ethyl mandelate 10.0 min).
1-Phenylethanol (2e)
[α]D
25=+40.0° (c 0.5 chloroform) lit.3 [α]D
25=+36.0° (c
1.0 chloroform).
1H-NMR (300 MHz, CDCl3): δ 7.20–7.35 (m, 5H), 4.85
(q, J=6.4 Hz, 1H), 1.46 (d, J=6.4 Hz, 3H) ppm. 13C-NMR
(75 MHz, CDCl3): δ 145.9, 128.5, 127.5, 125.4, 70.4,
25.2 ppm.
The enantiomeric excess (ee %) was determined by HPLC
using Chiralcel OD column (n-hexane/i-PrOH 95:5, 0.7 mL/
min, 254 nm): tr (R)-1-phenylethanol 14.2 min, tr (S)-1-
phenylethanol 18.0 min.
1-Phenylpropanol (2f)
[α]D
25=+20.5° (c 0.2 chloroform) lit.4 [α]D
20=+22.2° (c
1.0 chloroform).
1H-NMR (300MHz, CDCl3): δ 7.35–7.22 (m, 5H), 4.54 (t,
J=6.5 Hz, 3H), 2.20 (br s, 1H, OH), 1.83–1.68 (m, 2H), 0.89
(t, J=7.5 Hz, 3H) ppm.
13C-NMR (75 MHz, CDCl3): δ 144.6, 128.4, 127.5, 126.0,
76.0, 31.9, 10.1 ppm.
The enantiomeric excess (ee %) was determined by HPLC
using Chiralcel OD-H column (n-hexane/i-PrOH 98:2,
1.0 mL/min, 254 nm): tr (R)-1-phenylpropanol 16.5 min, tr
(S)-1-phenylpropanol 19.5 min.
1-Phenylbutanol (2g)
[α]D
25=−40.5° (c 0.2 chloroform) lit.7 [α]D
25=−43.5° (c
1.0 chloroform).
1H-NMR (300 MHz, CDCl3): δ 7.34–7.32 (m, 4H), 7.27–
7.24 (m, 1H), 4.66 (t, J=6.5 Hz, 1H), 1.93 (br s, 1H, OH),
1.80–1.63 (m, 2H), 1.46–1.27 (m, 2H), 0.92 (t, J=7.5 Hz, 3H)
ppm.
13C-NMR (75MHz, CDCl3): δ 145.0, 128.4, 127.5, 125.9,
74.4, 41.2, 19.0, 13.9 ppm.
The enantiomeric excess (ee %) was determined by HPLC
using Chiralcel OD column (n-hexane/i-PrOH 99:1, 0.5 mL/
min, 254 nm): tr (R)-1-phenylbutanol 19.4 min, tr (S)-1-
phenylpbutanol 23.2 min.
1-Pyridin-3yl-ethanol (2i)
[α]D
25=−38.04° (c 0.4 ethanol) lit.4 [α]D
20=−39.0° (c 0.93
ethanol).
1H-NMR (300 MHz, CDCl3): δ 8.46–8.33 (m, 2H), 7.75–
7.70 (m, 1H), 7.24 (dd, J1=8.0 Hz, J2=5.0 Hz, 1H), 4.90 (q,
J=6.5 Hz, 1H), 4.5 (br s, 1H, OH), 1.49 (d, J=6.5 Hz, 3H)
ppm.
13C-NMR (75 MHz, CDCl3): δ 148.0, 147.0, 141.8, 133.5,
123.5, 67.5 25.1 ppm.
The enantiomeric excess (ee %) was determined by HPLC
using Phenomenex Lux cellulose 2 column (n-hexane/i-PrOH
90:10, 0.7 mL/min, 254 nm): tr (R)-(1-pyridin-3yl)ethanol
20.46 min, tr (S)-(1-pyridin-3yl)ethanol 25.30 min.
1-Pyridin-3yl-propanol (2j)
[α]D
25=−40.0° (c 0.2 methanol) lit.6 [α]D
20=−41.4° (c 2.1
methanol).
1H-NMR (300 MHz, CDCl3): δ 8.31 (m, 1H), 8.25 (m,
1 H), 7.63 (m, 1 H), 7.15 (m, 1 H), 4.90 (s, 1 H), 4.51 (t, J=
6.6 Hz, 1 H), 1.68 (m, 2 H), 0.82 (t, J=7.41 Hz, 3 H) ppm.
13C-NMR (75MHz, CDCl3,): δ 147.9, 147.4, 140.6, 133.9,
123.3, 72.8, 31.9, 9.8 ppm.
The enantiomeric excess (ee %) was determined by
HPLC using Phenomenex Lux cellulose 2 column (n-
hexane/i-PrOH 90:10, 0.7 mL/min, 254 nm): tr (R)-(1-
pyridin-3yl)propanol 18.2 min, t r (S)-(1-pyridin-
3yl)propanol 21.1 min.
(1-Thiophen-2-yl)ethanol (2k)
[α]D
25=−20.80° (c 0.2 chloroform) lit.4 [α]D
20=−23.2° (c
0.79 chloroform).
1H-NMR (300 MHz, CDCl3): δ 7.25–7.18 (m, 1H), 6.95–
6.92 (m, 2H), 5.07 (q, J=6.5 Hz, 1H), 2.54 (br s, 1H, OH),
1.56 (d, J=6.5 Hz, 3H) ppm.
13C-NMR (75 MHz, CDCl3): δ 150.0, 126.6, 124.4, 123.2,
66.2, 25.2 ppm.
The enantiomeric excess (ee %) was determined by HPLC
using Phenomenex Lux cellulose 3 column (n-hexane/i-PrOH
90:10, 0.5 mL/min, 254 nm): tr (S)-(1-thiophen-2-yl)ethanol
13.5 min, tr (R)-(1-thiophen-2-yl)ethanol 15.90 min.
(1-Furan-2-yl)ethanol (2l)
[α]D
25=−20.5° (c 0.2 chloroform) lit.4 [α]D
20=−13.6° (c
0.55 chloroform).
1H-NMR (400 MHz, CDCl3): δ 7.36 (dd, J
1=2.0 HzJ2=
1.0 Hz, 1H,), 6.32 (dd, J1=3.0 HzJ2=2.0 Hz, 1H,), 6.22 (d,
J=3.0 Hz, 1H,), 4.86 (q, J=6.5 Hz, 1H,), 2.35 (br s, 1H, OH),
1.52 (d, J=6.5 Hz, 3H,) ppm.
13C NMR (100 MHz, CDCl3): δ 157.7, 141.8, 110.1,
105.1, 63.6, 21.2 ppm.
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The enantiomeric excess (ee %) was determined by HPLC
using Phenomenex Lux cellulose 3 column (n-hexane/i-PrOH
98:2, 0.5 mL/min, 220 nm): tr (S)-(1-furan-2-yl)ethanol
19.3 min, tr (R)-(1-furan-2-yl)ethanol 21.3 min.
3-Hydroxy-3-phenylpropanenitrile (2m)
[α]D
25=−40.5° (c 0.2 ethanol) lit.8 [α]D
20=−57.7° (c 2.6
ethanol).
1H-NMR (300 MHz, CDCl3) δ 7.30–7.45(m, 5H), 5.1 (t,
J=6.0,1H), 2.79 (d, J=6 Hz, 2H), 2.36 (br s, 1H, OH) ppm.
13C-NMR (75 MHz, CDCl3) δ 140.1, 128.9, 128.8, 125.5,
117.6, 70.2, 28.1.
The enantiomeric excess (ee %) was determined by HPLC
using Chiralcel OJ column (n-hexane/i-PrOH 90:10, 1 mL/
min, 216 nm): tr (S)-3-hydroxy-3-phenylpropanenitrile
21.4 min, tr (R)-3-hydroxy-3-phenylpropanenitrile 25.0 min.
2-Hydroxy-1-phenylpropan-1-one (2v)
[α]D
25=−100° (c 0.2 chloroform) lit.8 [α]D
27=−91.1° (c
0.3 chloroform).
1H-NMR (300 MHz, CDCl3) δ 7.87 (d, J=8.2 Hz, 2H),
7.57 (t, J=7.42 Hz, 1H), 7.46 (t, J=7.7 Hz, 2H), 5.17 (m,
1H), 3.5 (br s, 1H, OH), 1.45 (d, J=7.0 Hz, 3H) ppm.
13C-NMR (75 MHz, CDCl3) δ 202.3, 133.9, 133.4, 128.7,
128.6, 69.3, 22.2.
The enantiomeric excess (ee %) was determined by HPLC
using Chiralcel OD column (n-hexane/i-PrOH 95:5, 0.4 mL/
min, 254 nm): tr (R)-2-hydroxy-1-phenylpropan-1-one
17.2 min, tr (S)-2-hydroxy-1-phenylpropan-1-one 21.9 min.
3-Hydroxy-1-phenyl-butan-1-one (2w)
[α]D
25=+54.2° (c 0.1 chloroform) lit.10 [α]D
27=+67.5° (c
1.2 chloroform).
1H-NMR (300 MHz, CDCl3) δ 7.97 (dd, J
1=8.5, J2=
2.0 Hz, 2H ), 7.50 (m, 3H), 4.42 (m, 1H), 3.24 (br s, 1H,
OH), 3.10 (d, J=6.0 Hz, 2H) 1.30 (d, J=6.4 Hz 3H) ppm.
13C-NMR (75MHz, CDCl3) δ 200.95, 136.8, 133.6, 128.8,
128.1, 64.1, 46.5, 22.5 ppm.
The enantiomeric excess (ee %) was determined by HPLC
using Chiralcel OD-H column (n-hexane/i-PrOH 95:5,
0.8 mL/min, 254 nm): tr (R)-3-hydroxy-1-phenyl-butan-1-
one 12.1 min, tr (S)-3-hydroxy-1-phenyl-butan-1-one
13.6 min.
Accession numbers
GenBank accession number of KRED1-Pglu gene is
KR080472.
Results
Analysis of the genome of Pichia glucozyma CBS 5766 re-
vealed the occurrence of a sequence (called KRED1-Pglu)
with high homology with known benzil reductases. The cor-
responding His-tagged protein was successfully expressed in
E. coli, yielding an active enzyme accounting for about 40 %
of the total protein content of the cell extract.
Activity and enantioselectivity
The activity of KRED1-Pglu was first investigated for reduc-
tion of benzil, observing that the enzyme is NADPH-depen-
dent. The enzyme exhibited the highest activity at pH between
7.0 and 8.0, being stable at pH between 6.0 and 8.0 (residual
activity of 90 % and 80 %, respectively). KRED1-Pglu
showed the highest activity between 30 °C and 35 °C and
was quite stable up to a temperature of 30 °C, above which
its activity started to decrease. As a compromise between ac-
tivity and stability, the following studies have been carried out
at 30 °C in 50 mMTris/HCl buffer pH 8.0. Kinetic parameters
for monoreduction of benzil by KRED1-Pglu were deter-
mined using 0.07 mg/ml of protein, NADPH as cofactor, at
30 °C and pH 8.0 (Table 1).
The initial rates of the biotransformation of different aro-
matic ketones and ketoesters were determined using a
substrate-independent assay (Table 2, column 5); relative ac-
tivities were expressed as per cent values versus benzil. Molar
conversion and enantioselectivity were determined by
performing the reduction of the substrates on a 50 mg scale,
using an Benzyme-coupled^ system (glucose/glucose dehy-
drogenase, GDH) (Table 2).
Preparative reduction of benzil (1a) resulted in total conver-
sion into (S)-benzoin (ee >98 %) in 2 h; bulky benzophenone
(1b) (which is transformed at low rates) was reduced to
diphenylmethanol in 24 h with good yields (66 %), showing
that a sluggish initial activity does not necessarily imply low
conversion, as already observed for the reduction of aromatic
ketones using LBADH (Rodríguez et al. 2014). Ethyl 2-oxo-2-
phenylacetate (1d) was totally reduced within 30 min, albeit
with mediocre S-enantioselectivity (ee 40 %). No consistent
trend could be detected between bulkiness of the substrates
and initial rates; for instance, the series 1e-h showed an erratic
tendency of activities with respect to the increasing bulkiness of
the substrate, similar towhat observedwith LBADH (Rodríguez
et al. 2014). KRED1-Pglu gave pronounced anti-Prelog
stereorecognition in the reduction of acetophenone (1e) and
propiophenone (1f) to yield the corresponding (R)-1-aryl-2-
ethanol, whereas other aromatic ketones (1g and 1i-1m) provid-
ed the corresponding (S)-alcohol (Prelog rule) with high
enantioselectivity. This remarkable switch of enantioselectivity
between similar substrates is not common among ketoreductases
able to reduce aromatic ketones (Lavandera et al. 2008; Zhu
et al. 2006). Finally, KRED1-Pglu showed no activity towards
much hindered substrates like β-γ-ketoesters (1n-1u).
Table 1 Kinetic parameters for monoreduction of benzil by KRED1-
Pglu
kcat (s
−1) Km (mM) kcat/Km (s
−1 mM−1)
0.14±0.02 0.64±0.10 0.22
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1-Phenylpropane-1,2-dione (1v) and 1-phenylbutane-1,3-
dione (1w) were also tested; both diketones were exclusively
reduced at the less hindered carbonyl group with formation of
(S)-2-hydroxy-1-phenylpropan-1-one (2v) and (S)-3-hy-
droxy-1-phenylbutan-1-one (2w) as the only reaction prod-
ucts, with complete enantioselectivity (Fig. 1).
The observed activities and enantioselectivity cannot be
explained by simply assuming a model of the active site with
two hydrophobic pockets differing in size, where the large
pocket binds the phenyl moiety, while the small one defines
whether the other substituent can be properly accommodated
and thus controls reaction rates and enantioselectivity. Since
the experimental results were unpredictable on the basis of just
the steric properties of the substrates, a molecular modelling
study was carried out for understanding the structural deter-
minants for the observed stereorecognition.
As the starting point for homology modelling, the PDB
database (http://www.rcsb.org/pdb/) was scanned with
BLAST against the target sequence of the KRED1-Pglu while
setting the maximal E-threshold=100; the search retrieved
several items. The top-scoring identified template, an
uncharac te r i zed ox idoreductase YIR035C from
Saccharomyces cerevisiae (UniProt entry P40579), and the
target share 46 % identity; YIR035C has been crystallized in
its apo form (X-ray structure as PDB entry 3KZV). The two
sequences were automatically aligned and manually adjusted,
and a model for the target protein was built by comparative
modelling. The structure so obtained did not allow, however,
for any effective docking of NAD(P)H to it. The second best
match, cis-2,3-dihydrobiphenyl-2,3-diol dehydrogenase from
Comamonas testosteroni (UniProt entry Q46381), shares
31 % identity with the target and has been crystallized in a
complex with NAD (PDB entry 2Y99). After alignment of the
sequences with T-coffee and superposition of the cognate
structures, NAD was imported from the template to the model
and the complex was energy-minimized, which resulted in
minor RMSD overall and a negligible displacement of the
amino acids predicted to be involved in the catalytic process
(annotations to UniProt entry P40579). However, once more,
Table 2 Investigation of the substrate range of KRED-Pglu concerning the reduction of different aromatic ketones and ketoesters
Entry Substrate Ar R Activity (%)a Yield (%) ee (%) Time (h)b
1 1a Phenyl COPh 100 >95 >98 (S) 2
2 1b Phenyl Phenyl 15 66 – 24
3 1c Phenyl CH2Ph <5 <5 <5 24
4 1d Phenyl COOEt 115 >95 40 (S) 0.5
5 1e Phenyl CH3 21 40 95 (R) 24
6 1f Phenyl CH2CH3 25 60 97 (R) 24
7 1g Phenyl CH2CH2CH3 18 56 97 (S) 24
8 1h Phenyl CH2CH2CH2CH3 <5 <5 <5 24
9 1i 3-Pyridyl CH3 58 >95 >98 (S) 24
10 1j 3-Pyridyl CH2CH3 60 >95 >98 (S) 24
11 1k 2-Thienyl CH3 51 >95 >98 (S) 24
12 1l 2-Furanyl CH3 48 >95 >98 (S) 24
13 1m Phenyl CH2CN 55 >95 95 (S) 24
14 1n Phenyl CH2COOEt <5 <5 <5 24
15 1o Phenyl CH2COOtBu <5 <5 <5 24
16 1p Phenyl CH(CH3)COOEt <5 <5 <5 24
17 1q Phenyl CH(CH3)COOtBu <5 <5 <5 24
18 1r Phenyl CH2CH2COOEt <5 <5 <5 24
19 1s Phenyl CH2CH2COOtBu <5 <5 <5 24
20 1t Phenyl CH2CH(CH3)COOEt <5 <5 <5 24
21 1u Phenyl CH2CH(CH3)COOtBu <5 <5 <5 24
aRelative activities measured using the benzil-reductase activity test and expressed as percent values referred to benzil
bReferred to the maximum yield
O O
O
O
O OH
O
OH
1v                                                                  2v
1w                                                                 2w
yield  > 95%
ee     > 98%
yield  = 60%
ee     > 98%
KRED1-Pglu
buffer pH 8.0 / 30 °C
NADP+/glucose/GDH
KRED1-Pglu
buffer pH 8.0 / 30 °C
NADP+/glucose/GDH
Fig. 1 Reduction of 1-phenylpropane-1,2-dione (1v) and 1-
phenylbutane-1,3-dione (1w) with KRED1-Pglu
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no effective docking of the test substrates could be obtained to
the model•NAD complex.
Various PDB entries of holo enzymes, crystallized as to
contain both NAD and a substrate/substrate analog/inhibitor
(2JAP, 1NAS, 4NBU), were thus inspected from the previous
BLAST output; clavulanic acid dehydrogenase from
Streptomyces clavuligerus (UniProt entry Q9LCV7; PDB entry
2JAP; 30 % identity with the target) was selected as further
template because of the comparable size of its substrate to our
test substrates. After superposition of the structures, substrate
clavulanic acid was imported from 2JAP to our model•NAD.
Effective docking was possible to the ternary complex
model•NAD•clavulanic acid after energyminimization; wewill
refer to the outcome of this procedure as KRED1-Pglu model.
Docking to KRED1-Pglu model was carried out using dif-
ferent protocols (rigid receptor, induced fit), various forcefields
(MMF94x, Amber12:EHT) and different electrostatics setups
(distance-dependent dielectric, reaction field); comparing the
position of the redox centre in the top scoring poses for the test
substrates in each procedure with that of the redox centre of
clavulanic acid taken as reference suggested that the combina-
tion: rigid receptor, Amber12:EHT, and distance-dependent
dielectric performs best. This protocol was then used to dock
to the KRED1-Pglu model all selected substrates.
The procedures of molecular modelling provided insight
into the ways of enzyme-substrate interaction and allowed
computing the affinities (dissociation constant values, Kds)
for different substrates, with an accuracy within one order of
magnitude, as discussed by Eberini et al. (2006). Table 3 lists
the in silico affinities of the enzyme for selected substrates
alongside the in vitro activities (same as in Table 2). Binding
of a substrate to the enzyme active site is necessary, but not
sufficient for catalysis to take place: once this prerequisite is
met, the rate of the process is controlled by the
stereoelectronic property of the substrate, a feature not directly
addressed by the classical docking procedure. Within these
boundaries, the relative order of the computational data is in
agreement with the experimental results and the enzyme is
most active on benzil (entry 1), the substrate with the highest
affinity for the catalytic site.
When the series of aryl aliphatic ketones is docked into the
enzyme active site, the orientation of the top-scoring
placements changes depending on the length of the aliphatic
chain, which defines the stereochemistry of the reductive reac-
tion. Figure 2 shows the relative placement of acetophenone
(substrate 1e; colour = green) and butyrophenone (substrate
1h; colour = yellow), and their position with respect to the
reductive hydride (arrow) of NAD(P)H (CPK colours).
Lengthening the aliphatic chain produces steric clashes with
amino acids in the enzyme catalytic site (specifically, W147
and L208) and results in an inversion of the predominant ori-
entation during the interaction. As a result, the stereochemistry
predicted for the stereocenter of the alcohol products is different
in either case and identical to what is obtained in vitro.
Discussion
Ketoreductases (KREDs) stereoselectively reduce prochiral ke-
tones giving access to optically pure secondary alcohols (Hall
and Bommarius 2011; Hollmann et al. 2011). Bulky aromatic
ketones can be reduced by specialised KREDs (Haberland et al.
2002; Stampfer et al. 2004; Lavandera et al. 2008; Huisman et al.
2009). Benzil reductases (Maruyama et al. 2002; Johanson et al.
2005; Pennacchio et al. 2013) are specific KREDs with high
affinity towards very hindered 1,2-diphenyl-ethanediones.
Sequence comparison among the benzil reductases frombacteria,
yeasts and mammals showed that conserved amino acid residues
are essential for benzil reductase activity and can be useful for
fishing out their genes from genomes. Whole cells of wild-type
Pichia glucozyma CBS 5766 have been used for a number of
reductions of aromatic ketones, including symmetric and asym-
metric 1,2-diaryl-ethanediones (benzils); the genome of
P. glucozyma CBS 5766 was annotated and a putative gene for
benzil reductase was identified based on sequence homology
with known benzil reductases and cloned in E. coli. The His-
tagged protein (named as KRED1-Pglu) was purified and used
for the reduction of different aromatic ketones; the enzyme
showed a marked preference for NADPH and was used on
Table 3 In silico affinities of KRED-Pglu for selected substrates
Entry Substrate Ar R Activity (%) Ki
1 1a Phenyl COPh 100 7.94×10−6
2 1b Phenyl Phenyl 5 1.21×10−5
5 1e Phenyl CH3 11 6.15×10
−5
6 1f Phenyl CH2CH3 35 3.36×10
−5
7 1g Phenyl CH2CH2CH3 10 2.32×10
−5
8 1h Phenyl CH2CH2CH2CH3 <5 1.38×10
−5
Fig. 2 Close-up to the catalytic site in the model of KRED1-Pglu.
NADH is rendered with CPK colors; the hydride atom involved in the
reduction process is marked with a dotted circle. Two substrates,
acetophenone (1e) and butyrophenone (1 h) are rendered in green and
yellow. Their orientation in the enzyme pocket is opposite, leading to
inverted configuration in the alcohol products
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preparative scale coupled with a glucose dehydrogenase (GDH)
for cofactor recycling. Benzil was reduced giving (S)-benzoin as
the sole observable product, whereas the use of whole cells
yielded lower enantiomeric excesses and further reduction to
hydrobenzoin (Fragnelli et al. 2012), indicating the occurrence
in P. glucozyma of other KR(s) active not only on benzil but also
on benzoin. Very hindered benzophenone was also reduced, as
previously observed with selected KRs (Truppo et al. 2007).
Aromatic ketoesters were poorly reduced by KRED1-Pglu,
whereas whole cells of P. glucozymaCBS 5766 were very effec-
tive and sometimes highly enantioselective on these substrates,
indicating the occurrence of other enantioselective KRs in this
unconventional yeast (Contente et al. 2014). Acetophenone and
propiophenone were reduced to the corresponding (R)-alcohols
(anti-Prelog’s rule), whereas butyrophenone was converted into
the corresponding alcohol with different stereobias, giving (S)-
phenylbutanol with high enantioselectivity. This shift of
stereopreference was explained by modelling the interaction be-
tween substrate and protein and observing that the length of the
aliphatic chain governs the stereochemistry of the biotransforma-
tion, determining which prostereogenic face of the ketone can be
favourably attacked by the hydride. The key role of the aliphatic
chain can also be seen in the case of valerophenone, where the
longer chain determines steric clashes with amino acids in the
enzyme catalytic site and the ketone is not reduced. KRED1-
Pglu was also employed for the reduction of 1-phenylpropane-
1,2-dione and 1-phenylbutane-1,3-dione leading to the
enantioselective formation of the α-methyl alcohols as the only
product, suggesting that KRED1-Pglu has potential as catalyst
for the preparation of hydroxyketones with high chemical and
optical purity.
In conclusion, a new (bio)catalyst for the preparation of
bulky aromatic chiral alcohols and hydroxyketones with high
enantioselectivity by reduction of the corresponding ketones
has been identified and produced from an unconventional
yeast. The different and erratic stereopreferences towards sim-
ple aromatic ketones were explained on the basis of modelling
studies. Further studies could be useful/help to identify,
generate and analyse KRED1-Pglu mutants, in which the
stereoselectivity of the reductive reaction can be carefully
tuned in order to customize and scale-up specific reactions
with industrial relevance.
Acknowledgments Recombinant GDH from Bacillus megateriumwas
kindly provided by Prof. Daniela Monti (Istituto di Chimica del
RiconoscimentoMolecolare, C.N.R., ViaMario Bianco 9, 20131Milano,
Italy).
Compliance with ethical standards This article does not contain any
studies with human participants or animals performed by any of the
authors.
Conflict of interest All the authors declare they have no conflict of
interest.
References
Baerga-Ortiz A, Popovic B, Siskos AP, O’Hare HM, Spiteller D,
Williams MG, Campillo N, Spencer JB, Leadlay PF (2006)
Directed mutagenesis alters the stereochemistry of catalysis by iso-
lated ketoreductase domains from the erythromycin polyketide syn-
thase. Chem Biol 13:277–285. doi:10.1016/j.chembiol.2006.01.004
Bechtold M, Brenna E, Femmer C, Gatti FG, Panke S, Parmeggiani F,
Sacchetti A (2012) Biotechnological development of a practical syn-
thesis of ethyl(S)-2-ethoxy-3-(p-methoxyphenyl)propanoate (EEHP):
over 100-fold productivity increase from yeast whole cells to recom-
binant isolated enzymes. Org Process Res Dev 16(2):269–276
BradfordMM (1976) A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 72:248–254
Contente ML, Molinari F, Zambelli P, De Vitis V, Gandolfi R, Pinto A,
Romano D (2014) Biotransformation of aromatic ketones and
ketoesters with the non-conventional yeast Pichia glucozyma.
Tetrahedron Lett 55(51):7051–7053
Contente ML, Zambelli P, Galafassi S, Tamborini L, Pinto A, Conti P,
Molinari F, Romano D (2015) A new chemoenzymatic approach to
the synthesis of Latanoprost and Bimatoprost. JMol Catal B Enzym.
doi:10.1016/j.molcatb.2014.05.022
Eberini I, Fantucci P, Rocco AG, Gianazza E, Galluccio L, Maggioni D,
Ben ID, Galliano M, Mazzitello R, Gaiji N, Beringhelli T (2006)
Computational and experimental approaches for assessing the interac-
tions between the model calycinβ-lactoglobulin and two antibacterial
fluoroquinolones. Proteins 65:555–567. doi:10.1002/prot.21109
Forzato C, Gandolfi R, Molinari F, Nitti P, Pitacco G, Valentin E (2001)
Microbial bioreductions of γ- and δ-ketoacids and their esters.
Tetrahedron 12:1039–1046. doi:10.1016/S0957-4166(01)00184-7
Fragnelli MC, Hoyos P, Romano D, Gandolfi R, Alcántara AR, Molinari
F (2012) Enantioselective reduction and deracemisation using the
non-conventional yeast Pichia glucozyma in water/organic solvent
biphasic systems: preparation of (S)-1,2-diaryl-2-hydroxyethanones
(benzoins). Tetrahedron 68:523–528. doi:10.1016/j.tet.2011.11.014
Gandolfi R, Cesarotti E, Molinari F, Romano D (2009) Asymmetric re-
ductions of ethyl 2-(benzamidomethyl)-3-oxobutanoate by yeasts.
Tetrahedron 20:411–414. doi:10.1016/j.tetasy.2009.02.023
Haberland J, Kriegesmann A, Wolfram E, Hummel W, Liese A (2002)
Diastereoselective synthesis of optically active (2R,5R)- hexanediol.
Appl Microbiol Biotechnol 58:595–599
Hall M, Bommarius AS (2011) Enantioenriched compounds via enzyme-
catalyzed redox reactions. Chem Rev 111:4088–4110. doi:10.1021/
cr200013n
Hollmann F, Arends IWCE, Holtmann D (2011) Enzymatic reductions
for the chemist. Green Chem 13:2285–2314
Hoyos P, Sansottera G, FernándezM,Molinari F, Sinisterra JV, Alcántara AR
(2008) Enantioselective monoreduction of different 1,2-diaryl-1,2-
diketones catalysed by lyophilised whole cells from Pichia glucozyma.
Tetrahedron 64:7929–7936. doi:10.1016/j.tet.2008.06.019
Huisman GW, Liang J, Krebber A (2010) Practical chiral alcohol manu-
facture using ketoreductases. Current Opinion in Chemical Biology
14:122–129. doi:10.1016/j.cbpa.2009.12.003
Husain SM, Stillger T, Dünkelmann P, Lodige M, Walter L, Breitling E,
Pohl M, Bürchner M, Krossing I, Müller M, Romano D, Molinari F
(2011) Stereoselective reduction of 2-hydroxy ketones towards syn-
and anti-1,2-diols. Adv Synth Catal 353:2359–2362. doi:10.1002/
adcs.201100150
Johanson T, KatzM, Gorwa-GrauslundMF (2005) Strain engineering for
stereoselective bioreduction of dicarbonyl compounds by yeast re-
ductases. FEMS Yeast Res 5:513–525. doi:10.1016/j.femsyr.2004.
12.006
Lavandera I, KernA, Ferreira-Silva B, Glieder A, deWildeman S, Kroutil
W (2008) Stereoselective bioreduction of bulky-bulky ketones by a
Appl Microbiol Biotechnol
novel ADH from Ralstonia sp. J Org Chem 73:6003–6005. doi:10.
1021/jo800849d
Li H, ZhuD, Hua L, Biehl ER (2009) Enantioselective reduction of diaryl
ketones catalyzed by a carbonyl reductase from Sporobolomyces
salmonicolor and its mutant enzymes. Adv Synth Catal 351:583–
588. doi:10.1002/adsc.200900045
Liang J, Lalonde J, Borup B,Mitchell V,Mundorff E, TrinhN, Kochrekar
DA, Cherat RN, Pai GG (2010) Development of a biocatalytic pro-
cess as an alternative to the (−)-DIP-Cl-mediated asymmetric reduc-
tion of a key intermediate of Montelukast. Org Process Res Dev 14:
193–198. doi:10.1021/op900272d
Maruyama R, Nishizawa M, Itoi Y, Ito S, Inoue M (2002) The enzymes
with benzil reductase activity conserved from bacteria to mammals.
J Biotechnol 94:157–169. doi:10.1016/S0168-1656(01)00426-6
O’Hare HM, Baerga-Ortiz A, Popovic B, Spencer JB, Leadlay PF (2006)
High-throughput mutagenesis to evaluate models of stereochemical
control in ketoreductase domains from the Erythromycin polyketide
synthase. ChemBiol 13:287–296. doi:10.1016/j.chembiol.2006.01.003
Rimoldi I, Cesarotti E, Zerla D, Molinari F, Albanese D, Castellano C,
Gandolfi R (2011a) Chemo- and biocatalytic strategies to obtain
phenylisoserine, a lateral chain of Taxol by asymmetric reduction.
Tetrahedron: Asymmetry 22:597–602. doi:10.1016/j.tetasy.2011.
11.017
Rimoldi I, Pellizzoni M, Facchetti G, Molinari F, Zerla D, Gandolfi R
(2011b) 3-(Hydroxy(phenyl)methyl)azetidin-2-ones obtained via
catalytic asymmetric hydrogenation or by biotransformation.
Tetrahedron: Asymmetry 22:2110–2116. doi:10.1016/j.tetasy.2011.
03.007
Rodríguez C, Borzęcka W, Sattler JH, Kroutil W, Lavandera I, Gotor V
(2014) Steric vs. electronic effects in the Lactobacillus brevisADH-
catalyzed bioreduction of ketones. Org Biomol Chem 12:673–681.
doi:10.1039/C3OB42057D
Sambrook J, Russell DW (2001) Molecular Cloning: A
Labora tory Manua l , 3rd edn. Cold Spr ing Harbor
Laboratory, New York
Stampfer W, Edegger K, Kosjek B, Faber K, Kroutil W (2004) Simple
biocatalytic access to enantiopure (S)-1-heteroarylethanols
employing a microbial hydrogen transfer reaction. Adv Synth
Catal 346:57–62
Truppo MD, Pollard D, Devine P (2007) Enzyme-Catalyzed
enantioselective diaryl ketone reductions. Org Lett 9:335–338. doi:
10.1021/ol0627909
Zhu D, Yang Y, Hua L (2006) Stereoselective enzymatic synthesis of
chiral alcohols with the use of a carbonyl reductase from Candida
magnoliae with anti-prelog enantioselectivity. J Org Chem 71:4202–
4205
Zhu D, Yang Y, Majkowicz S, Pan T (2008) Inverting the
enantioselectivity of a carbonyl reductase via substrate−enzyme
docking-guided point mutation. Org Lett 10:525–528. doi:10.
1021/ol702638j
Appl Microbiol Biotechnol
KRED1-Pglu 
 
82 
 
Enzymatic reduction of acetophenone derivatives: electronic and 
steric effects on activity and enantioselectivity 
 
6.1 Correlation between structure and activity 
 
The ketoreductase KRED1-Pglu from P. glucozyma was used for the 
enantioselective reduction of different mono-substituted acetophenones in order to study 
the correlation between reaction rates and electronic effects described by σ-Hammett 
coefficients. In fact, it is known that some ketoreductases show a quite broad substrate 
acceptance which is often limited by the electronic structure and polarization as well as by 
size and chirality of the substrates.
93
 In particular, the biocatalytic reduction of 
acetophenones is influenced by the different substituents of the aromatic ring.
94
 
The effects of ring substituents on electrophilic aromatic substitution (SNAr) 
have been studied and quantified for the first time in the 1930 by Hammett
95
 which 
correlated the electronic effects of the substituents and the consequent ionization constant 
of substituted benzoic acids with reaction rate in SNAr.
96
 This model was subsequently 
expanded in order to predict different chemical and biochemical reactions, moreover the 
new equation provides σ Hammett coefficients for various substrate structures.97 
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6.2 Hammet equation 
 
The Hammett equation relates the electronic and steric effects of functional 
groups present on a molecule with the reactivity of the same molecule. It allows to 
estimate the effects of various substituents able to change the electronic distribution both 
with inductive and mesomeric effects on the reactivity of a molecule. 
 
Log K= ρσ 
 
Fig. 44 Hammet equation 
 
 K is the equilibrium constant, while ρ and σ indicate respectively the reaction 
constant (depending on the type of reaction but not on the substituent) and the substituent 
constant, a measure of the total electronic effects exerted by the substituents on the 
reaction centre, σ is a positive value for electron withdrawing groups and negative for 
electron donor groups.  
Although it has been calculated for the dissociation reaction of different benzoic 
acids, the σ value is not dependent on the type of reaction and therefore can be used to 
estimate the influence of the introduction of a substituent on any type of reactions. 
The reaction constant ρ is the slope of the line correlating Log K with the σ 
values of the substituents. The sign of the slope tells if a reaction rate is enhanced or 
suppressed by electron donating versus electron withdrawing groups. Whereas negative ρ 
is diagnostic for the presence of positive charge at the reactive centre in the transition state, 
KRED1-Pglu 
 
84 
 
the meaning of positive ρ is the development of a negative charge during the transition 
state. In the first case the reaction rate is suppressed by electron withdrawing substituents, 
while in the second case the reaction rate is enhanced by electron withdrawing 
substituents. The magnitude of ρ describes the susceptibility of the reaction to the 
electronic features of the substituents. 
In our study the σ Hammett parameters were used to assess the influence of the 
nature of para- and meta-substituents on the kinetic of the hydride transfer to 
acetophenone. σ Hammett coefficients were in excellent correlation with reaction rates of 
para-acetophenones (R
2
= 0.934), showing that the activity of KRED1-Pglu was 
predominantly dependent on electronic properties, while substrate size and/or 
hydrophobicity had negligible effects (ρ > 0) as a consequence of the negative charge in 
the transition state caused by the attack of the hydride on the carbonyl group.  
The collected data about meta-derivatives showed a co-occurrence of steric and 
electronic effects in fact a low correlation between reaction rates and σ Hammett 
coefficients (R
2
= 0.721) was observed. This was confirmed by the reduction of ortho-
derivatives: only the substrates bearing substituents with low steric impact (F and CN) 
were reduced by KRED1-Pglu. (Data not published). 
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A ketoreductase from Pichia glucozyma (KRED1-Pglu) was employed for the 
enantioselective reduction of various mono-substituted acetophenones. Reaction rates of 
the reduction of meta- and para-derivatives were mostly consistent with the electronic 
effects described by σ-Hammett coefficients; Only ortho-substituted acetophenones with 
low steric impact (i.e., F and CN substituted) showed activity.  
Introduction 
 
Substituted 1-phenylethanols comprise an important structural class of compounds 
for synthetic purposes, and their obtainment by enantioselective reduction of the 
corresponding acetophenones has been thoroughly studied using chemocatalysis 
[1] and biocatalysis [2, 3]. Various microbial alcohol dehydrogenases (ADHs), 
carbonyl reductases (CRs), and ketoreductases (KRs) are able to reduce 
acetophenone derivatives giving access to both the enantiomers of the 
corresponding 1-phenylethanols [4]. An ADH from Rhodococcus erythropolis 
proved efficient in the reduction of a number of mono-, di- and tri-substituted 
KRED1-Pglu 
 
86 
 
acetophenones, giving always the corresponding (S)-1-phenylethanols (Prelog rule) 
[5]; the same stereopreference  was observed with others ADHs, i.e., from 
Ralstonia sp. [6] and from Thermoanaerobacter sp. [7]. A general preference for 
Prelog rule was also detected in a screening with 24 recombinant KRs tested on 
thirteen mono-susbstituted acetophenones [8]. Conversely, optically pure (R)-1-
phenylethanol can be prepared by reduction of (unsubstituted) acetophenone 
using specific enzymes, such as LK-ADH from Lactobacillus kefir [9], PF-ADH from 
Pseudomonas fluorescens [10] and carbonyl reductase from Candida magnoliae 
(CMCR) [11]. The effect of ring-substituents on catalytic efficiency of a number of 
mono-substituted acetophenone derivatives was studied using Candida tenuis 
xylose reductase (CtXR), which showed, in all the cases, preference for the 
formation of (S)-1-phenylethanols [12]. For this enzyme, σ-Hammett coefficients of 
para- and meta-substituents were in good correlation with the reaction velocities, 
indicating again that enzyme-substrate binding has a subordinated influence on 
the CtXR catalytic efficiency on these substrates; interestingly, ortho-derivatives 
were sometimes reduced with higher rates, indicating a beneficial mode of 
binding, in spite of steric effects. An interesting effect of the nature of the para -
substituents was observed with ADH from Lactobacillus kefir and 
Thermoanaerobacter sp., where acetophenones with neutral para -substituents 
were efficiently and selectively reduced, whereas those with ionizable substituents 
could not be reduced [13]. Whole cells of the non-conventional yeast Pichia 
glucozyma enantioselectively reduced different aromatic ketones [14-16], 
including acetophenone, with a marked preference for the formation of (S)-1-
phenylethanol [17, 18]; interestingly, a  benzil ketoreductase (KRED1-Pglu) isolated 
from the same yeast reduced acetophenone as recombinant protein with opposite 
enantioselectivity [19]. In this study we have investigated the reduction of different 
mono-substituted acetophenones using KRED1-Pglu for evaluating the potential of 
this new KR as enantioselective biocatalyst and understanding the correlation 
between enzymatic activity and the stereoelectronic features of the substrates. 
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Results and discussion 
 
The recombinant benzil ketoreductase KRED1-Pglu [19] was initially investigated 
using different para-substituted acetophenone derivatives (1a-1c and 1e-1h); 
acetophenone (1d) was used for comparative purposes (Table 1). The substrates 
were transformed with very different rates, being 4’-aminoacetophenone 1a (entry 
1, Table 1)  the only substrate not accepted. Reduction followed Prelog rule, giving 
the corresponding (S)-1-phenylethanols; most of the biotransformations occurred 
with high enantioselectivity, with the exception of 4’-methoxyacetophenone 1b 
(entry 2, Table 1), which was reduced with only 60% ee. The observed 
stereopreference is opposed to the one obtained with (unsubstituted) 
acetophenone 1d, which furnished (R)-1-phenylethanol 2d with 95% ee.  
KRED1-Pglu was also used for the reduction of a set of meta-substituted 
acetophenones (Table 2), having the same substituents of the para-acetophenones 
previously tested (1i-1o). In addition, in this case, the substituent affected the 
reaction rate and only poor reaction could be observed with the amino derivative 
1i. All the meta-derivatives were reduced to the corresponding  (S)-1-
phenylethanols with high-to-excellent enantioselectivity. Notably, 3’-
methoxyacetophenone 1j was reduced to optically pure (S)-1-(3-
methoxyphenyl)ethanol 2j, whereas the corresponding para-derivative 1b gave 
moderate enantioselectivity. 
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Table 1                                                                                         Table 2 
aInizial rates were calculated from initial progress curves 100% corresponds to the activity of the highest reacting 
substrate (1h). 
bMolar conversion after 24h 
 
The σ-Hammett coefficients were used to evaluate the influence of the nature of 
the para  and  meta - substituents on the kinetics of the hydride  transfer to 
acetophenone. The initial rates were plotted against the σ-values of the 
substituents; σpara and σmeta were independently correlated (Figure 1). 
σpara-Hammett coefficients were in excellent correlation with the reaction rates, 
showing that for para-substituents, the activity of KRED1-Pglu was mostly 
dependant on electronic properties, and substrate size and/or hydrophobicity had 
Entry Substrate X Rel. rate (%)a Yield (%)b ee (%) 
1 1i NH2 7 10 - 
2 1j OCH3 30 67 > 98 S 
3 1k CH3 15 18 > 98 S 
4 1d H 22 40 95 R 
5 1l F 61 85 > 98 S 
6 1m CF3 31 25 94 S 
7 1n CN 46 49 95 S 
8 1o NO2 53 78 > 98 S 
Entry Substrate X Rel. Rate (%)a Yield (%)b ee (%) 
 1 1a NH2 0 0 - 
2 1b OCH3 16 20 60 S 
3 1c CH3 23 30 > 98 S 
4 1d H 22 40 95 R 
5 1e F 35 40 93 S 
6 1f CF3 51 42 95 S 
7 1g CN 68 70 97 S 
8 1h NO2 100 100 > 98 S 
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negligible effects; as expected, since the attack of the hydride on the carbonyl 
cause a negative charge in the transition state, the reaction rate is consequently 
accelerated by electron withdrawing groups (ρ > 0). Electronic charge density 
distribution and C=O length have been previously used as parameters for 
correlating the activity of ADHs on different mono-substituted acetophenones [12, 
13]. Hence, we correlated the activity of KRED1-Pglu with the electronic charge 
distribution on the carbonyl (Figure 2) and with C=O length (Figure 3); electronic 
charge on the C=O carbon and C=O lengths were calculated in the gas phase 
through the MOE SCF Calculation interface to the GAMESS software [20]. The DFT 
calculations were based on the B3LYP hybrid functional with the 6-31G* basis [21].  
A high correlation between activity and electronic features of the substituents was 
found with para-derivatives, whereas a much lower correlation could be detected 
with meta-derivatives as detected with other enzymes [12, 31]. This behaviour is 
different from the one observed with ADHs from Lactobacillus brevis and 
Thermoanaerobacter sp., where the electron withdrawing or donating properties 
of the substituents did not exert a significant effect [13]. All these collected data 
indicate that para derivatives are reduced with reaction rates not dependent on 
steric interactions of the substrates with the enzyme, whereas steric effects have a 
(minor) impact on the reactivity of meta derivatives. The co-occurrence of steric 
effects for meta-derivatives is confirmed by the observation that 3’-
fluoroacetophenone 1l (bearing the less sterically hindered substituent still being 
an electron withdrawing group) was the preferred substrate. 
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Figure 1 Correlation between activity and the Hammett σ-values.  
Figure 2 Correlation between activity and charge distribution on the C=O Carbon. 
Figure 3 Correlation between activity and C=O length. 
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Ortho-derivatives were finally assayed (Table 3). KRED1-Pglu showed activity only 
towards 2’-fluoroacetophenone 1s and 2’-cyanoacetophenone 1u, the substrates 
bearing electron withdrawing with the lower steric impact. Ortho-substituents 
introduce significant steric effects in the reactivity of acetophenone derivatives, 
and therefore a simple Hammett's approach to quantify the substituent effects on 
a reaction center cannot be applied. Other enzymes, such as Candida tenuis xylose 
reductase [12], reduce ortho-substituted acetophenones better than para- and 
meta-derivatives, pointing out the crucial role of the binding mode between 
enzyme and substrate which is still in progress. 
 Table 3 
Entry Substrate X Rel. rate (%)a Yield (%)b ee (%) 
1 1p NH2 0 - - 
2 1q OCH3 0 - - 
3 1r CH3 0 - - 
4 1d H 22 40 95 R 
5 1s F 76 97 95 S 
6 1t CF3 0 - - 
7 1u CN 82 98 > 98 S 
8 1v NO2 0 - - 
aInizial rates were calculated from initial progress curves 100% corresponds to the activity of the highest reacting substrate 
(1h). bMolar conversion after 24h
92 
KRED1-Pglu 
In conclusion, we showed that benzil reductase from Pichia glucozyma (KRED1-Pglu) is an 
efficient biocatalyst for the enantioselective reduction of various mono-sobstituted 
acetophenones. Reaction rates of meta- and para-derivatives were consistent with the 
electronic effects described by σ-Hammett coefficients; on the contrary, molecular 
modelling studies to understand the enantioselectivity determined by binding mode 
between enzyme and substrate, are still in progress. Reduction of ortho-derivatives 
occurred only with the substrates bearing substituent with low steric impact (i.e. F, CN).
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Materials 
All reagents and solvents were obtained from Sigma–Aldrich–Fluka and used without 
further purification or drying. TLC was performed with Merck silica gel 60 F254 pre-
coated plates. Silica gel column chromatography was carried out on silica gel 60 M (40–63 
mm). Recombinant KRED1-Pglu was produced in Escherichia coli and purified to apparent 
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homogeneity as described earlier [19]. Recombinant glucose dehydrogenase (GDH) was a 
kind gift from Dr. Daniela Monti. For each compound the alcohol racemic mixture was 
obtained by NaBH4 reduction (0.25 x mMol of substrate).  
Analyticals 
1H-NMR and 13C-NMR spectra were recorded with a Varian Mercury 300 (300 MHz) or 500
(500 mHz) spectrometer. Chemical shifts (δ) are expressed in ppm, and coupling 
constants (J) are expressed in Hz. GC analyses were performed with a Dani 6500 
gascromatograph: gas carrier H2 (0.6 bar, T=100°C), Detector FID (Flame Ionization 
Detector), Tmax = 300°C. Chiral capillary GC columns used: DMePeBeta-CDX-PS086 
(diameter 0.25 mm, length 25 m, thickness 0.25 μ, MEGA) and Mega-Dex DET beta 
(diameter 0.25 mm, length 25 m, thickness 0.25 μ, MEGA). HPLC analyses were 
performed with a Jasco Pu-980 equipped with a UV-vis detector Jasco UV-975. Chiral 
HPLC columns used: Chiralcel OD-H (250 x 4 mm, Daicel), Chiralcel OD (250 x 4 mm, 
Daicel), Lux cellulose-2 column (4.6 x 150 mm, Phenomenex) and Lux cellulose-3 column 
(4.6 x 150 mm, Phenomenex). Rotary power determinations were carried out using a 
Jasco P-1010 spectropolarimeter, coupled with a Haake N3-B thermostat. 
Enzymatic activity 
Enzymatic activity was measured spectrophotometrically at 340 nm by determining the 
consumption of NADPH during the reduction of acetophenones at 22°C in a half-micro 
cuvette (total volume 1 mL) for 5 min. The cuvette contained the ketone (0.47 mM) 
dissolved in DMSO (final concentration 0.1%) and NADPH (0.25 mM) in Tris-HCl 50 mM 
pH 8.0 buffer (up to 1 mL). The reaction was initiated by the addition of KRED1-Pglu 
(0.07mg). The reaction rates were calculated from measurements determined in 
triplicate. One unit (U) of activity is defined as the amount of enzyme which catalyses the 
consumption of 1 µmol of NADPH per minute. Relative rates were calculated taking into 
account the maximal activity registered (towards 4’-nitroacetophenone). 
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Preparative reduction of acetophenones 
General procedure for the ketone reduction using a NADPH recycle system was as 
follows: reductions were carried out in 10 mL screw-capped test tubes with a reaction 
volume of 5 mL with KRED1-Pglu (20 mU/mL), GDH (1 U/mL), NADP+ (0.1 mM), substrate 
(1 g/L), glucose (4 x mMol of substrate) suspended in 50 mM Tris/HCl buffer pH 8.0. The 
samples were extracted with ethyl acetate (3 x 5 mL). The organic extracts were dried 
over anhydrous sodium sulfate and subjected to chiral GC or HPLC analysis.  
 
Characterization of the products 
(S)-2b (1-(4’-methoxyphenyl)ethanol): [α]D
25 = - 25.0° (c 0.2 chloroform ) lit.[22] [α]D
25 = - 
51.9° (c 0.718 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.25-7.30 (m, 2H), 6.83-6.87 (m, 
2H), 4.82 (q, J = 6.5 Hz, 1H ), 3.78 (s, 3H), 1.44 (d, J = 6.5 Hz, 3H) ppm. 13C-NMR (75 MHz, 
CDCl3): δ = 158.5, 138.0, 126.4, 114.0, 69.7, 55.1, 25.0 ppm. The enantiomeric excess (% 
ee) was determined by HPLC using Chiralcel OD-H column (n-hexanes/i-PrOH 99:1, 1 
mL/min, 210 nm): tr (R)-1-(4’-methoxyphenyl)ethanol min, tr (S)-1-(4’-
methoxyphenyl)ethanol 22.6 min. 
 
(S)-2c (1-(4’-tolyl)ethanol): [α]D
20 = - 51.4.0° (c 0.2 chloroform ) lit.[23] [α]D
20 = - 53.4° (c 
0.85 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.20-7.24 (m, 2H), 7.10-7.15 (m, 2H) 4.8 
(q, J = 6.5 Hz, 1H ), 2.32 (s, 3H), 1.45 (d, J = 6.5 Hz, 3H ) ppm. 13C-NMR (75 MHz, CDCl3): δ = 
143.0, 136.5, 129.1, 128.3, 124.7, 68.6, 25.1, 21.0 ppm. The enantiomeric excess (% ee) 
was determined by GC using Mega-dex DET Beta column, gas carrier: H2 (0.6 bar, T = 
100°C), detector FID (flame ionization detector), temperature: 70-170°C 4°/min: tr (S)-1-
(4-tolyl)ethanol 14.1 min, tr (R)-1-(4-tolyl)ethanol 14.6 min. 
 
(R)-2d (1-phenylethanol): [α]D
25 = + 40.0° (c 0.5 chloroform ) lit.[24] [α]D
25 = + 36.0° (c 1.0 
chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.20–7.35 (m, 5H), 4.85 (q, J = 6.4 Hz, 1H), 
1.46 (d, J = 6.4 Hz, 3H) ppm.13C-NMR (75 MHz, CDCl3): δ = 145.9, 128.5, 127.5, 125.4, 70.4, 
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25.2 ppm. The enantiomeric excess (% ee) was determined by HPLC using Chiralcel OD 
column (n-hexanes/i-PrOH 95:5, 0.7 mL/min, 254 nm): tr (R)-1-phenylethanol 14.2 min, tr 
(S)- 1-phenylethanol 18.0 min. 
 
(S)-2e (1-(4’-fluorophenyl)ethanol): [α]D
20 = - 78.6.0° (c 0.2 chloroform ) lit.[23] [α]D
20 = - 
81.5° (c 1.58 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.30-7.35 (m, 2H), 7.00-7.05 (m, 
2H) 4.85 (q, J = 6.5 Hz, 1H ), 1.45 (d, J = 6.5 Hz, 3H ) ppm. 13C-NMR (75 MHz, CDCl3): δ = 
162.0 (d, J = 242.5 Hz), 140.8 (d, J = 2.5Hz), 126.8 (d, J = 8.8 Hz), 114.4 (d, J = 20.0 Hz, Ar-
C), 70.0 (CH), 25.2 ppm. The enantiomeric excess (% ee) was determined by GC using 
Mega-dex DET Beta column, gas carrier: H2 (0.6 bar, T = 100°C), detector FID (flame 
ionization detector), temperature: 70-170°C 4°/min: tr (S)-1-(4-Fluorophenyl)ethanol 12.9 
min, tr (R)-1-(4-Fluorophenyl)ethanol 13.5 min. 
 
(S)-2f (1-(4’-trifluoromethylphenyl)ethanol): [α]D
20 = - 40.50° (c 0.2 chloroform ) lit.[23] 
[α]D
20 = - 32.0° (c 0.86 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.58 (d, J = 8.0 Hz, 2H,), 
7.45 (d, J = 8.0 Hz, 2H,), 4.95 (q, J = 6.5 Hz, 1H,), 1.46 (d, J = 6.5 Hz, 3H,) ppm. 13C-NMR (75 
MHz, CDCl3): δ = 148.9, 129.5 (q, J = 32.0 Hz), 124.3, 125.4 (q, J = 3.9 Hz), 123.1, 70.0 (CH), 
25.2 ppm. The enantiomeric excess (% ee) was determined by HPLC using Chiralcel OD-H 
column (n-hexane/EtOH 98:2, 0.8 mL/min, 220 nm): tr (S)-1-(4-
trifluoromethylphenyl)ethanol 16.5 min, tr (R)-1-(4-trifluoromethylphenyl)ethanol 17.25 
min. 
 
(S)-2g (1-(4’-cyanophenyl)ethanol): [α]D
20 = - 45.2° (c 0.2 chloroform ) lit.[23] [α]D
20 = - 
46.4° (c 2.40 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.61 (d, J = 8.5 Hz, 2H,),7.50 (d, J 
= 8.0 Hz, 2H,), 4.98 (q, J = 6.5 Hz, 1H,), 1.48 (d, J = 6.5 Hz, 3H,) ppm. 13C-NMR (75 MHz, 
CDCl3): δ = 151.5, 133.4, 126.1, 119.0, 111.0, 69.5, 25.2 ppm. The enantiomeric excess (% 
ee) was determined by GC using Mega-dex DET Beta column, gas carrier: H2 (0.6 bar, T = 
100°C), detector FID (flame ionization detector), temperature: 70-170°C 4°/min: tr (S)-1-
(4-cyanophenyl)ethanol 23.7 min, tr (R)-1-(4-cyanophenyl)ethanol 24.0 min. 
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(S)-2h (1-(4’nitrophenyl)ethanol): [α]D
25 = - 25.0° (c 0.2 chloroform ) lit.[25] [α]D
20 = - 22.6° 
(c 1.0 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 8.18 (d, J = 8.5 Hz, 2H,), 7.51 (d, J = 8.0 
Hz, 2H,), 4.95 (q, J = 6.5 Hz, 1H,), 1.50 (d, J = 6.5 Hz, 3H,) ppm. 13C-NMR (75 MHz, CDCl3): δ 
= 153.1, 147.1, 126.1, 123.7, 69.4, 25.4 ppm. The enantiomeric excess (% ee) was 
determined by HPLC using Phenomenex LUX Cellulose-3 column (n-hexane/ i-PrOH 90:10, 
0.5 mL/min, 254 nm): tr (S)-1-(4-nitrophenyl) ethanol 23.4 min, tr (R)-1-(4-nitrophenyl) 
ethanol 24.9 min. 
 
(S)-2j (1-(3’-methoxyphenyl)ethanol): [α]D
20 = - 40.2° (c 0.2 chloroform ) lit.[23] [α]D
20 = - 
38.9° (c 1.27 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.20-7.25 (m, 1H, ), 6.90-6.95 (m, 
2H,), 6.80 (ddd, J = 8.5 Hz, 1.5 Hz and 1.0 Hz, 1H,), 4.84 (q, J = 6.5 Hz, 1H,), 3.80 (s, 3H), 
1.46 (d, J = 6.5 Hz, 3H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 159.8, 147.6, 130.0, 116.5, 
113.0, 111.0 , 70.3, 56.2, 25.1 ppm. The enantiomeric excess (% ee) was determined by 
HPLC using Chiralcel OD column (n-hexane/i-PrOH 95:5, 0.5 mL/min, 216 nm): tr (R)-1-(3-
methoxyphenyl)ethanol 23.1 min, tr (S)-1-(3-methoxyphenyl)ethanol 26.4 min. 
 
(S)-2k (1-(3’-tolyl)ethanol): [α]D
20 = - 45.4.0° (c 0.2 chloroform ) lit.[23] [α]D
20 = - 47.2° (c 
1.09 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.00-7.25 (m, 4), 4.84 (dq, , J = 6.5 Hz and 
3.5 Hz, 1H), 2.35 (s, 3H), 1.47 (d, J = 6.5 Hz, 3H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 144.0, 
137.1, 128.4, 128.2, 126.1, 122.4 , 68.4, 25.1, 21.4 ppm. The enantiomeric excess (% ee) 
was determined by GC using Mega-dex DET Beta column, gas carrier: H2 (0.6 bar, T = 
100°C), detector FID (flame ionization detector), temperature: 70-170°C 4°/min: tr (S)-1-
(3’-tolyl)ethanol 14.8 min, tr (R)-1-(3’-tolyl)ethanol 15.1 min. 
 
 
(S)-2l (1-(3’-fluorophenyl)ethanol): [α]D
20 = - 25.60° (c 0.2 chloroform ) lit.[26] [α]D
20 = - 
24.4° (c 1.24 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.25-7.32 (m, 1H), 7.10-7.15 (m, 
1H), 6.88–6.98 (m, 2H), 4.85 (q, J = 6.5 Hz, 1H ), 1.45 (d, J = 6.5 Hz, 3H ) ppm. 13C-NMR (75 
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MHz, CDCl3): δ = 163.0 (d, J = 246.1 Hz), 148.5 (d, J = 6.4 Hz), 129.9 (d, J = 7.7 Hz), 120.9 (d, 
J = 2.6 Hz), 114.2 (d, J = 21.2 Hz), 112.3 (d, J = 21.2 Hz), 69.7 (d, J = 2.1 Hz), 25.2 ppm. The 
enantiomeric excess (% ee) was determined by GC using Mega-dex DET Beta column, gas 
carrier: H2 (0.6 bar, T = 100°C), detector FID (flame ionization detector), temperature: 70-
170°C 4°/min: tr (S)-1-(3’-fluorophenyl)ethanol 17.0 min, tr (R)-1-(3’-fluorophenyl)ethanol 
17.5 min. 
 
(S)-2m (1-(3’-trifluoromethylphenyl)ethanol): [α]D
20 = - 30.50° (c 0.2 chloroform ) lit.[23] 
[α]D
20 = - 27.6° (c 1.05 chloroform).1H-NMR (300 MHz, CDCl3): δ = 7.63-7.25 (m, 4H), 4.91 
(q, J = 6.5 Hz, 1H,), 1.48 (d, J = 6.5 Hz, 3H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 146.7, 130.8 
(q, J = 32.5 Hz), 128.9, 128.8, 124.2 (q, J = 4.6 Hz), 124.1 (q, J = 270.8 Hz), 122.2 (q, J = 4.4 
Hz), 69.8, 25.2 ppm  
The enantiomeric excess (% ee) was determined by HPLC using Chiralcel OD-H column (n-
hexane/EtOH 98:2, 0.8 mL/min, 220 nm): tr (S)-1-(3’-trifluoromethylphenyl)ethanol 18.5 
min, tr (R)-1-(3’-trifluoromethylphenyl)ethanol 19.3 min. 
 
 
(S)-2n (-1-(3’-cyanophenyl)ethanol): [α]D
20 = - 25.2° (c 0.2 chloroform ) lit.[27] [α]D
20 = - 
26.6° (c 0.3 chloroform). 1H-NMR (300 MHz, CDCl3): δ =  7.66 (s, 1H,), 7.60 (d, J = 7.3 1H,), 
7.52-7.55 (m, 1H,), 7.40-7.45 (m, 1H), 4.90 (q, J = 6.1 Hz, 1H,), 1.48 (d, J = 6.1 Hz, 3H,) 
ppm. 13C-NMR (75 MHz, CDCl3): δ = 146.5, 130.5, 129.9, 129.0, 128.5, 119.0, 111.0, 69.5, 
25.2 ppm. The enantiomeric excess (% ee) was determined by GC using Mega-dex DET 
Beta column, gas carrier: H2 (0.6 bar, T = 100°C), detector FID (flame ionization detector), 
temperature: 70-170°C 4°/min: tr (S)-1-(3’-cyanophenyl)ethanol 23.7 min, tr (R)-1-(3’-
cyanophenyl)ethanol 24.0 min. 
 
(S)-2o 1-(3’-nitrophenyl)ethanol: : [α]D
25 = - 22.0° (c 0.2 chloroform ) lit.[28] [α]D
25 = - 14.5° 
(c 1.0 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 8.18 (t, J = 1.8. Hz, 1H,), 8.05 (ddd, J = 
8.3, 2.1 and 0.9 Hz, 1H,), 7.65 (d, J = 7.8, 1H), 7.50 (t, J = 7.8. Hz, 1H,), 4.95 (q, J = 6.5 Hz, 
1H,), 1.50 (d, J = 6.5 Hz, 3H,) ppm. 13C-NMR (75 MHz, CDCl3): δ = 149.1, 147.1, 131.5, 
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129.1, 123.7, 120.2, 69.4, 25.4 ppm. The enantiomeric excess (% ee) was determined by 
HPLC using Phenomenex LUX Cellulose-2 column (n-hexane/i-PrOH 98:2, 0.5 mL/min, 254 
nm): tr (R)-1-(3’-nitrophenyl)ethanol 60.0 min, tr (S)-1-(3’-nitrophenyl)ethanol 67.5 min. 
 
(S)-2s (1-(2’-fluorophenyl)ethanol): [α]D
20 = - 43.1° (c 0.2 chloroform ) lit.[29] [α]D
25 = - 
47.8° (c 1.46 chloroform). 1H-NMR (300 MHz, CDCl3): δ = 7.45-7.50 (m, 1H), 7.27-7.20 (m, 
1H), 7.15–7.05 (m, 1H), 7.04-6.98 (m, 1H), 4.85 (q, J = 6.5 Hz, 1H ), 1.43 (d, J = 6.5 Hz, 3H ) 
ppm. 13C-NMR (75 MHz, CDCl3): δ =  159.9 (d, J = 246.1 Hz), 132.5 (d, J = 13.4 Hz), 128.9 (d, 
J = 8.2 Hz), 126.9 (d, J = 4.6 Hz), 124.2 (d, J = 3.4 Hz), 115.3 (d, J = 21.2 Hz), 65.7, 24.2 ppm. 
The enantiomeric excess (% ee) was determined by GC using Mega-dex DET Beta column, 
gas carrier: H2 (0.6 bar, T = 100°C), detector FID (flame ionization detector), temperature: 
70-170°C 4°/min: tr (S)-1-(2’-fluorophenyl)ethanol 12.09 min, tr (R)-1-(2’-
fluorophenyl)ethanol 13.9 min. 
 
(S)-2u (1-(2’-cyanophenyl)ethanol): [α]D
20 = - 45.6° (c 0.2 dichloromethane ) lit.[30] [α]D
20 = 
- 47.6° (c 1.0 dichloromethane). 1H-NMR (500 MHz, CDCl3): δ =  7.60-7.70 (m, 1H,), 7.55 
(d, J = 7.3 2H,), 7.20-7.36 (m, 1H,), 5.20 (q, J = 6.4 Hz, 1H,), 1.48 (d, J = 6.4 Hz, 3H,) ppm. 
13C-NMR (125 MHz, CDCl3): δ = 148.9, 133.1, 132.5, 127.8, 125.4, 116.5, 109.0, 66.7, 24.2 
ppm. The enantiomeric excess (% ee) was determined by GC using Mega-dex DET Beta 
column, gas carrier: H2 (0.6 bar, T = 100°C), detector FID (flame ionization detector), 
temperature: 70-170°C 4°/min: tr (S)-1-(2’-cyanophenyl)ethanol 26.4 min, tr (R)-1-(2’-
cyanophenyl)ethanol 27.2 min. 
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Stereoselective enzymatic reduction of ethyl secodione: preparation 
of key-intermediates for the total synthesis of steroids 
 
7.1 Nature and action of hormones  
 
In the superior organisms the functional integration of the various organs is 
possible by the “information” transmitted via nervous system or through bloodstream. 
Although functionally distinct, these two information and regulation systems are closely 
coordinated by a common control center, the hypothalamus. The hormones are chemical 
messengers secreted in the blood and distributed throughout the body to explicate their 
action on target cells having receptor able to recognize them. Target cells also have 
elements for translating the hormonal stimulation in appropriate functional and metabolic 
changes in order to adapt the organism to the internal or external environment conditions 
maintaining the homeostasis. 
Chemically heterogeneous, the hormones can be classified in i) peptide 
hormones such as insulin, glucagon, pituitary hormones, ii) steroidal hormones, sexual and 
adrenocortical ones, iii) derivatives of amino acids such as adrenalin, noradrenalin, 
thyroxin, triiodothyronine. The hydrophilic hormones circulate in the free form in the 
bloodstream whereas the hydrophobic ones are carried out in the blood by specific binding 
proteins.  
The hormones are not secreted with regular rhythm, but following cycles or after 
stimulation. For example gonadotropins are released following menstrual cycle or after 
occasional events such as pregnancy or breastfeeding, the insulin and glucagon secretion is 
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regulated by the glycaemia level, the calcitonin and parathormone release by level of 
serum calcium.    
The hormone’s average life is short: once explicated their action, molecules are 
quickly inactivated for example using proteolysis, in this way the need of a controlled and 
transitory response is satisfied. The continuity of hormone response, when necessary, is 
assured by pulsing secretions.  
Another characteristic of hormones is to exert their action at very low 
concentrations  (10
-9
-10
-12 
M).
98
 
 
7.2 Progesterone 
 
Progesterone, that in the adrenal cortex is the key intermediate for the synthesis 
of adrenocortical hormones, is synthesized in high amount in the ovarian corpus luteum 
after the stimulation of pituitary LH (luteinizing hormone). It is the predominant hormone 
in the second part of menstrual cycle and, essentially, it acts in the uterus for the 
endometrium preparation to fecundated ovum implantation. In case of pregnancy the 
secretion of progesterone, supported by placenta, is maintained until the labor. The 
administration of progesterone during specific periods of menstrual cycle inhibits the 
ovulation. On this action is based its use as contraceptive. 
All the steroidal hormones derive from cholesterol through pregnenolone. The 
transformation of pregnenolone in progesterone consists of in two different steps: in the 
first the hydroxyl in 3 position is oxidized into the corresponding ketone by the 3-β-olo-
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dehydrogenase. In the second step the carbon-carbon double bond is transferred in delta
4 
position by delta 4,5 isomerase. Both the reactions occur in the cytosol. 
99
 
 
 
 
Fig. 45 Synthesis of progesterone in the human cells 
  
7.3 Levonorgestrel  
 
 
 
Fig. 46 Structure of Levonorgestrel 
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Norgestrel was synthesized in 1950s as racemic mixture. Many studies about 
pharmacokinetics and pharmacodynamic parameters showed that norgestrel was an 
extremely potent progestogen with progestational and anti-ovulatory activities higher than 
those existing progestogens. The total activity of norgestrel resides in the left-handed  
isomer levonorgestrel, so it quickly become the progestogen used in therapy as a 
contraceptive both in association with ethinylestradiol as birth control pill, and in 
monotherapy as an emergency contraceptive.
100
 Its activity on the prevention of ovulation 
and fecundation,
101
 in particular the transformation of the endometrium in unsuitable 
environment for the implantation of the embryo makes it one of the most used and 
effective nonsurgical method for spacing and fertility control.
102
 Levonorgestrel is a 
second-generation progestin agonist having high affinity for progesterone receptors. It 
binds the intracellular cytosolic receptors formed by three different regions: the amino 
terminal responsible for the dimerization of the receptor, the central portion that presents 
affinity for specific DNA sequences and the carboxy-terminal region responsible for the 
binding with ligand and for the migration of the complex ligand-receptor in the cell 
nucleus. The carboxy-terminal domain when occupied by the hormone or by an agonist 
confers the active conformation upon the receptor. In this domain are present two 
subdomains, one participant in the modulation of transcription process and the other 
binding particular proteins called HSP (heat shock proteins). As long as HSPs are bonded, 
the central interaction domain with DNA is locked and the receptor is inactive. The 
hormone entry, inducing the receptor dimerization, removes the HSPs transforming the 
receptor in its active form. After dimerization the receptor enters the cell nucleus and 
                                                          
100
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101
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binding specific DNA sequences, facilitates or inhibits transcription. The difference in the 
central receptor regions is the reason of the binding specificity with DNA sequences called 
HRE (Hormone Responsive Elements) responsible for the transcription triggering and for 
the activation of signal transduction pathway with the consequent release of second 
messengers. These, intervening on the state of protein phosphorylation produce effects of 
metabolic regulation. 
103
  
Fig. 47 Action mechanism of progesterone and its receptor 
103
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Based on this key role in metabolism, progesterone derivatives are compounds of 
great interest for pharmaceutical industry. Their complex and multi-functional structure 
requires highly selective synthetic strategies. Our chemoenzymatic synthesis, exposed 
above, combines the flexibility of chemical synthesis and the high selectivity encontered 
with enzymatic transformations both using whole cells of various yeasts and 
the recombinant benzil-reductase from P. glucozyma, being an effective approach 
for the preparation of Levonorgestrel. 
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Stereoselective enzymatic reduction of ethyl secodione: 
preparation of a key-intermediate for the total synthesis of 
steroids 
Martina Letizia Contente,[a] Francesco Molinari,[a] Immacolata Serra,[a] Andrea Pinto,*[b] Diego Romano*
[a]   
Abstract: Ethyl secodione (1) has been enantioselectively reduced 
using different biocatalysts for the preparation of (13R, 17S)-2a. The 
recombinant ketoreductases KRED1-Pglu converted the substrate
with the highest reaction rate and stereoselectivity (ee > 98%), 
whereas whole cells of Pichia minuta CBS 1708 showed the highest 
productivity. Stereoselective reduction of 1 provides the key chiral 
precursor for the synthesis of a number of hormonal contraceptives 
(i.e., desogestrel, norgestrel, gestodene).  
Chemoenzymatic synthesis combines the flexibility of chemical 
synthesis and the high (stereo)selectivity often encountered with 
enzymatic transformations, being an effective approach for the 
synthesis of many drugs, including steroids.[1] Total synthesis of 
steroids has become widely applicable mostly due to the 
discovery by Ananchenko and Torgov of a straightforward 
process making possible the assembly of a steroidal A/B bicyclic 
core.[2, 3] This strategy can be used for the synthesis of second 
generation oral contraceptives, after reduction of the easily 
available ethyl secodione derivative 1. Only 13-(R)-ethyl secols 
are useful for the synthesis of contraceptive hormones (i.e., 
desogestrel, levonorgestrel, gestodene (Figure 1).[3]  
Figure 1. Second generation oral contraceptives from ethyl secodione 1.
Although biocatalytic reduction of compound 1, has been 
studied by industrial groups since the mid-sixties,[4] no detailed 
(stereo)chemical characterization of the reduction products of 1 
has been reported in literature. To this aim, compound 1 was 
reduced with NaBH4 and the four possible stereoisomers of 2
were isolated and fully characterized (Scheme 1). 
Scheme 1. Monoreduction of ethyl secodione 1 using NaBH4. 
Firstly, syn racemate (±)-2a was separated from the anti
racemate (±)-2b by semi-preparative silica HPLC. The relative 
stereochemistry of compounds (±)-2a and (±)-2b was initially 
deduced from the NOESY spectra.  
Figure 2. NOESY correlations in syn racemate (±)-2a and anti racemate (±)-
2b. 
Concerning derivative (±)-2a, the observation of NOESY 
correlations from H-17 to H-12 and H-11, and from H-18 to 17-
OH, indicated that 17-OH and ethyl group are in a syn
configuration (Figure 2). On the other hand, for derivative (±)-2b,
the observation of NOESY correlations from H-12 to 17-OH, and 
from H-18 to H-17, indicated that 17-OH and ethyl group are in 
an anti configuration. The racemates (±)-2a and (±)-2b were, in 
turn, resolved into their pure enantiomers by semi-preparative 
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E-mail: andrea.pinto@unimi.it 
  
O
O
OH
H
O
O
OH
H
3
4
5
6
7
8
9
10
1
2
11
12
13
14 15
16
17
(±)-2a (±)-2b
18
19
3
4
5
6
7
8
9
10
1
2
11
12
13
14 15
16
17
18
19
  
chiral HPLC using, in both cases, tris-(3,5-
dimethylphenyl)carbamoyl amylose as chiral stationary phase 
(see Supplementary information).  
We then succeeded in growing diffraction-quality crystals of 
one of the two enantiomers of 2b The relative stereochemistry 
was unequivocally determined as syn by accurate single-crystal 
X-ray experiments (Figure 3), confirming the results obtained by 
the NOESY technique (see Supplementary information for 
further details).  
Figure 3. X-ray structure of the asymmetric unit of ()-2b at room temperature, 
with the atom numbering scheme. Thermal ellipsoids are drawn at the 30% 
probability level.
To assign the absolute configuration of the four stereoisomers, 
we decided to follow the Mosher’s methodology. To this aim 
starting from enantiomerically pure ()-2a and ()-2b, (R)- and 
(S)-MTPA esters of the alcohol at C-17 were prepared and the 
absolute configuration at C-17 was unambiguously assigned as 
17S in both cases (see Supplementary information). Based upon 
the already assigned relative configuration, the absolute 
configuration of ()-2a was established as 13R, 17S and the 
absolute configuration of ()-2b was established as 13S, 17S.  
Corey and coworkers developed a method for stereoselective 
reduction of methyl secodione (Torgov’s diketone) using 
oxazaborolidine catalysis, which furnishes enantiopure (13R, 
17R)-methyl secol in 86% yield with 99% ee after 
recrystallization,[5]  whose preparation opened the route to a 
stereoselective version of Torgov’s synthesis of estrone. Our 
attempts to apply Corey’s method to the reduction of 1 gave 
poor results, with formation of (13R, 17R)-2b in low yields (25-
30%) and poor enantioselectivity (75% ee).  
Biocatalytic reduction (either using isolated ketoreductases or 
ketoreductases bound to whole microbial cells) is an effective 
alternative for obtaining enantiopure compounds.[6] A 
recombinant ketoreductase (KRED1-Pglu), recently reported as 
an efficient stereoselective biocatalyst for the reduction of bulky 
diketones,[7] was employed for the reduction of 1. KRED1-Pglu 
was used in the presence of a catalytic amount of NADP+ and an 
enzyme-coupled system (glucose/glucose dehydrogenase, 
GDH) for the regeneration of the cofactor. Different parameters 
of the biotransformation (substrate and enzyme concentrations, 
pH, type and co-substrate concentrations) were optimized using 
a Multisimplex, approach, previously used for 
biotransformations;[8] KRED1-Pglu under optimized conditions 
(0.05M Tris-HCl at pH 8.0, 30°C, 6.5 mM substrate 
concentration in the presence of 3.2% EtOH and 2.5% glucose) 
gave the desired stereoisomer (13R, 17S)-2a with outstanding 
stereoselectivity (> 98% ee) and good reaction rates, but with 
moderate yields (65% after 6 hours). Notably, no further 
reduction to diol was observed even at prolonged times, 
indicating the total selectivity of KRED1-Pglu. 
The relative low yield observed with the recombinant 
ketoreductases, led us screening various yeasts for finding more 
productive biocatalysts. The screening was carried out with 
yeasts previously known for their ability to reduce structurally 
different ketones.[9-12] Table 1 gives the results of the 
biotransformation at the time of maximum production (only 
reactions with yields above 50% are reported). 
Table 1. Reduction of ethyl secodione 1 using different yeasts  
Yeastsa Product eeb
(%) 
Yield 
(%) 
Time 
(h) 
Pichia anomala DBVPG 2873 (13R,17S)-2a 20 65 24 
P. capsulata CBS 1993 (13R,17S)-2a 51 62 96 
P. etchellsii CBS 2011 (13R,17S)-2a 50 75 24 
P. glucozyma CBS 5766 (13S,17S)-2b 94 85 2 
P. minuta CBS 1708 (13R,17S)-2a 90 80 24 
Rhodotorula glutinis NRRL 
1587
(13S,17S)-2b 90 78 24 
R. rubra MIM146 (13S,17S)-2b 76 92 24 
S. cerevisiae CEN.PK113-7D (13R,17S)-2a 96 81 48 
a To compare yields, all biotransformations were performed with the same 
optical density of yeast culture (OD600/ml = 60). b Determined by analytical 
chiral HPLC (details in the Supporting Information).  
Six strains (Pichia etchellsii CBS 2011, Pichia glucozyma CBS 
5766, Pichia minuta CBS 1708, Rhodotorula glutinis NRRL-
Y1587, Rhodotorula rubra MIM 146, Saccharomyces cerevisiae
CEN.PK113-7D) gave monoreduction of 1 with yields higher 
than 70%. P. minuta CBS 1708 and S. cerevisiae CEN.PK113-
7D afforded the desired stereoisomer (13R, 17S)-2a with ee ≥
90%; different stereoselectivity was detected with P. glucozyma
CBS 5766 and R. glutinis NRRL-Y1587, giving (13S, 17S)-2b in 
high ee. The biotransformation with P. minuta CBS 1708 and S. 
cerevisiae CEN.PK113-7D were further optimized by evaluating 
different parameters (temperature, pH, substrate and cells 
concentration, and co-substrate type and concentration).
Table 2 reports the comparison between the results obtained 
in the biotransformation of 1 accomplished at 1 litre scale with 
the best-performing biocatalysts (recombinant KR or yeasts) 
  
used under optimized conditions. Although S. cerevisiae and the 
recombinant ketoreductase furnished the highest 
stereoselectivity, P. minuta allowed for the obtainment of the 
highest amounts of enantiomerically pure (13R, 17S)-2a after a 
single crystallization from diisopropyl ether (DIPE). Actually, P. 
minuta allowed us to perform the biotransformation at substrate 
concentration up to 4.7 g/L (15 mM) with > 95% yield, whereas S. 
cerevisiae and KRED1-Pglu provided high yields only at much 
lower concentrations.  
Table 2. Optimized reduction of 2 into (13R, 17S)-4a.
Biocatalyst ee (%) Yielda (%) Product recoveredb (g) Time (h) 
P. minutac 92 > 95 3.42 24 
S. cerevisiaed > 98 > 95 2.75 24 
KRED1-Pglue > 98 65 1.15 8 
a Analytical yield determined by HPLC b After crystallization from DIPE c 
Conditions: 0.1 M phosphate buffer at pH 7.2, 30°C, 15 mM substrate 
concentration in the presence of 3.2% EtOH and 25 gdry weight/L of yeast cells; d 
Conditions: 0.1 M phosphate buffer at pH 6.5, 30°C, 10 mM substrate 
concentration in the presence of of 3.5% EtOH and 30 gdry weight/L of yeast 
cells; e Conditions: 0.05M Tris-HCl buffer at pH 8.0, 28°C,  6,5 mM substrate 
concentration in the presence of 3.2% EtOH, 2.5% glucose, KRED1-Pglu and 
GDH.
In summary, we used different biocatalysts (yeasts or 
recombinant ketoreductase) for chemo- and stereoselective 
carbonyl reduction of secodione derivative 1. This approach is a 
simple and complementary strategy for the enzymatic 
generation of optically pure intermediates to be used for the 
synthesis of commercially relevant steroids.  
Experimental Section 
General procedure for the preparative asymmetric reduction with 
recombinant enzyme 
Biotransformation using KRED1-Pglu was carried out by addition of 
substrate (6.5 mM) dissolved in ethanol (32 mL) to a solution containing 
KRED1-Pglu (20 mU/mL), GDH (1 U/mL), NADP+ (0.1 mM), and glucose 
(25 mM) in 50 mM Tris/HCl buffer pH 8.0 (1 L). The reaction mixture was 
stirred at 28°C for 6 hours and then extracted with 600 mL of EtOAc; the 
aqueous phase was extracted twice more with 500 ml of EtOAc. The 
organic phases were collected and dried over Na2SO4 and the solvent 
evaporated. The crude residues were crystallised with DIPE. 
General procedure for the preparative asymmetric reduction with 
whole cells of yeasts 
Biotransformation using Pichia minuta and Saccharomyces cerevisiae
was carried out by addition of substrate as ethanolic solution (32 mL of 
ethanol in the case of P. minuta, 35 mL of ethanol in the case of S. 
cerevisiae). The biotransformation was kept under reciprocal shaking 
(150 rpm) at 30°C. When the reaction was over, 600 mL of EtOAc were 
added and the resulting mixture was shaken and centrifuged; the 
aqueous phase was extracted twice more with 500 ml of EtOAc. The 
organic phases were collected and dried over Na2SO4 and the solvent 
was evaporated. The crude residues were crystallised with DIPE.  
See Supporting Data for all the details about preparation of the 
biocatalysts, stereochemical analysis and analytical data of the products. 
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General 
All reagents and solvents were obtained from commercial suppliers and were used 
without further purification. Substrate 1 was kindly furnished by Dr. Roberto 
Lenna (Industriale Chimica). Elemental analyses were carried out on a Carlo Erba 
Model 1106 (Elemental Analyzer for C, H, and N), and the obtained results are 
within 0.4% of theoretical values. Merck Silica gel 60 F254 plates were used for 
analytical TLC; flash column chromatography was performed on Merck Silica gel 
(200–400 mesh). 1H and 13C NMR spectra were recorded on a Varian Gemini 300 
MHz spectrometer using the residual signal of the deuterated solvent as internal 
standard. 1H and 13C chemical shifts (δ) are expressed in ppm, and coupling 
constants (J) in hertz (Hz). IR spectra were recorded on a FT-IR PerkinElmer 16 
PC. Rotary power determinations were carried out using a Jasco P-1010 
spectropolarimeter, coupled with a Haake N3-B thermostat. MS analyses were 
performed on a Thermo-Finnigan LCQ ADVANTAGE mass spectrometer 
equipped with an electrospray ionization (ESI) source. HPLC analyses were 
performed with a Jasco PU-980 pump equipped with a UV/Vis detector Jasco UV- 
975 (l 220 nm) and a Lux 5µ Cellulose-2 column (4.6 X 250 mm, Phenomenex) at 
a flow rate of 0.5 mLmin‒1. Preparative HPLC was performed with a 1525 
Extended Flow Binary HPLC pump equipped with a Waters 2489 UV/Vis detector 
and Luna 5 μm C18 (2) 100 A, (21.2 X 250 mm; Phenomenex) or a Kromasil 5-
AmyCoat column (21.2 X 250 mm, AkzoNobel) at a flow rate of 15 mLmin‒1. 
Preparation of (13R*, 17S*)-E-13-ethyl-3-methoxy-8,14-secogona-
1,3,5(10),9(11)-tetraene-17-ol-14-one [(±)-2a] and (13R*, 17R*)-E-13-ethyl-3-
methoxy-8,14-secogona-1,3,5(10),9(11)-tetraene-17-ol-14-one [(±)-2b] 
 
To a solution of ethyl secodione 1 (200 mg, 0.64 mmol) in EtOH (4 mL) was added 
NaBH4 (6.1 mg, 0.16 mmol) and the reaction mixture was kept under agitation at 
room temperature. After 15 minutes, the reaction was evaporated under vacuum 
and the crude residue was purified by flash chromatography (n-hexane/EtOAc  6/4) 
to give a mixture of (±)-2a and (±)-2b (102 mg, 0.32 mmol). (±)-2a and (±)-2b 
were separated by preparative HPLC under the following conditions: Luna 5 μm 
C18 (2) 100 A, (21.2 X 250 mm; Phenomenex); hexane/isopropanol 95:5; 15 
mLmin‒1; Retention times of (±)-2a and (±)-2b were 21.6 and 22.9 minutes, 
respectively. 
(±)-2a: Rf= 0.61 (n-hexane/EtOAc 1:1); 1H NMR (300 MHz,C3D6O): δ= 0.91 (t, J 
= 7.5 Hz, 3H; CH3[19]), 1.63-1.73 (m, 2H; CH2 [18]), 1.78 (qui, J = 6.3 Hz, 2H; 
CH2 [8]), 1.88-1.97 (m, 1H; CH [16]), 2.13-2.40 (m, 5H; CH2 [12], [15]; CH [16]), 
2.49 (t, J = 5.6 Hz, 2H; CH2 [9]), 2.73 (t, J = 6.2 Hz, 2H; CH2 [7]), 3.77 (s, 3H; -
OCH3), 4.05 (d, J = 4.4 Hz, 1H; OH ), 4.32 (q, J = 5.5 Hz, 1H; CH [17]), 5.86 (t, J 
= 7.5 Hz, 1H; CH [11]), 6.65 (d, J = 2.8 Hz, 1H; CHar [4]), 6.72 (dd, J= 2.8, 8.7 Hz, 
1H; CHar [2]), 7.46 (d, J = 8.7 Hz, 1H; CHar [1]) ppm; 13C NMR (300 
MHz,C3D6O): δ= 8.0 (CH3), 21.6 (CH2), 23.4 (CH2), 26.7 (CH2), 27.9 (CH2), 30.5 
(CH2), 30.7 (CH2), 35.0 (CH2), 54.8 (CH3), 56.6 (Cq), 75.2 (CH), 112.7 (CH), 
113.2 (CH), 117.1 (CH), 125.2 (CH), 129.3 (Cq), 135.9 (Cq), 138.7 (Cq), 159.0 
(Cq), 218.8 (C=O) ppm; MS (ESI+ m/z %): 337.4 (100) [M+Na]+; 315.4 (36) 
[M+H]+; IR (KBr pellet): 3500, 2943, 2835, 1723, 1602, 1570, 1496, 1454, 1442, 
1304, 1232, 1166, 1150, 1118, 1040, 957, 826, 801, 789, 735, 723, 675, 563, 530 
cm-1; elemental analysis: calcd (%) for C20H26O3 (314.2): C 76.40, H 8.33; found:  
C 76.74, H 8.56. 
 
(±)-2b: Rf= 0.58 (n-hexane/EtOAc 1:1); 1H NMR (300 MHz,C3D6O): δ= 0.82 (t, J 
= 7.5 Hz, 3H; CH3 [19]), 1.53 (non, J = 7.5 Hz, 2H; CH2 [18]), 1.78 (qui, J = 6.2 
Hz, 2H; CH2 [8]), 1.95-2.07 (m, 1H; CH [16]), 2.23-2.31 (m, 3H; CH2 [15]; CH 
[16]), 2.43-2.46 (m, 2H; CH2 [12]), 2.51 (t, J = 6.2 Hz, 2H; CH2 [9]), 2.74 (t, J = 
6.2 Hz, 2H; CH2 [7]), 3.77 (s, 3H; CH3 [20]), 4.13 (d, J = 4.2 Hz, 1H; OH ), 4.32 (q, 
J = 5.3 Hz, 1H; CH [17]), 6.0 (t, J = 7.5 Hz, 1H; CH
 
[11]), 6.64 (d, J = 2.8 Hz, 1H; 
CHar [4]), 6.72 (dd, J= 2.8, 8.7 Hz, 1H; CHar [2]), 7.50 (d, J = 8.7 Hz, 1H; CHar [1]) 
ppm; 13C NMR (300 MHz,C3D6O): δ= 8.2 (CH3), 23.6 (CH2), 25.3 (CH2), 26.6 
(CH2), 26.8 (CH2), 28.4 (CH2), 30.9 (CH2), 34.8 (CH2), 54.9 (CH3), 57.2(Cq), 75.1 
(CH), 112.8 (CH), 113.2 (CH), 118.1 (CH), 125.3 (CH), 129.6 (Cq), 135.4 (Cq), 
138.7 (Cq), 159.0 (Cq), 219.1 (C=O) ppm; MS (ESI+ m/z %): 315.3 (100) [M+H]+; 
337.3 (52) [M+Na]+; IR (KBr pellet): 3405, 2968, 2935, 2916, 2835, 1716, 1606, 
1573, 1497, 1456, 1440, 1316, 1234, 1164, 1088,  1037, 902, 824, 792, 741, 703, 
675, 629, 545 cm-1; elemental analysis: calcd (%) for C20H26O3 (314.2): C 76.40, H 
8.33; found:  C 76.65, H 8.66 
 
Preparative chiral HPLC resolution of (±)-2a 
Preparative chiral HPLC conditions: Kromasil 5-AmyCoat column (21.2 X 250 
mm, AkzoNobel); hexane/isopropanol 9:1; 15 mLmin‒1; Retention times of (−)-2a 
and (+)-2a were 14.0 and 19.4 minutes, respectively. 
(−)-2a: [α]D20 = −14.5 (c= 1.0 in dioxane); 
(+)-2a: [α]D20 = +14.5 (c= 1.0 in dioxane). 
 
Preparative chiral HPLC resolution of (±)-2b 
Preparative chiral HPLC conditions: Kromasil 5-AmyCoat column (21.2 X 250 
mm, AkzoNobel); hexane/isopropanol 9:1; 15 mL/min; Retention times of (+)-2b 
and (−)-2b were 12.8 and 14.0 minutes, respectively. 
(+)-2b: [α]D20 = +11.0 (c= 1.0 in dioxane); 
(−)-2b: [α]D20 = −11.0 (c= 1.0 in dioxane). 
 
Single-crystal X-ray diffraction.  
Colourless prismatic crystals of (‒)-2b were grown by slow evaporation from 
diisopropyl ether at room temperature. Two diffraction-quality specimen were 
selected for the subsequent X-ray analysis. Diffraction data were measured at room 
temperature by a Bruker three-circle SMART APEX diffractometer equipped with 
an APEX II CCD area detector. Graphite-monochromated Mo Kα radiation (λ = 
0.71073 Å) was employed to perform a full data collection up to a maximum 
resolution of sinθ/λ = 0.65 Å–1 for both the specimens. As independent data 
processing led to identical structural results, the two sets of diffraction intensities 
were scaled and merged together, giving an overall 99.8 % complete dataset 
consisting of 45511 reflections (4028 unique) with Rint = 0.0334. The crystal 
system is orthorhombic, space group P212121 (nº 19), with lattice constants a 
=7.324(2) Å, b = 10.495(8) Å, c =22.664(2) Å and cell volume V = 1742(1) Å3. 
The molecular structure was solved by direct methods and refined through the 
shelx software package,[1] giving final agreement factors as low as R1(F) = 0.0462 
(3388 Fo > 4σ(Fo)), R1(F) = 0.0569 and wR(F2) = 0.1355 (all data),  goodness-of-
fit = 1.057. The maximum and minimum Fourier residuals were as low as +0.21 / –
0.28 e·Å–3. Due to the lacking of anomalous scatterers in the unit cell, it was not 
possible to unequivocally determine the absolute structure of (‒)-2b. Anyhow, the 
relative configurations of the two stereogenic centres were determined as syn. 
CCDC1437502 contains the supplementary crystallographic data for this paper. 
The data can be obtained free of charge from The Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/getstructures. 
 
(‒)-2b crystal structure 
Figure S1 shows the X-ray diffraction-derived structure of the compound (‒)-2b.  
 
 
Figure S1. X-ray structure of the asymmetric unit of (‒)-2b at room temperature, 
with the atom numbering scheme. Thermal ellipsoids are drawn at the 30% 
probability level.  
 
Figure S2 displays the main packing features of (‒)-2b.  
 
(a) (b) 
Figure S2. Ball-and-stick representation of the crystal packing of (‒)-2b, as seen 
along the a (a) and b (b) cell edges. Carbon atoms are drawn in grey, Oxygen 
atoms in red and Hydrogen atoms as small white spheres. Short O–H···O 
hydrogen-bonded contacts are highlighted as dashed red lines. 
 
The molecule bears a unique hydrogen donor group (–OH), which is involved in a 
short hydrogen-bonded contact with the facing keto Oxygen atom O1 at –x, –
1/2+y, 3/2–z (Table S1). Antiparallel chains of hydrogen-bonded molecules 
determine the formation of zig-zag motifs along the b cell edge (Figure S2 (a)). 
The –C19H2–C20H3 ethyl group is accommodated in the free space between 
adjacent layers of molecules along the c axis (Figure S2 (b)). 
 
Table S1. Hydrogen-bonded contact geometry for the symmetry-independent O3–
H3···O1 interaction. Least-squares estimated standard deviations from the 
structural refinement are given in parentheses. 
 
Donor-H···Acceptor D–H / Å H···A / Å D···A / Å D-H·· ·A / deg 
     
O3–H3···O1 0.93(4) 1.88(4) 2.796(3) 166(4) 
 
 
Synthesis of Mosher’s esters of (−)-2a  
To a solution of (−)-2a (20 mg, 0.064 mmol) in anhydrous CH2Cl2 at 4°C was 
added (R)-MTPA (16.8 mg, 0.072 mmol). The reaction mixture was kept at 4°C 
under stirring and DCC (15.6 mg, 0.075 mmol) DMAP (2.5 mg, 0.020 mmol) were 
added; the reaction was left at room temperature for 2 hours, then filtered and the 
filtrate was concentrated under vacuum. The crude residue was purified by flash 
chromatography (n-hexane/EtOAc  9/1) to give 30 mg of (R)-MTPA ester of (−)-
2a.  
(R)-MTPA ester of (−)-2a: 
1H NMR (300 MHz,C3D6O): δ= 0.73 (t, J = 7.5 Hz, 3H; CH3), 1.32-1.60 (m, 2H; 
CH2), 1.77 (qui, J = 6.2 Hz, 2H; CH2 ), 2.11-2.18 (m, 1H; CH), 2.23-2.35 (m, 2H; 
CH2) 2.39-2.45 (m, 3H; CH2; CH), 2.49-2.60 (m, 2H; CH2), 2.73 (t, J = 6.2 Hz, 2H; 
CH2 ), 3.57 (s, 3H; CH3), 3.76 (s, 3H; CH3), 5.59 (t, J = 5.7 Hz, 1H; CH17), 5.75 (t, 
J = 7.5 Hz, 1H; CH11), 6.64 (d, J = 2.8 Hz, 1H; CHar), 6.70 (dd, J = 2.8, 8.7 Hz, 
1H; CHar )7.42-7.49 (m, 4H; CHar) 7.55-7.57 (m, 2H; CHar) ppm.  
 
The remaining Mosher’s esters were prepared using the above general procedure: 
(S)-MTPA ester of (−)-2a: 
1H NMR (300 MHz,C3D6O): δ= 0.87 (t, J = 7.5 Hz, 3H; CH3), 1.50-1.70 (m, 2H; 
CH2), 1.77 (qui, J = 6.2 Hz, 2H; CH2 ), 1.90-2.07 (m, 1H; CH), 2.21-2.36 (m, 5H; 
CH2; CH), 2.40-2.56 (m, 2H; CH2), 2.73 (t, J = 6.2 Hz, 2H; CH2 ), 3.52 (s, 3H; 
CH3), 3.75 (s, 3H; CH3), 5.59 (t, J = 5.7 Hz, 1H; CH17), 5.80 (t, J = 7.5 Hz, 1H; 
CH11), 6.65 (d, J = 2.8 Hz, 1H; CHar), 6.72 (dd, J = 2.8, 8.7 Hz, 1H; CHar )7.45-
7.47 (m, 4H; CHar) 7.52-7.56 (m, 2H; CHar) ppm.  
 
(R)-MTPA ester of (−)-2b: 
1H NMR (300 MHz,C3D6O): δ= 0.77 (t, J = 7.5 Hz, 3H; CH3), 1.35-1.60 (m, 2H; 
CH2), 1.66-1.75 (m, 2H; CH2 ), 2.16-2.38 (m, 4H; CH2) 2.42 (t, J = 7.9 Hz, 2H; 
CH2), 2.53-2.64 (m, 2H; CH2), 2.70 (t, J =6.2 Hz, 2H; CH2 ), 3.57 (s, 3H; CH3), 
3.77 (s, 3H; CH3), 5.68-5.76 (m, 2H; CH17; CH11), 6.64 (d, J = 2.8 Hz, 1H; CHar), 
6.74 (dd, J = 2.8, 8.7 Hz, 1H; CHar ), 7.38-7.49 (m, 4H; CHar) 7.55 (d, J = 7.5 Hz, 
2H; CHar) ppm. 
 
(S)-MTPA ester of (−)-2b: 
 1H NMR (300 MHz,C3D6O): δ= 0.84 (t, J = 7.5 Hz, 3H; CH3), 1.54-1.64 (m, 2H; 
CH2), 1.67-1.78 (m, 2H; CH2 ), 2.08-2.19 (m, 1H; CH), 2.22-2.43 (m, 5H; CH2; 
CH), 2.46-2.58 (m, 2H; CH2), 2.71 (t, J =6.2 Hz, 2H; CH2 ), 3.52 (s, 3H; CH3), 
3.75 (s, 3H; CH3), 5.67 (t, J =5.7 Hz, 1H; CH17 ), 5.86 (t, J =7.5 Hz, 1H; CH11), 
6.65 (d, J = 2.8 Hz, 1H; CHar), 6.71 (dd, J = 2.8, 8.7 Hz, 1H; CHar) 7.36-7.48 (m, 
4H; CHar) 7.54 (d, J = 7.5 Hz, 2H; CHar) ppm.  
 
Determination of the absolute configuration of 2a 
 
Based upon the already assigned relative configurations of (‒)-2a and (‒)-2b and 
assuming also that the Mosher’s esters adopt the conformations shown in Figure 1 
(CF3, carbonyl and methine hydrogen in the same plane), the hydrogens that are on 
the same side of the phenyl ring would be shielded by the phenyl ring and thus 
further upfield in the 1H NMR spectrum. 
 
 
 
This is indeed the case for the (R)- and the (S)-Mosher’s esters of (−)-2a shown 
above. So for instance, H-11 and H-19 in the (R)-Mosher’s ester of (−)-2a are on 
the same side of the molecule as the phenyl ring, and they are further upfield (5.75 
and 0.73 ppm respectively) than the H-11 and H-19 in the (S)-Mosher’s ester in 
which are opposite to the phenyl ring (5.80 and 0.87 ppm respectively). These 
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observations are in agreement with an absolute configuration of (13R, 17S) for (−)-
2a.  
 
 
The same holds true for compound (−)-2b. H-11 and H-19 in the (R)-Mosher’s 
ester of (−)-2b are on the same side of the molecule as the phenyl ring, and they are 
further upfield (5.75 and 0.77 ppm respectively) than the H-11 and H-19 in the (S)-
Mosher’s ester, in which these hydrogens are opposite to the phenyl ring (5.86 and 
0.84 ppm respectively). These observations are in agreement with an absolute 
configuration of (13S, 17S) for (−)-2b.  
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Preparation of the biocatalysts 
Yeasts were cultured in liquid medium (malt extract + 0.5% yeast extract medium, 
pH 5.8) in 3.0 L fermenters with 1.0 L of liquid medium for 48 h, at 28°C and 
agitation speed 150 rpm. Fresh cells from submerged cultures were centrifuged and 
washed with 0.1 M phosphate buffer, pH 7.0 prior the use for biotransformation.  
KRED1-Pglu was prepared as recombinant protein in Escherichia coli.[2] KRED1-
Pglu gene was amplified from the genomic DNA of P. glucozyma by PCR using 
the following primers, carrying NdeI and HindIII restriction sites: 
Forward: 5’-ATACCATATGACGAAGGTGACTGTTGTGAC-3’ 
Reverse: 5’-AGAGAAGCTTGGCGTACTCCTTCAACTCTG-3’ 
The amplified gene was then cloned into a pET26b(+) vector using the NdeI and 
HindIII restriction sites. With this cloning strategy, the resulting protein is 
expressed with an N-terminal His6 tag. The correct construction of the expression 
plasmid was confirmed by direct sequencing. 
Cultures of E. coli BL21(DE3)Star transformed with the resulting plasmid were 
grown overnight at 37 °C in LB medium supplemented with 25 µg/mL kanamycin. 
The seed culture was then diluted into a stirred fermenter containing 4 L of 
cultivation medium (Terrific Broth, 12 g/L bacto-tryptone, 24 g/L yeast extract, 
4 g/L glycerol, 2.3 g/L KH2PO4, 9.4 g/L K2HPO4, pH 7.2) to an initial OD600nm of 
0.05. Cultivation was carried out in batch-mode at 37 °C, 250 rpm stirring and 
250 L/h aeration rate. Cells were grown until OD600nm reached the value of 0.8. The 
cultures were induced for 20 h with IPTG (isopropyl-β-D-thiogalactopyranoside) to 
a final concentration of 0.5 mM. Cells were then harvested by centrifugation at 
4500 rpm for 30 min, washed once with 20 mM phosphate buffer at pH 7.0 and 
stored at -20 °C.  
Protein purification was carried out with cells suspended in 50 mM Tris-HCl, 100 
mM NaCl, 6 mM imidazole, pH 8.0 buffer. Proteins were extracted by sonication 
(5 cycles of 30 s each, in ice, with 1 min interval) and cell debris were harvested by 
centrifugation at 15000 rpm for 30 min at 4 °C. The enzyme was purified by 
affinity chromatography with HIS-Select® Nickel Affinity Gel. Briefly, the 
column was equilibrated with 50 mM Tris-HCl, 100 mM NaCl, 6 mM imidazole, 
pH 8.0 and the crude extract loaded; column was then washed with 50 mM Tris-
HCl, 100 mM NaCl, 6 mM imidazole; finally, the adsorbed enzyme was eluted 
with 50 mM Tris-HCl, 100 mM NaCl, 250 mM imidazole, pH 8.0. 
 
Biotransformations: screening with yeasts 
Screening of the biotransformation of 1 with yeasts was carried out in 100 mL 
screw-capped test tubes with a reaction volume of 50 mL with cells (25 g/L, dry 
weight) suspended in 0.1 M phosphate buffer, pH 7.0. Ethyl secodione 1 (80 mg) 
was added as hot ethanolic solution (1.25 mL of ethanol). The biotransformation 
was kept under alternative stirring at 28°C. At different times, 2 ml of the 
biotransformation medium were withdrawn, extracted with 2 mL of EtOAc and the 
resulting mixture was shaken and centrifuged. The organic phase was collected and 
dried over Na2SO4 and the solvent was evaporated. The crude residues were 
analysed by TLC (n-hexane/EtOAc 1/1) and by chiral HPLC under the following 
conditions: Lux 5µ Cellulose-2 (4.6 X 250 mm, Phenomenex); hexane/isopropanol 
85:15; 0.5 mL/min; Retention times of (13S, 17S)-2b, (13S, 17R)-2a, (13R, 17S)-2b 
and (13R, 17S)-2a were 18.9, 20.6, 23.3, 24.6 minutes, respectively. 
 
Biotransformation of 1 with recombinant ketoreductase KRED1-Pglu  
The enzymatic reaction was optimized by performing biotransformations at 2 ml-
scale, using an enzyme-coupled system (glucose-glucose dehydrogenase – GDH – 
from Bacillus megaterium; for cofactor recycling. Reactions were carried out in 5 
mL screw-capped test tubes with a reaction volume of 2 mL with KRED1-Pglu (20 
mU/mL), GDH (1 U/mL), and NADP++ (0.1 mM).  
Preparative biotransformation using KRED1-Pglu was carried out by addition of 32 
mL of ethanol containing 0.20 mol of substrate (6.5 mM) dissolved in ethanol (32 
mL) to a solution containing KRED1-Pglu (20 mU/mL), GDH (1 U/mL), NADP++ 
(0.1 mM), and glucose (25 mM) in Tris/HCl buffer pH 8.0 (0.05M, 1 L). The 
reaction mixture was stirred at 28°C for 6 hours and then extracted with 600 mL of 
EtOAc; the aqueous phase was extracted twice more with 500 ml of EtOAc. The 
organic phases were collected and dried over Na2SO4 and the solvent was 
evaporated. The crude residues were crystallised with diisopropyl ether (DIPE), 
furnishing (13R, 17S)-2a as a pure single stereoisomer (1.15 g, 56% yield). 
 
Preparative biotransformation of 1 with Pichia minuta 
Centrifuged cells (25 gdry weight) were suspended in 1 L of phosphate buffer (pH 7.0, 
0.1M) and 32 mL of ethanol containing 0.47 mol of substrate were added. The 
biotransformation mixture was kept under reciprocal shaking (150 rpm) at 30 °C. 
After 24 hours, 600 mL of EtOAc were added and the resulting mixture was shaken 
and centrifuged; the aqueous phase was extracted twice more with 500 ml of 
EtOAc. The organic phases were collected and dried over Na2SO4 and the solvent 
was evaporated. The crude residues were crystallised with diisopropyl ether 
(DIPE), furnishing (13R, 17S)-2a as a pure single stereoisomer (3.42 g, 73% yield). 
 
Preparative biotransformation of 1 with Saccharomyces cerevisiae 
Centrifuged cells (30 gdry weight) were suspended in 1 L of phosphate buffer (pH 6.5, 
0.1M) and 35 mL of ethanol containing 0.30 mol of substrate were added. The 
biotransformation mixture was kept under reciprocal shaking (150 rpm) at 30 °C. 
After 24 hours, 600 mL of EtOAc were added and the resulting mixture was shaken 
and centrifuged; the aqueous phase was extracted twice more with 500 ml of 
EtOAc. The organic phases were collected and dried over Na2SO4 and the solvent 
was evaporated. The crude residues were crystallised with diisopropyl ether 
(DIPE), furnishing (13R, 17S)-2a as a pure single stereoisomer (2.75 g, 87% yield). 
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 8.1 Conclusions
 
 
In summary, different efficient and sustainable methods for the stereoselective 
reduction of prochiral ketones using both whole cells of unconventional yeasts such as P. 
glucozyma CBS 5766 and the isolated enzyme KRED1-Pglu have been proposed in this 
PhD work. 
 
The biocatalytic potential of whole cells of P. glucozyma have been studied 
through biotransformations using substrates of different chemical nature having interesting 
pharmaceutical and synthetic aspects. After optimization of the reaction conditions through 
the transformation of acetophenone in (S)-1-phenylethanol, the attention was focused on 
the reduction of different aromatic ketones. All the reactions occurred with high yields and 
high enantiomeric excess for the corresponding (S)-alcohols. 
 
Aromatic ketoesters were also assayed; it is known that biotransformations of β-
ketoesters with yeasts take place with competition between ester hydrolysis and carbonyl 
reduction, due to the occurrence of cell-bound esterase activities; this competitive 
enzymatic activity can be modulated by using appropriate co-substrate concentrations: 
with high co-substrate concentrations (e.g. glucose > 50 g/L) the activity of ketoreductases 
is generally predominant, as a consequence of redox cofactor regeneration, while esterase 
activity is predominant in absence of co-substrates. Biotransformations were performed in 
the optimal conditions for favouring ketone reduction, obtaining also in this case 
enantiomerically enriched alcohols.  
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The co-occurrence of different enzymatic activity in the whole cells of yeasts led 
us to investigate the possibility to carry out multi-steps enzymatic reactions using a single 
yeast. The target was to develop an alternative chemoenzymatic synthesis of Bimatoprost 
and Latanoprost utilized in the glaucoma treatment, which utilizes a stereoselective 
sequence of biotransformations catalyzed by enzymes belonging to a single 
microorganism. The best results were obtained using another yeast of the Pichia family: 
P. anomala CBS 110 that gave Lactondiol B or Lactondiol L, respectively key intermediate 
for the preparation of prostaglandins analogues Bimatoprost and Latanoprost, only 
changing the co-subtsrate for the regeneration of co-factors. 
The good results obtained with whole cells of P. glucozyma led us to isolate the 
enzyme(s) responsible for the reduction of the previous substrates, in order to overexpress 
and characterize it (them). 
The genome of Pichia glucozyma was sequenced and annotated by Baseclear 
company (Leiden, The Netherlands). Whole cells of P. glucozyma were able to efficiently 
reduce benzil, a substrate not easily reduced with high enantioselectivity by most of the 
known ketoreductase. Among all the dehydrogenases present in this yeast, only one was 
described as a “benzil-reductase”; the corresponding gene named KRED1-PGLU 
(GeneBank accession number KR080472) was amplified from the genomic DNA of P. 
glucozyma and cloned into BL21DE3STAR E. coli cells (pET 26 b+ expression vector) as 
a His-tagged construct. The pure protein was obtained (15.6 mg/gcells) with one purification 
step through a Nickel Affinity Chromatography.   
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After biochemical characterization (pH, temperature profiles, km, kcat) the pure 
protein was investigated for the reduction of different aromatic ketones using an enzyme-
coupled system (glucose-glucose dehydrogenase – GDH – from Bacillus megaterium) for 
cofactor recycling. KRED1-Pglu showed high activity and selectivity for the production of 
(S)- alcohols, but lower activity towards acetophenone and derivates such as β- and γ-
ketoesters compared to whole cells of P. glucozyma. Surprisingly (R)-phenylethanol, the 
opposite enantiomer obtained using whole cells was obtained; these results indicate the 
existence of at least another enzyme in P. glucozyma able to reduce these substrates with 
opposite enantioselectivity. 
 
A deep study to understand the correlation between electronic and steric effects on 
the activity and enantioselectivity for the reduction of various mono-substituted 
acetophenones with KRED1-Pglu was carried out.  
 
Reaction rates of the reduction of meta- and para-derivatives were mostly 
consistent with the electronic effects described by σ-Hammett coefficients; since 
unsubstituted acetophenone has been reduced to (R)-1-phenylethanol (95% ee), whereas all 
the other meta- and para-derivatives have been reduced to (S)-1-phenylethanols, generally 
with good enantioselectivity, molecular modelling studies in order to determine the 
substrate binding mode are still in progress.  Otrho-substituted acetophenones were poorly 
reduced, with the remarkable exception of derivatives with low steric impact (F and CN). 
 
Finally, the diastereoselective reduction of secodione for obtaining the key 
intermediate for the industrial relevant synthesis of Levonorgestrel was studied. Although 
Conclusions 
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KRED1-Pglu was completely regio-  and stereoselective, the best results in terms of 
productivity were obtained using whole cells of P. minuta CBS 1708 as a biocatalyst.  
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